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Dopamine (DA) receptors belong to the G-protein coupled receptors (GPCRs) family, 
divided in to two groups based on their high homology transmembrane domains; D1-like DA 
receptors (D1, D5) and D2-like DA receptors (D2-D4). DA receptor specific ligands have been 
exploited as a means for studying the prognosis and curing several CNS disorders. Though several 
efforts have been devoted to discover selective and potent DA receptor ligands, complete 
selectivity within the DA receptor subtypes remains a challenge. 
Tetrahydroprotoberberines (THPBs) are a group of naturally occurring tetracyclic 
alkaloids that belong to the tetrahydroisoquinoline family. A wide range of biological activities 
are associated with the THPB scaffold. Noted examples of THPB alkaloids, (-)-stepholidine 2.1 
(SPD), (-)-tetrahydropalmatine 2.2 (THP), (-)-isocorypalmine 2.3 (ICP), and (-)-canadine 2.4, are 
known to possess high affinity for DA receptors and have been studied widely for their utility in 
various CNS disorders. (-)-Stepholidine is endowed with DA D1 agonist and D3 antagonist dual 
pharmacological profile, which makes it a potential candidate for the treatment of schizophrenia 
and psychostimulant drug abuse. Limitations on the unavailability of efficient synthetic methods, 
scarcity of structure-activity relationship (SAR) data at DA receptors and metabolic instability 
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need to be addressed to make (-)-SPD 2.1 an ideal drug candidate for schizophrenia and 
psychostimulant drug addiction.  
In our work we have addressed prominent issues and missing gaps towards the synthesis 
and SAR studies of THPBs at dopamine D1, D2 and D3 receptors. A novel route to synthesize 
(±)-SPD (2.1) was developed over eight synthetic steps with 30% overall yield via the 
intermediacy of easily obtainable diester 3.7. In addition to the superior yield, this approach is 
advantageous in terms of conciseness and ease of synthetic manipulations. This route was 
deployed to produce C10 THPB analogues for SAR studies at DA receptors. Employing vital 
intermediate lactone 2.102, the enantioselective synthesis of (-)-SPD (2.1) was accomplished in 
23% overall yield from commercially available starting materials in a fourteen step sequence. The 
crystal structure of (-)-SPD (2.1) was determined by single crystal X-ray diffraction. Synthesis of 
lactone 2.102 was straightforward, scalable and high yielding. This synthetic pathway was applied 
to generate C3 chiral THPB analogues of THPB for bioactivity studies. 
In order to understand the structural tolerance of the THPB core required for selective 
D1/D3 receptor binding, a thorough SAR study was designed. Consequently, a diverse library of 
C3 and C10 THPB analogues was synthesized and evaluated for affinity at DA D1, D2 and D3 
receptors. Results from the SAR studies demonstrate that the C10 THPB analogues exhibit a 
general preference for the D1 receptor. Binding affinity evaluation at D3 receptor indicates that 
larger alkoxy groups are not tolerated at C10 position. In general, small alkoxy substituents are 
well tolerated at C10 position of THPB scaffold for D1 and D3 receptor affinity. Novel enantiopure 
C3 analogues of THPB were designed and synthesized to assess the optimum size of the alkoxy 
group at this position required for DA D1 and D3 receptor affinity. The results for binding affinity 
data suggest that C3 alkoxy substitution, decreases D1 and D3 receptor affinity while improving 
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selectivity at D3 versus D2 receptor when compared with parent compound (-)-SPD (2.1). Reduced 
affinity at D2 receptor for these analogues signifies the importance of the C3 alkoxy group to 
suppress affinity at the D2 receptor. These compounds will further expand our understanding of 
the tolerance of the THPB core required for DA D1 and D3 receptor activity. 
In order to rationalize the affinity of ligands, molecular docking studies were conducted at the D3 
receptor. The ligand binding energies from the D3 receptor docking studies show some similarities 
and minor discrepancies compared to the experimentally derived affinities. These docking studies 
have revealed key receptor–ligand interactions, including the critical protonated tertiary N—
Asp110 salt bridge motif, H-bonds to Ser192 and Cys181 and hydrophobic interactions to Phe106 
and Phe345. 
Novel series of conformationally flexible analogues of (-)-SPD (2.1) were synthesized and 
evaluated in order to identify potent and selective DA D1 and D3 receptor ligands. Two groups of 
analogues were synthesized and assayed for binding affinity at DA receptors, one group having 
truncated THPB scaffold while the other featured a tetrahydroisoquinoline (THIQ)/arylamide 
hybridized pharmacophore core. Results of this study indicate that de-rigidification of the THPB 
scaffold nullifies the DA receptor activity and the intact THPB scaffold of (-)-SPD is necessary 
for the DA receptor activity. On the other hand, THIQ/arylamide hybrid analogues have 
demonstrated high potency and selectivity for D3 receptor. 
Representative compounds were studied in order to test the metabolic stability of 
synthesized THPB analogues. The results of this metabolic study indicate that having phenolic 
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Chapter 1: Dopamine receptor: subtypes, selective ligands and therapeutic 
relevance  
 
1.1  Introduction 
Dopamine (DA) is a vital catecholamine neurotransmitter in the mammalian brain that 
controls important functions including motor co-ordination, cognition, working memory, learning, 
neuroendocrine regulation and positive reinforcement. Moreover, it contributes to the regulation 
of several autonomic and peripheral functions including cardiovascular, renal and hormone 
secretion. 1-4 
Much research over the last 50 years has been directed towards understanding the role of 
the dopaminergic system in several pathological conditions such as Parkinson’s disease, 
schizophrenia, psychostimulant drug abuse, restless leg syndrome, attention deficit hyperactivity 
disorder, hyperprolactinemia, and Tourrete’s syndrome.5-8 
Efforts have been made to modulate the dopamine activity in these ailments through 
different dopamine receptor agonist and antagonist agents, but adverse drug effects have stymied 
positive clinical outcome due to lack of selectivity of the drugs. The etiology of neurological 
disorders has not been clearly resolved, but the study of dopaminergic systems with various 
dopamine receptor ligands has enabled a greater understanding of the dopaminergic system.9  
A new momentum to the exploration in the DA field came from gene-cloning procedures 
to receptor biology brought into play three decades ago, which discovered more complicated 




1.2 Dopamine receptors  
Dopamine receptors belong to the G-protein coupled receptors (GPCRs) family, which are 
prime targets for >25% of marketed drugs.11 One prominent physiological response of dopamine 
is to increase the synthesis of cAMP by activating the adenylyl cyclase enzyme.12 Various 
compounds have also been demonstrated to mimic this effect of dopamine to increase adenylyl 
cyclase activity.13 On the other hand, there are physiological responses of dopamine not associated 
with stimulation of adenylyl cyclase or elevation of intracellular cAMP. An example here is 
dopamine induced inhibition of prolactin release from mammotrophs. The biochemical, 
physiological and pharmacological evidence have shown the presence of dopamine receptors on 
the mammotrophs and work as endogenous hypothalamic factor to inhibit prolactin release while 
there is no evidence found that dopamine mediated inhibition of prolactin release is associated 
with increased cAMP level.14 Amongst various other examples of studies where dopamine 
receptors have shown discrepancy in physiological response, one includes a considerable range of 
potency at DA receptors from micromolar to nanomolar in different tissues by dopamine itself.15, 
16 In 1978, Kebanian and Calne concluded this diversity into the classification of two different DA 
receptor populations, one positively coupled to adenylyl cyclase is the D1 receptor and one 
independent of this factor is D2 receptor.17  
The original classification of DA receptors served as the base for the study of DA receptors 
for a decade. However, molecular cloning and recombinant DNA techniques revealed the 
existence of five DA receptor subtypes (D1-D5).18-20 Structural, pharmacological and biochemical 
studies of the cloned receptors put them into two families based on their high homology in 




1.2.1 Structures of dopamine receptor subtypes 
The structural analysis of the cloned DA receptors revealed that they are members of the 
seven transmembrane (TM) domain G protein-coupled receptor families and share most of their 
structural characteristics. In their TM segment, the D1 and D5 receptors share 78% homology, 
while D3 receptor and D4 receptor have respectively 75% and 53% identity with the parent D2 
receptor.21, 25   
The NH2-terminal stretch has a similar number of amino acids in all the receptor subtypes 
while having a variable number of N-glycosylation sites. The D1 and D5 receptors possess two 
such sites, the D2 receptor has four, the D3 has three, and the D4 possesses only one N-
glycosylation site.22, 23, 26 The COOH terminal is about seven times longer for the D1-like receptors 
than for the D2-like receptors and is rich in serine, threonine, and cysteine residues. In the D1-like 
receptors, this cysteine residue is located near the beginning of the COOH terminus, whereas in 
the D2-like receptors it is located in end of the terminus. As in all G protein-coupled receptors, 
DA receptors possess two cysteine residues in extracellular loops 2 and 3, which have been 
suggested to form an intramolecular disulfide bridge to stabilize the receptor structure.27, 28 The 
D2-like receptors have a long third intracellular loop, which is common to receptors inhibiting 
adenylyl cyclase, whereas the D1-like receptors have a short third loop. The D1 and D5 receptor 
third intracellular loop and the COOH terminus are similar in size but divergent in their sequence. 
The external loop between TM4 and TM5 is considerably different in the two receptor subtypes, 
shorter (27 amino acids) in the D1 receptor than in the D5 receptor (41 amino acids).22, 23, 26 Highly 
conserved residues are present in the core of the protein and define a binding pocket that is most 




The D2 receptor exists as two alternatively spliced isoforms D2S and D2L.30, 31 In spite of several 
efforts, no obvious differences have emerged so far between the two isoforms. Both variants share 
the same distribution pattern, both isoforms inhibited adenylyl cyclase and revealed the same 
pharmacological profile.30-32  
Splice variants of the D3 receptor have also been identified wherein one transcript carries 
a 113-bp deletion in TM3 and the second variant derives from a deletion of 54 bp between TM5 
and TM6 of the D3 receptor.33, 34 
 
1.2.2 Distribution of brain dopamine receptors 
In situ hybridization techniques and immunohistochemical analysis have been employed 
to study the distribution of DA receptor mRNAs in the brain. The dopaminergic neurons in 
substantia nigra pars compacta, ventral tegmental area, and hypothalamus give rise to three major 
dopaminergic pathways in the brain, the nigrostriatal, the mesolimbocortical, and the 
tuberoinfundibular.   
The DA D1 receptors are more widespread than any other receptors.  Using in situ 
hybridization and receptor autoradiography, expression and distribution of dopamine D1 receptor 
in the brain was examined. The mRNA for D1 receptor is most abundant in cortical, limbic, and 
hypothalamic brain regions as well as caudate, nucleus accumbens and olfactory tubercule .35 36 
This indicates its important role in cognitive, affective and neuroendocrine functions of the brain.37  
In contrast, no mRNA has been detected in the substantia nigra pars reticulata even though D1 
receptor protein is highly expressed in this region, suggesting that D1 receptors in this area are on 
terminals of the striatonigral pathway neurons.36, 38 
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In contrast to DA D1 receptors, DA D5 receptors are poorly expressed in rat brain. mRNAs 
of this receptor are expressed restrictively to the hippocampus, parafascicular nucleus of thalamus 
and the lateral mamillary nucleus.39, 40 Further studies have discovered the distribution of DA D5 
receptors in various forebrain regions including striatum, cerebral cortex, lateral thalamus, and 
diagonal band area.41-43 Progress in finding the DA D1 and D5 receptor specific antibodies have 
led to better insight about cellular and subcellular localization of these receptors.44  
In the neostriatum, both DA D1 and D5 receptor antibodies tagged the medium spiny 
neurons, on the other hand D5 receptor antibodies labeled the large spiny neurons only.  In the 
caudate nucleus, D5 antibodies mostly labeled the shafts, and rarely, the spines of these cells, 
whereas D1 receptor labeling was more intense in the spines and shafts of projection neurons. 44 
Within the same pyramidal neuron cells, D1 receptors are located on dendritic spines and D5 
receptors are on dendritic shafts.44, 45 The D1 receptors have been distributed into the pars reticulate 
of the substantia nigra, but D5 receptors are not detected in this structure. 46 These dissimilarities 
between D1 and D5 receptors at subcellular localization suggest that even though having 
analogous pharmacology, functionally they are different.  
In the rat brain, the highest concentration of D2 receptor mRNA was found in substantia 
nigra, nucleus accumbens, olfactory tubercle, neostriatum and ventral tegmental area.47 D2 
receptor is also distributed in granule cells of hippocampal formation, in the septal region, in 
cingulate, prefrontal, enthorinal and temporal cortex.23 In ventral tegmental area, substantia nigra, 
and hypothalamus regions, D2 receptor is expressed by dopaminergic neurons.47, 48  
 
Immunohistochemical analysis study has suggested that D2 receptors are more concentrated in 
spine heads and dendrices than in somata in the spiny neurons of striatum.46, 49 The 
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immunoreactivity of D2 receptor with specific monoclonal antibodies is also found in the central 
nucleus of amygdala and internal plexiform layers.49 
In situ hybridization histochemistry revealed the localization of DA D3 mRNAs in the 
islands of Calleja and in the nucleus accumbens, as well as low level of D3 mRNAs was spotted 
in putamen and in anterior caudate.50 In the rat brain, D3 receptor mRNAs, mainly detected in the 
islands of Calleja, hippocampus, nucleus accumbens, and stria terminalis.48 The granule cells of 
islands of Calleja are enriched with both D3 receptor binding RNAs and mRNAs, while in nucleus 
accumbens, they are mainly expressed in neurons of the ventromedial shell subdivisions and rostral 
pole.51       
The D4 receptor mRNAs shows a limited expression in the central nervous system. The 
hypothalamus, olfactory bulb, thalamus and frontal cortex are the main areas where mRNAs for 
D4 receptors are significantly expressed.52 Subtype specific antibodies binding study for these 
receptors revealed the presence of GABAergic interneuron modulator D4 receptors in cerebral 
cortex and in hippocampus as well as in globus pallidus and reticular nucleus of thalamus. 53 
        The D5 receptor mRNA is most abundant in hippocampal subfields, in discrete cortical areas 
(layers II, IV and VI), and in the dentate gyrus.54 in the rat brain, this receptor mRNAs are found 
to localized in parafascicular nucleus of the thalamus and in hippocampus.39 
 
1.2.3 Functions of brain dopamine receptors 
The importance of DA in the control of movements is well demonstrated in pathological 
conditions such as Parkinson’s disease. The role of DA receptors in motor functions, such as 
forward locomotion, grooming, catalepsy, rearing, and sniffing has been studied.55 D1, D2 and D3 
receptors in ventral striatum are primarily involved in forward locomotion. Decreased locomotor 
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activity is associated with decreased DA release triggered by activation of D2 autoreceptors.23 
Individual D1 receptor activation has barely or no effect on producing locomotor activity.56 
However, pharmacological studies have shown that the simultaneous stimulation of D1 receptor 
is crucial to produce maximal locomotor effect by D2 agonists, which indicates forward 
locomotion involves synergistic interaction between D1 and D2 receptors.57, 58 Targeted gene 
inactivation of D1 receptor in the mouse has confirmed these observations as well.59  
                The D3 receptors present in nucleus accumbens have an inhibitory role on locomotor 
activity. In fact, supported by physiological actions of selective agents, DA D3 agonists inhibit 
while, DA D3 antagonists induce the locomotion.24, 60 The opposite roles of DA D2 and D3 
receptors on neurotensin gene expression in nucleus accumbens may have some correlation with 
their differing effect on locomotion.61  
Although some biases are present in literature, the mesolimbocortical DA is considered as 
an important neurological system responsible for cognition and memory. In the monkey, DA 
neurons in the area A10 have been reported to be involved in the cognitive behavior and learning 
process via transient changes in impulsive activity.62 Dopaminergic neurons in the prefrontal 
cortex are known to play an important role in working memory. The activation of DA D1 and D2 
receptors in the hippocampus by post training administration of agonists has improved the working 
memory tasks in animal models, suggesting important role of hippocampus DA receptors in the 
retention of working memory.63, 64 The stimulation of DA D1 and D2 receptors in prefrontal cortex 
has been shown to enhance performance in working memory in the monkey.37, 65  
Increased DA transmission in mesolimbic areas after administration of drugs of abuse and 
psychostimulants and decreased level of DA after withdrawal of these drugs implies that 
mesolimbic DA is primarily involved in reward and reinforcement mechanisms.66-69 Amongst 
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various models developed for the study of drug abuse and dopamine release, drug self 
administration and intracranial self stimulation are commonly used in this area. In the case of drug 
self administration, both DA D1 and D2 receptors are associated with reinforcing effect of drugs, 
with D1 receptor playing an acquiescent role while D2 receptor mediates drug reinforcement.70, 71 
D1 and D2 receptors are mainly involved in this behavior as agonists and antagonists increase and 
decrease self administration of drug of abuse respectively.72, 73 Previous studies suggest that D1 
receptors in the nucleus accumbens are important for the reinforcing properties of cocaine.71 The 
opposite role of DA D1 receptor and DA D2 receptor was observed while studying the effects of 
agonists on cocaine seeking behavior. D1 agonists inhibited the cocaine seeking behavior, while 
D2 receptor agonists promoted this behavior.74 D3 receptors are also involved in modulating 
reward and reinforcement. Recently, D3 receptor partial agonists and antagonists have shown to 
inhibit cocaine self administration in animal models for cocaine addiction study.75, 76 Several 
additional behaviors, including yawning, hypothermia, ejaculatory behavior, alcohol consumption, 
and inhibition of sniffing are associated with nucleus accumbens D3 receptor.77  
The role of D4 and D5 receptors in the physiology of dopaminergic system is still mostly 
unknown. Studies have found pharmacological evidences to establish possible links between mood 
disorders and DA D4 gene polymorphism, however the findings are not consistent and need to be 
reevaluated.78-80 Because of a lack of selective agents that can differentiate the D1 receptor from 
D5 receptor, scarce data is available to decide the physiological role of D5 receptors in the CNS. 
Currently, gene knockout techniques are being used to study the involvement of D5 receptors in 
attention deficit hyperactivity syndrome (ADHD) and in the locomotor stimulant effect of 
cocaine.81, 82 Very recently, it has been revealed that DA D5 receptor is linked to the activation of 
brain-derived neurotrophic factor (BDNF) and protein kinase B signaling which indicates a 
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possible association with mood stabilizers and antidepressant effect.83  Further research into the 
role of DA D5 receptor in prefrontal cortex as a therapeutic target in neurological disorders is 
required, with the development of selective DA D5 receptor therapeutic agents. 
 
1.2.4  Regulation of dopaminergic system in schizophrenia and drug abuse  
1.2.4.1  Role of dopamine receptors in schizophrenia 
Schizophrenia is a psychological disorder characterized by disturbed thought process, poor 
emotional flow, auditory hallucinations, delusion and disorganized speech and thinking.84, 85 It is 
a heterogeneous mental disorder, prevailing in about 0.85% of the population worldwide.86 
Schizophrenia syndromes can be classified into positive symptoms and negative symptoms. 
Positive symptoms reflect excessive expression of normal functions, exemplified by hallucination, 
bizarre behavior and delusions. Loss of normal functions or decreased intensity of normal 
functions is associated with negative symptoms, characterized by defect in attention, social 
withdrawal and cognitive impairment, lack of interest, flattened affect and poverty of speech.87, 88 
The initial hypothesis of schizophrenia was based on the consideration that psychological 
outcomes in this ailment are due to a hyperdopaminergic state of the CNS.89 During the 1970s, a 
direct relation between the therapeutic effectiveness of neuroleptics and their affinity for DA 
receptors, further solidified this hypothesis.90, 91 At that time, the spotlight was on 
hyperdopaminergia and halting the transmission at dopaminergic neurons to treat schizophrenia. 
The study of various DA agonists and antagonists on schizophrenia provided indirect evidences to 
this hypothesis. However, inconsistent results obtained during the treatment as well as in different 
studies have turned this hypothesis inaccurate. Resistance in the treatment, no induction of 
schizophrenia even after augmentation of dopaminergic system in nonschizophrenic individual 
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and partial effectiveness of neuroleptics in alleviating negative symptoms are some examples to 
support this fact. In 1991, Davis et al revised this concept, calling it “a modified dopamine 
hypothesis of schizophrenia”, wherein they explained multiple facets of the hypothesis based on a 
subcortical hyperdopaminergia and prefrontal specific hypodopaminergia.92 Elevated levels of DA 
and its metabolite, homovanillic acid was observed in the striatum after lesions in prefrontal cortex, 
while decreased DA metabolite level in striatum by presence of DA agonists in prefrontal areas 
has provided more precise definition of schizophrenia i.e. prefrontal hypodopaminergia resulting 
in striatal hyperdopaminergia.93, 94  
Further evidence in schizophrenia in this line comes from PET imaging of DA receptors 
using different radiotracers. Numerous studies have confirmed the elevated DA D2 and D3 
receptor density in striatum because of intrinsic abnormalities in schizophrenia but not due to 
rebound effects of antipsychotics.95-98     
 
Figure 1.1: Mesolimbic dopamine hypothesis for positive and negative symptoms of 
schizophrenia (Source: Stahl’s Essential Psychopharmacology, 4th Edition)     
 
DA D1 receptors are rich in prefrontal cortex and mediate major dopaminergic 
transmission in this region, and D1 hypofunction is found to be connected to negative symptoms 
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and cognitive impairment in schizophrenia.99, 100 That concludes, impaired activity of dopamine 
D1 receptors in the medial prefrontal cortex is an important factor in producing the negative 
symptoms and cognitive disorders of schizophrenia, whereas D2 receptor hyperactivity might lead 
to the positive symptoms of the disorder (Schematic diagram shown in Figure 1.1). 
 
1.2.4.2  Abnormal dopamine transmission in drug abuse 
 Psychostimulant drug abuse is understood as a special case of operant attitude bolstered by 
the positive reinforcing properties of the abused drugs.101-103 Among the neural pathways that 
contribute in incentive the ones that operate dopamine emerge as that most diffusely involved in 
the action of drugs of abuse. As examined by brain microdialysis in rats, most drugs of abuse of 
various pharmacological classes increase extracellular DA in different areas of the brain, 
preferentially in nucleus accumbens and ventral tegmental area.104 This is explained in cocaine 
(1.1) like, amphetamine (1.2) like, nicotine (1.3), narcotic analgesics and phencyclidine (1.4) drug 





Figure 1.3: Schematic representation of mechanism of action of a) cocaine b) methamphetamine 
and c) nicotine (Source: NIH Curriculum Supplement Series, The Brain: Understanding 
Neurobiology through the Study of Addiction)  
 
Different drugs of abuse have varied mechanism of action by which they stimulate DA 
transmission directly or indirectly (shown in Figure 1.3). Amphetamine operates through carrier 
mediated non-exocytotic release of newly synthesized DA, while phencyclidine increase synaptic 
DA concentration by blocking the reuptake process.111 Nicotine activates the firing activity of DA 
units by directly stimulating excitatory nicotine receptors localized on the somato-dendritic region 
of DA neurons.112 Hyperpolarization of the interneurons by narcotic analgesic acting on opioid 
receptors attenuate the GABA mediated synaptic input to the DA cells, which lead to excitation of 
13 
 
the dopamine cells by disinhibition.113 Cocaine binds to the presynaptic DA transporters and 
inhibits its reuptake mechanism.114    
 
1.3 Dopamine receptor ligands 
The development of selective DA receptor agents has provided necessary tools to assess 
the role of these receptors in the nervous system. Over the several decades, DA receptor specific 
ligands have been exploited as the means for studying the prognosis and curing several CNS 
disorders. Agents possessing selectivity at one type of receptor may demonstrate distinct type of 
clinical actions in the neurological disorders. Though some sort of selectivity is achieved between 
main classes of receptors i.e. D1 versus D2 types, complete selectivity within the DA receptor 
subtypes remains a challenge. 
 
1.3.1  Clinical significance of dopamine receptor ligands 
1.3.1.1  Therapeutic significance of D1 receptor selective ligands  
The insufficient D1 receptor signaling in prefrontal region results in cognitive deficits in 
psychosis. Low doses of selective D1 receptor agonists, such as dihydrexidine (1.5), A77636 (1.6) 
and SKF81297 (1.7), have been reported to have cognitive-enhancing actions in nonhuman 
primates.115-117 The finding that full D1 receptor agonists can elevate working memory suggests 
that such type of agents can be a newer approach to treat negative and cognitive symptoms of 
schizophrenia.118, 119 Animal laboratory data indicate that D1 receptor agonists may have possible 
applicability for the treatment of cocaine abuse.  D1 agonists, such as, SKF81297 (1.7) and 
dihydrexidine (1.5)  have been shown to decrease cocaine craving in humans and motivation to 
seek cocaine, and masks the reinforcing effects of cocaine during self-administration.120, 121  These 
D1 agonists could serve as “methadone like” compound for their capacity to therapeutically 
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substitute psychomotor stimulant drugs.122 However, considering the addiction potential, 
development of tolerance and severe adverse effects limits their therapeutic liability as 
antipsychostimulant drug. 
 
The alternate approach along with this line is of using partial D1 agonist agents to avert the 
addiction potential of psychomotor stimulants. D1 partial agonists would be expected to act 
primarily as antagonists in the presence of cocaine, whereas in the absence of cocaine they would 
be expected to function as weak agonists.123 Various pharmacological studies have exhibited the 
antidrug abuse potential of D1 partial agonist agents like SKF 83959 (1.8), SKF 77434 (1.9) and 
SKF 38393 (1.10) (shown in Figure 1.4b). 123-125 
Based on preclinical studies, D1 antagonists are not found much effective as 
antipsychotics, but they are developed for the treatment of self-harming behavioral disturbances 
arise in Lesch−Nyhan Disease, as well as for the treatment of Tourette syndrome in children and 




1.3.1.2  Therapeutic significance of D2 receptor selective ligands 
Since the discovery of chlorpromazine (1.11), D2 antagonism is considered a fundamental 
necessity to positively modulate psychosis.129, 130 Since then, without exception, currently 
available antipsychotics all have some degree of D2 receptor antagonist property.131, 132  As shown 
in Figure 1.5, other examples of antipsychotics having D2 antagonist effect include fluphenazine 
(1.12), haloperidol (1.13), thiothixene (1.14), risperidone (1.15), clozapine (1.16), and quetiapine 
(1.17).   
Brain imaging studies including positron emission tomography (PET) indicate that the 
blocking of at least 65% of D2 receptors is necessary to achieve antipsychotic effects, at the same 
time, passing the threshold of 72%-78% blockade of D2 receptors, increases the risk of 
extrapyramidal motor symptoms (EPS) and hyperprolactinemia.130, 133  
A second approach to treat schizophrenia is to prevent the excessive D2 receptor activity 
using D2 partial agonists. D2 receptor antagonists block the action of endogenous DA, while 
partial agonists like aripiprazole (1.18), diminish the hyperactivity of the receptor by competing 
with endogenous DA to produce lower degree of action at DA receptors.134  D2 agonist compounds 
(shown in Figure 1.6) like bromocriptine (1.19), cabergoline (1.20), and quinagolide (1.21) are 
being used for the management of hyperprolactinaemic disorders and combination therapy with 






The enhanced reinforcing effect and self administration of cocaine was observed after the 
administration of D2 agonist as well as, clinical and pharmacological studies indicate that D2 
agonist agents are not effective against cocaine addiction because of the abuse potential in 




1.3.1.3  Therapeutic significance of D3 receptor selective ligands 
Cocaine and methamphetamine overdose fatalities have been associated with upregulation 
of D3 receptors in the ventral striatum and other D3 receptor rich regions in brain.139, 140 D3 
receptor antagonists SB277011A (1.23), have shown promise in reversing acquisition and 
expression of drug-seeking and cue-induced relapse in animals.141, 142 Rewarding effects of cocaine 
and cocaine-induced reinstatement of drug-seeking behavior was shown to be inhibited by D3 
receptor antagonist NGB 2904 (1.24).143 As shown in Figure 1.7, other examples of D3 receptor 
antagonists include SR21502 (1.25), PG01037 (1.26), and YQA14 (1.27) that have demonstrated 
to inhibit cocaine seeking behavior and cocaine self administration in animal models.144-146   
Moreover, it has been demonstrated that the D3 selective partial agonist BP 897 (1.28) inhibits 
cocaine seeking behavior caused by the presentation of drug-associated cues.76 
 
Elevated expression of D3 receptor was observed in a postmortem study of untreated 
schizophrenic patients, whereas D3 receptor level was normal in subjects having antipsychotic 
drugs treatment.147 There is increasingly strong evidence that D3 receptor antagonists will be 
effective antipsychotic agents. In this regard, refinement of the cognitive and negative symptoms 
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of schizophrenia holds the most promise for D3 receptor antagonists.148 Studies have shown that 
the D3 receptor antagonism can inhibit extrapyramidal symptoms and can positively affect the 
social behavior in schizophrenia.149  
 
1.3.1.4  Therapeutic significance of D4 receptor selective ligands 
Considerable work has been progressed to find selective D4 receptor binding compounds 
based on the hypothesis that the D4 receptors are likely involved in a psychosis, ADHD and 
erectile dysfunction. There are many studies suggesting that the selective D4 receptor antagonists 
might be a novel strategy towards schizophrenia.150, 151 Various D4 receptor selective antagonists 
(Figure 1.8) have reached clinical trials, for instance, sonepiprazole (1.29), NGD-94-1 (1.30), and 
L-745, 870 (1.31) but none of them have successfully demonstrated antipsychotic activity in 
schizophrenic patients.152-154 The effect of stimulating the D4 receptor using selective agonist 






1.3.1.5  Therapeutic significance of D5 receptor selective ligands 
A few studies have implicated the D5 receptor in the pathophysiology of hypertension and 
drug abuse, making it of pharmacological interest.156-158 It was shown in D5 knockout mice that 
the D5 receptor seems to be involved in the locomotor-stimulant effects of cocaine, whereas there 
is only little involvement in the discriminative stimulus effects of cocaine suggesting therapeutic 
relevance of D5 receptor in cocaine addiction.81 However, discrimination between D1 and D5 
receptors remains largely unexplored due to lack of highly selective ligands and of specific 
methods of biological characterization. There are some examples of selective D5 receptor 
antagonists (compounds 1.32 and 1.33 shown in Figure 1.9) under investigation for their anti-
addiction potential against cocaine.159  
 
Potential clinical importance of selective dopamine receptor ligands for different CNS disorders is 




 Table 1.1: Potential therapeutic applications of dopamine receptor ligands 
DA receptor ligand Therapeutic significance 
D1 receptor agonist - Parkinson’s disease 
- Cognitive and working memory deficits in 
schizophrenia 
- Psychostimulant drug abuse 
partial agonist - Psychostimulant drug abuse 
antagonist - Tourette syndrome 
- self-harming behavioral disturbances in 
Lesch−Nyhan Disease 
D2 receptor agonist - Hyperprolactinaemic disorders 
- Parkinson’s disease 
- Prolactinoma 
- Restless legs syndrome 
partial agonist - Parkinson’s disease 
- Restless legs syndrome 
- Schizophrenia 
- Bipolar disorders 
- Depression 
antagonist - Schizophrenia 
D3 receptor agonist - Hyperprolactinaemic disorders 
- Parkinson’s disease 
partial agonist - Psychostimulant drug abuse 
antagonist - Psychostimulant drug abuse 
- Schizophrenia 
D4 receptor agonist - Cognitive disorders 
- Erectile dysfunction  
antagonist - Schizophrenia 
- ADHD 
D5 receptor agonist        - 




1.3.2  Selective D1 receptor ligands 
1.3.2.1  Arylbenzazepines 
1.3.2.1.1  Simple arylbenzazepines 
Initial findings of D1 antagonists like SCH-23390 (1.34), followed by a number of selective 
D1 receptor ligands were developed in 1980s.160  All of these D1 receptor ligands (1.7, 1.8, 1.10, 
and 1.34-1.36) share a common template of phenyl tetrahydrobenzazepine (shown in Figure 1.10). 
Many useful D1 receptor selective compounds having agonist or antagonist activity with high D1 
affinity, for example SCH and SKF series (Figure 1.10), were acquired from this class. More 
diverse D1 receptor ligands were developed to enhance binding affinity and selectivity at D1 
receptor as well as to improve intrinsic efficacy and metabolic stability. In these compounds, β-
catechol-substituted ethylamine moiety, which resembles the catecholamine neurotransmitter DA, 
is associated with D1 receptor affinity. The chiral center at C1 position should be in the R 
configuration to be active at DA receptors.161 Variant substitutions on C1 phenyl ring, C6 or N3 
can modify the binding affinity and selectivity between D1 and D2 receptors. Usually, catechol-
benzazepines are D1 agonists, while C7 substituent can govern the functional activity from 
agonism to antagonism predominantly. As demonstrated by  benzazepine analogues 1.34 and 1.35, 
replacing the catecholic 7-OH group with halogen produces D1 antagonist activity.160, 162  SKF 
83959 (1.8) is one of the primary D1 receptor agonist with high binding affinity and selectivity. 
To overcome the limitations of having low intrinsic activity and poor metabolic stability, various 
analogues of SKF 83959 (compounds 1.37-1.44) were synthesized and studied for their affinity at 
DA receptors.163, 164 These SAR studies have revealed that 3’ or 2’ CH3 substitution on 1-phenyl 
ring and H, CH3 or allyl N-substituents as well as C6 halogens are important for the D1 receptor 






Table 1.2: Structure modification and binding affinities of catechol containing arylbenzazepines 
at DA D1 and D2 receptors 
 
Comp. Isomer R1 R2 R3 
Ki (nM) 
D1 D2 
(±)-1.8 RS-(±) Cl CH3 3’-CH3 1.18 920 
(+)-1.8 R-(+) Cl CH3 3’-CH3 0.49 515 
1.37 R-(+) Br CH2CH=CH2 H 2.29 2.09 
1.38 RS-(±) Cl CH3 2’-CH3 0.46 226 
1.39 RS-(±) Cl H 3’-CH3 0.60 ≥5000 
1.40 RS-(±) Br CH3 3’-CH3 0.19 440 
1.41 RS-(±) Br CH3 2’-CH3 1.10 409 
1.42 RS-(±) Br H 2’-CH3 1.81 19.5 
1.43 RS-(±) Cl CH2CH=CH2 3’-CH3 0.52 119 
1.44 RS-(±) Br CH2CH=CH2 3’-CH3 0.11 83.8 
1.45 RS-(±) 3-toluyl H H 39 >10000 
1.46 RS-(±) 2-naphthyl H H 56 >10000 
1.47 RS-(±) 3-toluyl H 3’-CH3 6.81 >10000 
1.48 RS-(±) 2-naphthyl H 3’-CH3 4.88 >10000 
 
agents exhibited higher D1 receptor      selectivity over D2 receptor with subnanomolar binding 
affinity (Table 1.2). For the same molecule (1.8), another series of analogues (1.45-1.48, Table 
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1.2) having an aryl group at 6 position, has been synthesized. The tolerance of larger aryl group at 
this position indicate a large hydrophobic pocket on D1 receptor around the C6 position of 
phenylbenzazepine.164 In the parent molecule SCH 23390 (1.34), various substituents were 
introduced at para position of pendant phenyl ring to generate novel D1 antagonists (1.49a-1.49f, 
Table 1.3).165 Most of these analogues have shown higher preference for D1 over D2 receptors 
with subnanomolar (0.5-0.9 nM) binding affinity (Table 1.3).  
Table 1.3: Structure modification and binding affinities of arylbenzazepines at DA D1 and D2 
receptors 
 
Comp. Isomer R1 R2 
Ki (nM) 
D1 D2 
1.49a R-(+) H n-Bu 0.9 2000 
1.49b R-(+) Ac n-Bu 0.2 159 
1.49c R-(+) SO2CH3 n-Bu 0.5 2000 
1.49d R-(+) SO2CH3 CH3 0.5 6000 
1.49e R-(+) SO2Ph CH3 0.6 331 
1.49f R-(+) Bn 2,4-F2C6H3 0.7 552 
 
 
1.3.2.1.2  Conformationally constrained arylbenzazepines 
Arylbenzazepines retain a noticeable mobility, and the proposed position of the aryl moiety 
in the binding pocket of D1 receptor is postulated to be equatorial.166, 167 One of the binding 
intercations of phenylbenzazepines with the D1 receptor was believed to be π-π interaction 
between C1 aryl group and Tyr, Phe or Trp terminals in the receptor active site.168 In the parent 
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compound SCH23390 (1.34), introducing an ethylene bridge between C2 and C2’ results in 
conformationally restrained benzazepine compound 1.50 (Figure 1.11).166 Binding study at D1 
receptor reveals that (R)-trans isomer has the highest affinity (Ki 1.9 nM) amongst all four isomers, 
supporting the fact that the pharmacologically active arylbenzazepine possesses R- configuration 
at C1 chiral center.166 Compound 1.50a (SCH 39166), also known as ecopipam, was studied 
extensively for the treatment of obesity, but it faces limitations of poor oral bioavailability.127  
 
To further explore this scaffold, novel D1 antagonist analogues (1.51a-1.51j, 1.52a-1.52c, Table 
1.4) having variant ring D substitutions at 3’ and 4’ positions in SCH 39166 were synthesized and 
their activity at D1 receptor was studied.165, 169 These compounds have shown nanomolar to 
subnanomolar D1 affinity (0.2-3.1 nM, Table 1.4) with better selectivity at D1 versus D2 receptor 
and improved pharmacokinetic properties as compared to parent compound 1.50a. Highest binding 
affinity was demonstrated by 4’ phenyl analogue 1.51g (0.2 nM) while compound 1.51c has shown 
>3000-fold selectivity at D1 (3.1 nM) versus D2 receptor (>10000 nM). 3’-sulfonyl derivative 
1.52b, showed to improved pharmacokinetics and oral bioavailability (Foral = 29% for 1.52b versus 






Table 1.4: Structure modification and binding affinities of conformationally constrained 





1.50a H 1.2 980 
1.51a CH2OH 2.0 1647 
1.51b OH 0.6 440 
1.51c 2-oxopurrolidine-1-yl 3.1 >10000 
1.51d NH2 2.8 2100 
1.51e NHCONHEt 2.4 900 
1.51f NHCO2Et 2.3 500 
1.51g Ph 0.2 79 
1.51h 4-OMePh 0.7 550 
1.51i Thien-2-yl 0.9 93 
1.51j 1H-indol-5-yl 0.6 51 
1.52a H 7.0 5400 
1.52b SO2Me 0.5 3000 
1.52c CONH(2,6-Cl2Ph) 0.7 1093 
 
 
1.3.2.1.3  Bioisosteres of benzazepines  
The metabolic susceptibility of arylbenzazepines arises because of O-glucuronidation of 
the catechol hydroxyl group and N-dealkylation of N-methyl functionality. The main approach to 
tackle this drawback is to replace catechol with its bioisosteres, which can mimic the hydrogen 
bond complement of phenol at the receptor binding site.170 Wu et al. developed heterocycle-fused 
phenol isostere compounds (Figure 1.12) as DA D1 receptor ligands having triazole (1.53, 1.54), 
indole (1.55), imidazole (1.56), imidazolone (1.57a, 1.57b) and thiazolone (1.58a, 1.58b).171 
Considerably poor binding affinity (Table 1.5) was displayed by the benzotriazole (1.53, 1.54) and 
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benzimidazole (1.56) analogues with Ki values of 583, 146, and 248 nM respectively. Remarkable 
higher binding affinity (Table 1.5 Ki = 2.1 to 16.5 nM) shown by benzimidazolone and 
benzthiozolone compounds (1.57a-b, 1.58a-b) signifies the importance of orientation and acidity 
of the NH moiety in these heterocycles. Based on this observation they conclude that, suitably 
aligned heterocycle with an NH group would be able to serve as surrogates for the phenolic OH 
group. As expected, these D1 receptor antagonists exhibited better pharmacokinetic profiles as 
compared to parent benzazepines.  
 




1.53 583 3000 
1.54 146 1530 
1.55 24.7 232 
1.56 248 984 
1.57a 7 1023 
1.57b 16.5 3270 
1.58a 2.1 257 




1.3.2.2  Dihydrexidine derivatives 
 Compound 1.59 represents a class of 4-phenyl substituted tetrahydroisoquinolines which 
has moderate, but selective DA D1 receptor affinity.172, 173 As shown in Figure 1.13, introduction 
of ethylene-bridge has rigidified this scaffold to give novel D1 receptor ligands 1.5, 1.5a, and 
1.5b.174 The trans configured compound 1.5, also known as dihydrexidine, is a highly selective 
and potent D1 receptor ligand. More significantly, compound 1.5 is a full DA D1 agonist with 
EC50 of 70 nM to activate adenylate cyclase. The cis isomer (1.60) of 1.5 is found inactive at DA 
receptors. The N-Me (1.5a) and N-Pr (1.1.5b) analogues demonstrated much lower binding 
affinity of 91 nM and 651 nM, respectively, with the reduction of intrinsic activity at the same 
time. Switching the substitution from 10, 11 dihydroxy in ring D of 1.60 to 9, 10 dihydroxy 
(compound 1.61) results in vanished D1 receptor activity.   
Applying the original idea of rigidifying compound 1.59 to develop dihydrexidine, similar 
D1 ligands (1.62a-1.62d) were designed wherein, two phenyl rings were connected through 
methylene-bridge and ethylene-bridge was removed in dihydrexidine. Binding affinity of 
compound 1.62a (also known as dinapsoline) was found to be 5.9 nM, comparable to 1.5, and it 
displayed D1 full agonistic profile.175 The C6-methyl (1.62b) and C6-ethyl (1.62c) compounds 
have nearly equal affinity to the D1 receptor with Ki of 11 and 14 nM, respectively, while C6-
fluoro analogue (1.62d) has biological activity consistent with dinapsoline. 176  
Replacing methylene bridge with ether linkage to tether phenyl rings in dinapsoline 
produced compound 1.63a, also known as dinoxyline.177 This novel ligand was found to possess 
remarkable affinity (3.9 nm) for D1 receptor and greater selectivity (22-fold) for D1 versus D2 
receptor. It also retained full agonistic profile (EC50 87 nM) at D1 receptor similar to dinapsoline. 
It has shown high binding affinity at D5 receptor with Ki value of 1.0 nM as well as at D3 receptor 
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(Ki 6.5 nm). Reduction in affinity was observed after N-alkyl insertion (compound 1.63b and 
1.63c) in the dinoxyline template. Compound 1.63a serves as the key example of ligands with 
improved affinity for all DA receptors and also endowed with the functional aspects akin to 
dopamine itself. Dinoxyline is under investigation for the treatment of Parkinson’s disease.178 
 
D1 agonists have been investigated as potential treatments for Parkinson’s disease and 
hypertension, and D1 antagonists have been tested in the treatment of psychotic disorders, 
including schizophrenia, though both efforts have yielded only limited success. Fenoldopam 
(Figure 1.13, 1.64), a benzazepine analog, remains the only D1-selective compound to reach the 





1.3.3  Selective D2 receptor ligands 
1.3.3.1  Dihydroindenes and oxime analogues 
To develop metabolically stable DA receptor ligands, trans-2-amino, 1-phenyl-2,3-
dihydroindene derivatives were designed. Compounds 1.65-1.67 (Figure 1.14) belong to this class 
of DA receptor ligands, having C2-amino group and C1-phenyl moiety in trans configuration to 
attain the receptor activity. Amino group substitution affects the activity at D2 receptors, as 
demonstrated by N,N di-alkyl substituted indenes having greater affinity and selectivity at D2 
receptors. Indene analogues 1.65, 1.66, and 1.67 have D2 affinity 650, 270, and 170 nM 
respectively and they possess D2 agonist effect.180, 181  
 
Aminotetralin compound 1.68 and its derivatives are known mixed DA D1/D2 agonists 
explored for the potential utility in the treatment of Parkinson’s disease. 182-184 To combat against 
the metabolic instability, series of oxime analogues (1.69-1.71, Figure 1.14) were developed as 
prodrug of 60.185 These compounds exhibited apparent and extended dopaminergic effects in 
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Parkinson’s disease behavioral model. Novel compounds 1.72 and 1.73 developed as DA agonists, 
since the thienylethylamine moiety can act as bioisosteres of DA.186 Though these compounds 
have moderate DA D2 receptor affinity (Ki 27 nM for 1.72 and Ki 20 nM for 1.73), they have 
improved oral bioavailability.  The benzoquinoline compound 1.74, is a potent DA D1 and D2 
receptor agonist with EC50 value of 25 nM (D1 receptor) and 0.64 nM (D2 receptor). The enone 
compound 1.75 is the prodrug of 1.74, which is an interesting lead compound for potential 
development of anti-Parkinson agents.187, 188 
 
1.3.3.2  Aporphine analogues 
Based on the fact that 1,2,3,4-tetrahydroisoquinoline compounds maintain the integrity of 
the phenethylamine portion of dopamine, several naturally occurring as well as synthetic 
tetrahydroisoquinoline derivatives have been screened for dopamine receptor activity.  1-benzyl-
1,2,3,4-tetrahydroisoquinoline alkaloids, for example, nor-roefractine (1.76, Figure 1.15) and nor 
armepavine (1.77, Figure 1.15) have affinity for both DA D1 and D2  receptors.189, 190 Among the 
tetrahydroisoquinolines and congeners, the conformationally rigid aporphines have been 
extensively studied with regard to their dopamine receptor activity.191 Apomorphine and some of 
its derivatives were among the earliest pharmacological tools used to characterize DA receptors.192 
Clinically, R-(-)-apomorphine (1.78) is being used as anti-Parkinson drug and for the treatment of 
male erectile dysfunction as D1 and D2 agonist.  
To resolve the drawback of poor bioavailability and short duration of action, diverse 
synthetic analogues (1.80-1.91, Figure 1.15) were developed and studied at DA receptors.193-195 




aporphines, for example (R)-(-)-N-n-propylnorapomorphine (NPA, 1.79 Ki = 4.80 nM). For DA 
receptor activity, apart from the structural requirements of tertiary nitrogen and 6a-R configuration, 
C-2 substitution is also considered a significant factor in aporphines. Differences in affinity (Table 
1.6) was observed between alkyloxy and 4-hydroxyphenyl substitutions at C-2 position. When 
compared to the parent compound APO (1.78), C2 alkoxy analogues (1.80, 1.81) were 4 to 8-fold 
less potent, while, hydrophilic substituent 4-hydroxyophenyl analogues (1.82, 1.83) were 5-fold 
more potent.196, 197 Insertion of alkylthio moiety at C2 position in aporphine scaffold yielded novel 
compounds 1.84-1.86 (Table 1.6). Methylthio analogue (1.84) was found to have improved 
potency (Ki 3.73 nM), while ethyl and propyl analogues have shown  reduced affinity (Ki 7.8 and 









1.78 214 13.2 
1.79 733 4.8 
1.80 2900 44 
1.81 3500 75 
1.82 124 1.5 
1.83 94 2.0 
1.84 - 3.73 
1.85 - 7.8 
1.86 - 15.6 
1.87 >10000 >10000 
1.88 >10000 >10000 
1.89 >10000 97 
1.90 130 28.0 
1.91 1690 44.0 
 
To improve the in vivo metabolic stability profile of aporphines, exclusion of one or both 
catecholic hydroxyl group or replacing them with bioisosteres was envisaged. Switching the 
catechol component with its aminothiazole bioisosteres, results in complete loss of activity at D2 
receptor (1.87, 1.88), while mono hydroxyl analogues (1.89-1.91) have shown to reduce the 
potency 3 to 8-fold as corresponds to their lead compounds 1.78 or 1.79.199  
  
1.3.3.3  Arylpiperazine/piperidine analogues 
Arylpiperazines or arylpiperidines belong to one of the largest groups of chemical structure 
with dopaminergic activities. Most of the recent widely used antipsychotics which have D2 
antagonistic activity (for example haloperidol, risperidone, olanzapine and clozapine) fall into this 
category. Current attempts to develop D2 ligands as superior antipsychotics with limited EPS, have 
targeted agents bearing moderate D2 antagonism or D2 partial agonistic effects, combined with 




Various analogues (1.92-1.104, Figure 1.16) were generated by modification of haloperidol 
(1.13) scaffold. The nitrogen/silicon exchange at the C-4 position of the piperidinyl ring, has 
produced sila-haloperidol (1.92) and sila-trifluperidol (1.93). Switching the chloro group of 
haloperidol with trifluoro moiety produces novel the compound 1.94.  Binding affinity at D2 
receptor for compound 1.92 and 1.93 is comparable to haloperidol, while compound 1.94 is 15-
fold less potent than haloperidol (Table 1.7).200 The role of hydroxyl group and other features in 
haloperidol were assessed through probing the D2 receptor activity of analogues 1.95-1.98.201 In 
this series, conformationally constrained tropane agents 1.95 and 1.96 have shown high D2 affinity 
(Ki = 0.31nM and 2.3 nM, respectively) while having low selectivity between D2 and D3 receptors. 
Removal of hydroxyl group has substantial effect on DA receptor activity as demonstrated by 
analogues 1.97 and 1.98 which have reduced affinities for all DA receptors as shown in Table 1.7.  
Another library of analogues (1.99-1.104, Figure 1.16) was generated by replacing the 
butyrophenone portion of haloperidol with 3-methylindole and 3-methylbenzofuran 
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heterocycles. Compounds 1.99 and 1.100 bind at D2 receptors with high affinity (Ki = 2.3 and 5.5 
nM) with more than 50-fold (1.99) and 100-fold (1.100) D2/D3 selectivity, and were found to be 
D2 antagonists.202, 203 Compounds 1.101-1.104 possess binding affinities ranging from 6.9 to 23.9 
nM and 10- to 28-fold selectivity for D2 versus D3 receptors.203  
 
Table 1.7: Binding affinities of haloperidol analogues at DA D2, D3 and D4 receptors 
Comp. 
Ki (nM) 
D2 D3 D4 
1.13, haloperidol 1.1 5.5 12.7 
1.92 3.0 - - 
1.93 15.0 - - 
1.94 1.5 - - 
1.95 0.31 0.81 12.1 
1.96 2.3 3.2 19.1 
1.97 16.3 46.0 25.9 
1.98 254 403 17.5 
1.99 2.3 190 840 
1.100 5.5 580 567 
1.101 10 104 449 
1.102 23.9 638 319 
1.103 6.9 111 1100 
1.104 21.0 28.0 167 
 
Because the “pure D2 antagonism” engenders extrapyramidal side effects, researchers tried 
to bring about molecules having weaker D2 antagonist profile mixed with other receptor activity, 
for instance 5-HT2A, to avoid the risk of EPS.204 Some compounds with phenylpiperazine 
connected to benzotriazole have exhibited antipsychotic effects, for example, analogue 1.105 have 
low D2 receptor affinity (Ki = 52 nM) and high 5-HT2A receptor affinity (Ki = 5.1 nM). Other 
examples include, compounds 1.106-1.109 (Figure 1.17) which having benzoisoxazole and 
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benzoisothiazole attached to piperazine ring have similar profile as atypical antipsychotics i.e. 
moderate D2 and high 5-HT2A affinity (Table 1.8).205 
 




1.105 51 5.1 
1.106 25.2 0.73 
1.107 27.7 0.12 
1.108 15 0.17 
1.109 4.0 1.07 
1.18 8.0 40 
1.110 2.6 7.4 
1.111 5.0 16 
1.112 0.14 0.81 
 
Enlarging the piperazine ring in aripiprazole (1.18) provided novel analogues 1.110 and 
1.111. With improved affinity for D2 receptor (Ki = 2.6 and 5.0 nM) and moderate affinity for 
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other DA as well as serotonin receptors (Table 1.8), these compounds possess potent antipsychotic 
activity.206 Structurally distinct from traditional antipsychotics, novel compound 1.112 
(blonanserin) has a dual D2/5HT2A receptor activity (Ki = 0.14 and 0.81 nM), but has similar risk 
of EPS as haloperidol.207 
 
1.3.3.4  Dibenzazepine analogues 
Dibenzazepines are another class, different from arylpiperazines or piperidines, found in 
several antipsychotics including clozapine (1.16), olanzapine (1.113), and sertindole (1.114). 
Considerable amount efforts have been made to enhance the antipsychotic activity of this class by 
optimizing the structural requirements of dibenzazepine core.208   
 
Clozapine analogues (Figure 1.18) 1.115, 1.116, 1.17 (quetiapine), and 1.117 were 
developed as D2 antagonists for the treatment of schizophrenia. Most of these compounds except 
1.117, exert EPS and prolactin elevating effects.209 A novel series of pyrrolobenzazepines and 
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pyrrolobenzothiazepine analogues (1.118a-1.118d, 1.119a-1.119c) have been developed.210 All 
these analogues demonstrated moderate to low affinity (Ki = 3.1 nM to 79 nM) at DA D2 receptors.  
 
1.3.4  Selective D3 receptor ligands 
1.3.4.1  2-Aminotetralin derived D3 ligands 
The concept of rigidifying the free aminoethyl side chain of dopamine led to development 
of 2-aminotetralin class of DA ligands. As shown in Figure 1.19, α- and β-rotamers (1.120a, 
1.120b) of dopamine were advanced to conformationally restrained 5-hydroxy and 7-hydroxy 
analogues 1.123 and 1.124. 2-aminotetralin derivative 7-OH-DPAT (1.122) was recognized as 
selective D3 agonist and suitable radioligand ([3H] 7-OH-DPAT) to analyze the pharmacological 
characteristics and brain distribution of DA D3 receptors.211 Later on, it was found out that, R-(+)-
7-OH-DPAT binds with 74-fold higher affinity to DA D3 receptors (Ki = 0.57 nM) than the 
corresponding S-(−)-enantiomer (42.1 nM), while 5-OH derivative resulted in the opposite trend, 
wherein the S-(−)-enantiomer was 140-fold more active than the R-(−)-enantiomer.212, 213 The S-(-
)-5-OH-DPAT analogue S-(−)-N-0437 (1.123, rotigotine) is known for its potent  agonistic activity 
at DA D2 and D3 receptors and exhibited similar efficacy in Parkinson’s disease symptoms and 
restless leg syndrome.214, 215  In a similar way, the iodinated analogue (1.124) of (+)-7-OH-DPAT 
(1.122) was developed to have improved selectivity (143-fold) at D3 over D2 receptors as 




Table 1.9: Structure modification and binding affinities of aminotetralin derivatives at DA D2 and 
D3 receptors 
 




1.125a RS 5-OH H H ND 340 ND 
1.125b RS 5-OH H n-Pr 0.50 0.75 0.67 
1.125c S 5-OH n-Pr n-Pr 14 0.54 26 
1.125d RS 5-OH n-Pr 2-thienylethyl 0.06 4.0 0.015 
1.125e RS 5-OH n-Pr phenylethyl 0.5 3.4 0.15 
1.126a RS 7-OH H H 3.3 5.1 0.64 
1.126b RS 7-OH H n-Pr 3.8 0.66 5.8 
1.126c R 7-OH n-Pr n-Pr 34 0.57 60 
1.126d RS 7-OH n-Pr 2-thienylethyl 0.76 0.75 1.0 
1.126e RS 7-OH n-Pr phenylethyl ND 2.0 ND 
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SAR studies of 2-aminotetralins at DA receptors suggest that meta OH (5 or 7 position) is 
significant for DA receptor activity.162, 182, 217 Moreover, n-propyl group is most favorable in size 
as N-alkyl substituents to increase the activity at D3 receptors. The affinity of the 5-OH derivative 
at D3 receptors has greatly increased by having mono substitution on nitrogen with n-propyl (Ki 
340 nM for compound 1.125a to 0.75 nM for compound 1.125b). As shown in Table 1.9, adding 
a second n-propyl group to the nitrogen significantly improved selectivity for D3 over D2 receptors 
in both the 5-OH (1.125c, 26-fold) and 7-OH derivatives (1.126c, 60-fold).213 Replacement of one 
n-propyl group with a sterically more demanding 2-thienylethyl or phenylethyl substituent results 
in minor to moderate decreases in D3 affinity (1.125d, 1.125e, 1.126d, 1.126e), but also in a loss 
of the D3 selectivity relative to the D2 receptor.  
Further development of 2-amonitetralins as D3 ligands turned to replacing the phenolic 
OH group with metabolically stable isosteres. An exemplary prototype for this transformation is 
pramipexole (1.127), wherein an aminothiazole component replaces the catechol of 
aminotetralin.218, 219 Advancement in this direction lead to development of potent mixed D2-D3 
agonists like 1.128, ropinirole (1.129), quinelorane (1.130), quinpirole (1.131), and pergolide 
(1.132) (shown in Figure 1.20).220-223       
Replacing the catechol OH group with enyne or endiyne functionalities produced novel 
nonaromatic tetralin analogues 1.133 and 1.134 (Figure 1.21).224, 225 These compounds have high 
affinity and selectivity at D3 receptor with Ki value of 9.1 nM and 3.2 nM for 1.133 and 1.134 
respectively. Another modification, having pyrazole and pyrazolopyridine element as isostere of  
phenol, results in compounds 1.135-1.138.226, 227  The fact that S-enantiomer of these analogues 
have demonstrated higher binding affinity (6.0 nM to 0.54 nM, Table 1.10) as well as higher 
selectivity (15 to 157-fold) at D3 receptor over D2 receptor, suggests that the sp2 nitrogen of 
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pyrazole 1.136 and thiazole of pramipexole (1.127) have significant role as pharmacophoric 
element. Introducing the enyne component in to the hybrids of arylpiperazine and aminotetralin 
produced new D3 receptor ligands. Representative compounds 1.139 and 1.140 have very high 






Table 1.10: Binding affinities of pramipexole analogues at DA D2 and D3 receptors 
Comp. 
Ki (nM) 
D2 D3 D2/D3 
1.127, pramipexole 2.07 0.49 4 
1.133 110 9.1 12 
1.134 54 3.2 17 
1.135 90 6.0 15 
1.136 180 4.0 45 
1.137 85 0.54 157 
1.138 230 16 14 
1.139 40 0.21 190 
1.140 610 1.3 469 
 
1.3.4.2  4-Phenylpiperazines and analogues 
In last 20 years, 4-phenylpiperazines have been thoroughly studied regarding their usage 
as potent and selective D3 ligands. Structural congener of DA antagonist nafadotride (1.141), 
1.142 has been developed, in which basic 4-phenylpiperazine is linked to naphthamide through 
ethyl chain.228 Even though having only two carbon alkyl linker, compound 1.142 has good 
binding affinity (Ki 8 nM) and 1250-fold selectivity at D3 receptor (Table 1.11).  In this chemical 
class, numerous analogues having diverse arylamide group and alkyl linker with 2,3-
dichlorophenylpiperazine or 2-methoxyphenylpiperazine moiety have been designed and studied 
for D3 receptor activity. Extending the alkyl chain and modifying the arylamide group to 
dichlorinated phenyl ring led to identification of novel tricyclic D3 receptor antagonists 1.24 (NGB 
2904) and 1.143 (NGB 2849) with a remarkable binding profile (1.24 Ki = 1.4 nM, 1.143 Ki = 0.9 
nM) with more than 160 to 290-fold selectivity for D3 receptor (Table 1.11).229 SAR examinations 
relating fluorene and oxo-fluorene derivatives 1.144 and 1.145 show modest and nonselective 
binding profile (Ki = 19 nM at D3 and Ki = 10 nM at D2) for 1.144, while 1.145 has nanomolar 
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affinity (1.4 nM) and 64-fold selectivity at D3 receptor.230 In this chemical class, the naphthamide 
derivative 1.28, (BP 897) is a high affinity D3 receptor ligand (Ki 0.92 nM) with 66-fold selectivity 
over D2 receptor having partial agonistic effect at D3 receptors.231 Though results are not 
promising, it is one of the most studied D3 partial agonist that had entered clinical trials for the 
treatment of drug addiction.232 
Following the parent compounds 1.28 (BP 897) and 1.24 (NGB 2904), other new selective 
D3 partial agonists and antagonist have been identified (Table 1.11). Replacing the naphthamide 
aryl ring system in BP 897 with benzofuran (1.146, 1.147) or benzothiophene (1.148, 1.149) results 
in a rise in D3 binding affinity (Ki 0.23–1.5 nM). More importantly, thiophene compound 1.149, 
is found to be one of the most selective D3 antagonists (7200-fold over D2 receptor) with greater 
potency (Ki 0.5 nM) while compound 1.148 is even more potent (Ki 0.23 nM) than 1.149 and 
having D3 partial agonist activity.233 With similar approach, two new compounds (1.150, 1.151) 
were discovered having indolcarboxamide as isostere of benzamide. Both of these compounds 
were recognized as highly potent and selective D3 receptor ligands (1.150 Ki = 0.56 nM, 5500-
fold vs D2, 1.151 Ki = 0.25 nM, 640-fold vs D2).234 Other remarkable compounds acquired by 
variation of arylamide portion are 1-methoxynaphthamide analogue (1.152) and 7-
methoxybenzofuran analogue (1.153), which have subnanomolar D3 affinities (1.152 Ki = 0.60 
nM and 1.153 Ki = 0.13 nM) and significant selectivities over D2 receptors (1400-fold for 1.152 
and 2800-fold for 1.153).235 Apart from modification at phenylpiperazine moiety, replacing the 
flexible alkyl spacer moiety with rigid cyclic structures has been studied towards the identification 




Table 1.11: Structure modification and binding affinities of 4-phenylpiperazine analogues at DA 
D2 and D3 receptors 
 




1.141     3.0 0.3 10 
1.142 - - - - >10000 8.0 >1250 
1.24 
NGB 2904  




Cl Cl - 260 0.9 290 
1.144 
 
Cl Cl - 10 19 0.53 
1.145 
 




OMe H - 61 0.92 66 
1.146 
 
OMe H O 110 1.1 100 
1.147 Cl Cl O 320 1.5 210 
1.148 OMe H S 87 0.23 380 
1.149 Cl Cl S 3600 0.50 7200 
1.150 
 
Cl Cl H 3100 0.56 5500 
1.151 OMe H CN 160 0.25 640 
1.152 
 
Cl Cl - 830 0.60 1400 
1.153 
 




Introduction of the cyclohexylethyl linker in place of simple alkyl chain generated 
compounds such as 1.154 and 1.155 (Figure 1.22).236 The 2-thienylcarboxamide analogue (1.154) 
has shown noticeable D3 affinity (Ki 0.02 nM), however D3 receptor selectivity is only 30-fold 
over D2 receptor. It has antagonist functional activity at D3 receptor.  Stereochemical 
conformation change in cyclohexyl ring has prominent impact on D3 receptor activity. Cis isomer 
of 1.155 has 90-fold reduced (1.8 nM) D3 affinity compared to trans isomer. 
Tetrahydroisoquinoline derivative 1.156 has somewhat low D3 affinity, while, 1.23 (SB-277011) 
is a potent and selective D3 receptor antagonist (Ki = 4.0 nM, >60-fold selective over other DA 
receptors).237, 238 Novel D3 antagonists having pyrazolyl substituted 
thiopropyltetrahydrobenzazepine (1.157) and its congener (1.158) having fused tricyclic 
benzazepine have been developed, possessing binding affinities 1.0 nM (1.157) and 2.1 nM (1.158) 
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with improved bioavailability profile.239, 240 The similar series of “C-linked” analogues were found 
to preserve high activity and preference at D3 receptor. The representative compounds 1.159 and 
1.160 have D3 Ki values of 3.2 nM and 2.5 nM and better selectivity (>100-fold) versus D2 
receptors. In addition both compounds displayed high oral bioavailability (84%) and longer half 
life (> 6h), which make them attractive lead compounds for further assessment.241   
Having discussed broadly, variant dopaminergic receptor activities present in several core 
molecular structures can be summarized as shown in Table 1.12.  
 
Table 1.12: Summary of dopaminergic properties displayed by different chemical scaffold 
Molecular Scaffold 
D1 receptor ligand D2 receptor ligand D3 receptor ligand 
Ag. Ant. P. Ag. Ag. Ant. P. Ag. Ag. Ant. P. Ag. 




 √        
Dihydrexidine, 
dinapsoline 
√   √      
Aporphine √   √  √    
Arylpiperazine/ 
piperidine 
    √ √  √ √ 
Dibenzazepine  √   √   √  
Aminotetralin √   √   √  √ 
4-phenylpiperazine  √ √  √  √ √ √ 





1.4 Limitations with dopaminergic agents related to their clinical use 
With respect to the clinical use of D1 dopamine agonists, poor pharmacokinetic profiles 
and adverse effects of the agent are likely to limit its clinical value. Hypotension was the major 
reason for the early termination of the pilot human trial on intravenous dihydrexidine (1.5). 242 
Several compounds, with high binding affinity and selectivity for the D1 receptor had even entered 
clinical trials as anti-parkinson or anti-psychotic drugs, but were discontinued later. These ligands 
include, for example, SKF-81297 (1.7), SKF-83959 (1.8), SKF-77434 (1.9), and SKF-38393 
(1.10).243-245 A-77636 (1.6) has  rewarding and antiparkinson effects in animal studies, but its high 
potency and long duration of action causes D1 receptor downregulation and tachyphylaxis.246 In 
addition to their low intrinsic partial agonist activity, the failure of these compounds was largely 
due to poor oral bioavailability and rapid tolerance. The catechol moiety, that seems a necessary 
component of D1 agonist activity, causes major problems related to low bioavailability. Ecopipam 
(1.50a) was studied extensively for the treatment of obesity, but it faces limitations of poor oral 
bioavailability. Moreover, it lacks apparent antipsychotic effect and fails to attenuate the subjective 
effects of cocaine.247, 248 Apomorphine (1.78) is one of the clinically available dopamine agonist 
that has been shown to be markedly efficacious for patients with advanced PD.  Its oral use is 
limited by both pharmacokinetics and drug-related azotemia. Parenteral use has been limited by 
side effects including severe nausea, vomiting, orthostatic hypotension, local skin irritation, plus 
the inconvenience of the pump required for drug administration.249, 250   
In terms of D2 receptor binding, for pure D2 antagonists, there is a narrow window between 
the threshold for antipsychotic efficacy and that for side effects like EPS and hyperprolactinemia. 
To avoid these adverse effects, atypical antipsychotics are endowed with mixed receptor binding 
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profile. However, some of these agents (especially clozapine 1.16, olanzapine 1.113, and 
quetiapine 1.17) strongly promote weight gain and result in adverse metabolic effects, including 
type 2 diabetes mellitus, hyperlipidemia, and hypertension.251  
Apart from the mixed D2 and D3 agonists, pramipexole (1.127), ropinirole (1.129), and 
rotigotine (1.123), selective high-potency D3 ligands (especially D3 partial agonists and 
antagonists) entering clinical trials are rare.  SB-277011A (1.23) is a highly selective D3 receptor 
antagonist with good oral availability and significant effects in many models of drug seeking and 
reinstatement. However, this compound was not studied clinically due to in vitro metabolism 
studies in liver microsomes that demonstrated rapid metabolism by aldehyde oxidase, predicting 
low bioavailability in humans.252 In a similar way, NGB2904 (1.24), could not enter in clinical 
trials because of its limited bioavailability and poor pharmacokinetics owing to its high 
lipophilicity.75 The most studied D3 partial agonist BP-897 (1.28) had entered clinical trials for 
the treatment of drug addiction, but the results are not promising. Nevertheless, its intrinsic 
efficacy at D3 receptors has been disputed, depending on what functional assay is used for 






Chapter 2: Tetrahydroprotoberberine alkaloids and derivatives 
 
2.1 Introduction  
Tetrahydroprotoberberines (THPBs) are a class of naturally occurring tetracyclic alkaloids 
that contain an isoquinoline core, and are a subclass of the protoberberine alkaloids. The general 
structure (Figure 2.1) contains two isoquinoline rings fused in [3,2-a] fashion to generate a 
stereocenter at C14 position. More commonly ring A and ring D are substituted with oxygen 
functionalities at C2, C3, C9 and C10 positions in THP natural products, for example, (-)-
stepholidine ((-)-SPD, 2.1), (-)-tetrahydropalmatine ((-)-THP, 2.2), (-)-isocorypalmine ((-)-ICP, 
2.3), (-)-canadine or (-)-tetrahydroberberine  ((-)-THB, 2.4), (-)-scoulerine ((-)-SCL, 2.5),  (-)-
stylopine (2.6), (-)-sinactine (2.7), and (-)-cheilanthifoline (2.8). While, less common is the class 
of “pseudo-THPBs” wherein the oxygen substitutions are on C2, C3, C10 and C11 positions, for 





The tetrahydroprotoberberines, occur in at least seven plant families including 
Menispermaceae, Papaveraceae, Annonaceae, and Euphorbiaceae.255-258 THPB alkaloids are 
widely distributed in various species of genus Stephania (Menispermaceae) and genus Corydalis 
(Papaveraceae).  The genus Stephania is a large family of about 350 species, distributed in warmer 
parts of the world. The members of this family are mostly slender herbs or shrubs but rarely trees 
with peltate leaves and umbelliform flowers. In traditional medicine, these plants have been used 
for the treatment of   tuberculosis, dysentery, asthma, inflammation fever, and intestinal 
complaints.259-261   Over the last 50 years, an ample amount of work has been done on several of 
these plants because of their medicinal importance. More than 200 alkaloids including 
tetrahydroprotoberberines along with other minor constituents have been isolated from these 
plants. Different THPB alkaloids isolated from different species of genus Stephania are listed in 







Table 2.1: THPB alkaloids from genus Stephania 
Stephania species THPB alkaloid/s 
Stephania bancroftii262 (-)-THP (2.2), (-)-corydalmine (2.12) 
Stephania elegans263 (-)-N-methylcorydalmine (2.13), (-)-cyclanoline(2.14) 
Stephania glabra264, 265 
(-)-ICP (2.3), (-)-capaurine (2.15), 
(-)-corydalmine (2.12), (-)-SPD (2.1), 
(-)-corynoxidine (2.16), (-)-tetrahydrojatrorrhizine (2.17), (-)-
tetrahydropalmatrubine (2.18) 
Stephania pierrei266 




(-)-SPD (2.1), (-)-THP (2.2) 




The genus Corydalis contains about 350 species such as C. melifolia, C. ambigua, C. 
decumbens, C. ternate, C. impatiens and C. yanhusuo in the family Papaveraceae. It is most diverse 
in China, which has over 290 species, mainly distributed in the southwest regions. Up to now, 
different classes of isoquinoline alkaloids have been found in Corydalis species including 
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aporphine, protopine, protoberberine, tetrahydroprotoberberine, benzo[c]phenanthridine, 
benzylisoquinoline, and morphinan. THPB alkaloids derived from Corydalis species as well as 
from other plants are listed in detail in Table 2.2 and the structures of these alkaloids are shown in 
Figure 2.3.   
Table 2.2: THPB alkaloids found in Corydalis species and other plants 
Plant source THPB alkaloid/s 
Corydalis impatiens268 
(-)-cavidine (2.20), (-)-stylopine  (2.6) 
(-)-tetrahydrocorysamine (2.21), (-)-apocavidine (2.22), (-)-
tetrahydroepiberbeine (2.23) 
(-)-cheilanthifoline (2.24), (-)-isoapocavidine (2.25) 
Corydalis yanhusuo269 
(-)-corydaline (2.26), (-)-THP (2.2), (-)-stylopine  (2.6), (-)-
canadine (2.4) 
(-)-ICP (2.3), (-)-corypalmine or tetrahydrojatrorrhizine 
(2.17) 
Corydzlis meifolia270 
(+)-sinactine ((+)-2.7), (-)-apocavidine (2.22) 
(-)-stylopine (2.6), (+)-cavidine (2.20) 
(-)-cheilanthifoline (2.24) 
Corydalis turtschaninovii 271 
(+)-stylopine (2.6), (+)-corydaline (2.26) 
(-)-demethylcorydalmine (2.27), (-)-ICP (2.3) 
Corydalis clarkei272 caseanidine (2.28),  clarkeanidine (2.29) 
Corydalis remota273 corymotine (2.30) 
Arcangelisia gusanlung 
(Menispermaceae)274 
(-)-gusanlung E (2.31), (-)- THP (2.2) 
oxotetrahydroplamatine (2.32),  gusanlung B (2.33), 
corydaline (2.26), tetrahydrothalifendine (2.34) 
Annona spinescens 
(Annonaceae)275 
(-)-pessoine (2.35), (-)-spinosine (2.36) 










2.3 Synthesis of THPBs 
Several approaches have been adopted to synthesize tetrahydroprotoberberines. Significant 
challenges that still persist in the synthesis of the THPB scaffold, are introducing the four 
substituents ortho to each other on the future ring D and introduction of the stereocenter at C14 
position. While building the THPB scaffold, based on which ring closure takes place last as shown 
in Figure 2.4, currently available synthetic methods can be categorized as below; 
2.3.1  Via late stage closure of ring B 
 2.3.1.1  Ring B closure via bond formation between ring A and C14 carbon 
 2.3.1.2  Ring B closure via bond formation between ring A and C5 carbon 
 2.3.1.3  Ring B closure by bond formation between C6 carbon and nitrogen 
2. 3.2  Via late stage closure of ring C 
 2.3.2.1  Ring C closure via adding C8 carbon between ring D and nitrogen 
 2.3.2.2  C-N bond formation between nitrogen and C8 carbon pre-established on ring D 




2.3.1 Via late stage closure of ring B 
2.3.1.1  Ring B closure via bond formation between ring A and C14 carbon 
One strategy for late stage construction of ring B of the THPB core structure, involves 
synthesizing the benzylisoquinoline portion in the end with the formation of a bond between the 
C14 carbon and aromatic ring A.278 According to this method (shown in Scheme 2.1), o-vanillin 
(2.54) was transformed to tosyl protected aminoacid (2.55) and this acid, after chlorination 
underwent Friedel-Craft condensation to get tetrahydroisoquinoline (2.56). In compound 2.56, 
deprotection and reduction was achieved in same step using sodium bis-methoxyethoxyaluminum 
dihydride (red Al) to furnish 2.57. Linkage with phenylethyl iodide (2.58) followed by ring closure 
with concentrated HCl produced THPB scaffold in compound (2.60).  The final cyclization step 
was quite low yielding (30 %) in this synthetic method. 
 
Amongst several approaches, one of the most commonly used to form the ring A/ring B 
tetrahydroisoquinoline motif of the THPB scaffold, is via using an appropriate Bischler 
Napieralski cyclization condition.279-281 Yasuda et al. designed and synthesized (±)-THP (2.2) 
using a similar synthetic strategy wherein, the ring B was formed towards the end of synthesis via 
Bischler Napieralski condition in the cyclic amide 2.64.282 As shown in Scheme 2.2, secondary 
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amine 2.62 derived after reductive amination of primary amine 2.61 and aldehyde 2.54, was 
acylated with α-chloro-α-(methylthio)acetyl chloride and subjected to intramolecular Friedel-
Crafts cyclization in presence of stannic chloride to yield isoquinoline compound 2.64. A 
secondary amine similar to 2.62 but 
 
without the bromine atom on ring A, proved unsuccessful due to providing a mixture of desired 
isoquinoline compound and the seven-membered lactam benzazepinone 2.65 having cyclization 
on ring A. Blocking the para position of methoxy group in ring A prevented this undesirable 
cyclization and produced product 2.64 solely. The Bischler-Napieralski cyclization of 2.64 





2.3.1.2  Ring B closure via bond formation between ring A and C5 carbon 
 
 
Another connectivity that has been utilized to form ring B, is through a bond formation 
between C-5 carbon and C-5α carbon; the Pomeranz-Fritsch reaction remained the prominent one 
to serve this purpose.  Using this strategy (shown in Scheme 2.3), (-)-THP (2.2) was synthesized 
from  (R)-1-amino-2-methoxymethylpyrrolidine (RAMP) hydrazone 2.66 and 2,3-dimethoxy-6-
methylbenzamide 2.67.283 In this synthesis, deprotonation of 2.67 was achieved by using the 
mixture of tetramethylethylenediamine (TMEDA) and sec-butyllithium. Nucleophilic addition of 
lithiated 2-methylbenzamide to the CN double bond of hydrazone (R)-2.66 from less hindered face 
followed by cyclization produced (S,R)-2.68. Chiral auxiliary on nitrogen was removed by using 
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BH3·THF followed by HCl with concomitant reduction of carbonyl group to prepare isoquinoline 
compound (S)-2.69. Pomeranz-Fritsch precursor 2.70 was obtained by addition of two carbon 
chain of bromoacetaldehyde diethyl acetal using SN2 condition. Pomeranz-Fritsch cyclization was 
carried out using the mixture of conc. HCl and acetone to render intermediate 2.71 as a 
diastereomeric mixture which was subjected to dehydration to afford (-)-THP (2.2) with 98% ee. 
Transformation from (S)-2.69 to (-)-THP (2.2) was also effected via the Pummerer reaction using 
2.72 (Figure 2.5), but after the cyclization, reductive desulfurization of the intermediate was a low 
yielding (30%) step. On the other hand, Friedel-Crafts cyclization conditions were not effective to 
induce the cyclization in compound 2.73 (Figure 2.5) to provide (-)-THP (2.2).283 
 
2.3.1.3  Ring B closure by bond formation between C6 carbon and nitrogen  
An alternate plan to construct ring B of the THPB scaffold is via forming the C-N bond in 
the final stage of the synthesis as demonstrated by Yang et al to synthesize (-)-SPD (Scheme 
2.2).284 This method to synthesize (-)-SPD (2.1) exploits a similar approach to install the chiral 
center as adopted by Enders to synthesize (-)-THP (2.2) (Scheme 2.3), i.e. chiral auxiliary aided 
nucleophilic addition of a tetrasubstituted future ring D moiety to an appropriate imine (2.66 in the 
case of (-)-THP and 2.79 in the case of (-)-SPD). As shown in Scheme 2.4, primary alcohol 2.75 
derived from substituted phenylacetic acid, was brominated and protected to grant 2.76. Lithium-
halogen exchange followed by reaction with DMF introduced the aldehyde group in compound 
2.77. After condensation with chiral sulfinylamide 2.65, aldehyde 2.77 was transformed to 
sulfinimine 2.79. Nucleophilic addition of lithiated tetrasubstituted benzonitrile 2.80 to sulfinimine 
2.79 followed by sequential steps of concomitant removal of silyl group and N-sulfinyl auxiliary, 
and hydrolysis of nitrile group produced 2.83. In final steps, tosylation of hydroxyl group rendered 
57 
 
cyclization of ring B which was followed by reduction and deprotection to procure (-)-SPD (2.1). 
Apart from having a lengthy procedure to synthesize 2.66 (5 steps) and 2.80 (6 steps) as well as 
their further transformation to (-)-SPD (2.1) (6 steps), the nucleophilic addition step was low 





2.3.2  Via late stage closure of ring C 
2.3.2.1  Ring C closure via adding C8 carbon between ring D and nitrogen 
The most commonly used approach to synthesize the THPB scaffold is via an 
intramolecular Mannich cyclization of a relevant benzyltetrahydroisoquinoline with 
formaldehyde. The major complication in this method is regiochemical control in the closure of 
ring C and getting a mixture of para and ortho cyclized products or exclusively giving the former 
product. This approach is the most widely utilized route to synthesize “pseudo-THPBs” in a 
racemic and enantioselective manner.279, 280, 285 Using this approach, Battersby et al. synthesized (-
)-SCL (2.5) and coreximine (2.85) (Scheme 2.5) wherein, benzyltetrahydroisoquinoline (2.84) 
bearing 3-hydroxy substituted benzyl group underwent Mannich condensation to produce a 2:1 
mixture of THPBs scoulerine (2.5) and coreximine (2.85).286 Varying the pH gave a higher yield 






To tackle this problem, a strategy was used wherein compound 2.84 was brominated to 
block the para position (2.86) for Pictet-Spengler cyclization to afford the single product 2.87 and 
it was transformed to (-)-SCL (2.5) by debromination. The disadvantage in this method apart from 
adding two more steps in the synthesis, was that the cyclization step was low yielding, most likely 
due to ring deactivation by halogen atom.288 
Another similar approach in the synthesis of 9,10 substituted THPBs is to use an 
preestablished ipso directing group in ring D. Schore et al. synthesized five different THPB alkoids 
using a trimethylsilyl moiety as an ipso-directing ring closure functionality.289 As shown in 
Scheme 2.6, aryl silyl agent 2.90, which mimics the substitution patern of ring D of THPB, was 
synthesized from tertiary amine 2.89 by introducing a TMS group into the benzene ring with the 
aid of n-BuLi. Subsequent synthetic transformation lead to benzyltetrahydroisoquinoline 2.92 with 
ipso-directing silyl substituted benzyl moiety. The Pictet-Spengler cyclization was accomplished 
using formaldehyde in acidic condition to produce (-)-THP (2.2) in 46% overall yield and 55% ee. 
In the case of (-)-sinactine (2.7) synthesis, the final cyclization no longer displayed regioselectivity 
and the product obtained was almost a 1:1 mixture of both (-)-sinactine (2.7) and 2.94. That 
indicates the ineffectiveness of this method when having strongly activating substituent like 
methylenedioxy group on ring D. 
In a similar manner, Pictet-Spengler cyclization involving the participation of the sulfinyl 
group as an ipso-director in the electrophilic aromatic substitution reaction, opened new synthesis 
of THPBs (shown in Scheme 2.7).290 Using this method, the synthesis of optically pure (-)-THP 
(2.2) and (-)-canadine (2.4) was performed with overall isolated yields of 33% and 34%, 
respectively. This synthesis was commenced by reaction of ortho-sulfinyl benzyl carbanion 
derived from 2.95 and N-sulfinylimines 2.96 and 2.97 to cater intermediates 2.98 and 2.99. 
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Subsequent sulfinyl- directed microwave assisted Pictet-Spengler cyclization produced (-)-THP 






Kroutil and group members came up with a unique approach in the synthesis of THPBs. 
As shown in Scheme 2.8, the biocatalytic property of berberine bridge enzyme (BBE) for oxidative 
C-C bond formation was employed to synthesize steroselectively (-)-SCL (2.5) from 
benzylisoquinoline (2.100).291 This transformation takes place via oxidative C-H activation of the 




2.3.2.2 C-N bond formation between nitrogen and C8 carbon pre-established on ring D 
To construct the continuously tetrasubstituted ring D is the most eminent problem towards 
the synthesis of a 9,10 substituted THPB scaffold. Having a tetrasubstituted pattern on ring D and 
closure of ring C during the late stage of synthesis is a common approach taken up in many 
synthesis of THPB scaffold, especially for (-)-SPD (2.1).293-295 Several examples of 
tetrasubstituted intermediates (shown in Figure 2.6) have been employed as a surrogate to ring D 





By executing a similar strategy, Yang and group members reported the first 
enantioselective synthesis of (-)-SPD (2.1) (Scheme 2.9).293 The key intermediate lactone (2.102) 
was synthesized from the substituted phenylacetic acid (2.101) through hydroxymethylation 
directed by phenylboronic acid in the presence of paraformaldehyde. Aminolysis of the lactone 
with substituted phenylethylamine produced amide (2.103). It was eventually transformed to (-)-
SPD (2.1) employing the key steps of Bischler-Napieralski cyclization, Noyori’s asymmetric 
reduction followed by ring C closure via chlorination of primary alcohol. This route seemed 
promising to apply further for the synthesis of diverse THPB compounds to study their biological 
activities. However, transformation from phenylacetic acid (2.101) to lactone (2.102) was 





Recently, the same group synthesized (-)-SPD (2.1) using bromo compound 2.109 which 
was derived from chiral auxiliary protected amine 2.108 and bromo substituted phenylacetic acid 
2.107 (Scheme 2.10).294 Serving as an alternate of lactone 2.102, tetrasubstituted phenylacetic  
 
acid 2.107 was employed in this synthesis to construct the ring D of (-)-SPD (2.1).  Dihydroxy 
benzaldehyde 2.104 was selectively protected with an isopropyl group, which was followed by 
ortho bromination to produce tetrasubstituted benzaldehyde 2.105. Sequential steps of reduction 
of aldehyde, chlorination of alcohol, cyanation, and hydrolysis of intermediate nitrile compound 
produced acid 2.107 from aldehyde 2.105. Acid 2.107 was coupled with chiral auxiliary protected 
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secondary amine 2.108 to afford amide 2.109. A sequence of reactions including Bischler-
Napieralski cyclization and reduction installed the chiral center in compound 2.110. The C-8 
carbon of ring D was introduced in compound 2.110 via lithium-halogen exchange followed by 
treatment with methyl chloroformate to provide compound 2.111. Removal of the chiral auxiliary 
proceeded with simultaneous closure of ring C to present the tetracyclic scaffold of compound 
2.112 which was further transformed to (-)-SPD (2.1) via reduction of the carbonyl group and 
deprotection of the phenolic hydroxyl groups. 
 
Engaging a similar strategy to synthesize (-)-THP (2.2) (as shown in Scheme 2.11), to 
furnish ring D, Meyers et al. employed carboethoxy compound 2.114 derived from tertiary amine 
2.113.295 Transformation from 2.113 to 2.114 was carried out via metalation followed by addition 
of a formyl group to afford intermediate alcohol which was protected with TBS group. Chiral 
formamidine 2.117 was synthesized from isoquinoline 2.115 by transamination with a valine 
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derivative 2.116. In this route, the crucial step involves addition of the carbanion of 2.114   to 
chiral formamidine 2.117 to furnish intermediate 2.118, which was advanced to compound 2.119 
via removal of the formamidine auxiliary. Deprotection of the silyl group was accompanied by 
ring closure to yield (-)-THP (2.2). Carbanions having an ortho carbonyl substituent in place of a 
methyl silyl ether in compound 2.114 were tried first, but owing to an unexplainable problem of 
racemization of the chiral center, this was switched to compound 2.114.   
  
2.3.2.3  Ring C closure via bond formation between ring D and C13 carbon 
Having stereocenter established in isoquinoline moiety and addition of ring D part followed 
by closing the ring C at C13 carbon is an interesting way to construct THPB core. Pyane employed 
chiral β-amino sulfoxide (2.120), conveniently prepared by conjugate addition of amine to chiral 
vinyl sulfoxide296, 297, to synthesize (+)-THP (2.2).298 Chiral aminosulfoxide 2.120 was condensed 
with aldehyde to provide intermediate compound 2.12, which was subjected to an intramolecular 
Pummerer reaction to grant a single diastereomer 2.122. Reductive desulfurization in compound 
2.122 provided (+)-THP (2.2).  
Very recently, Mhaske et al. synthesized various THPB  and 8-oxoprotoberberine alkaloids 
via a unique intramolecular Pd-catalyzed tandem oxidative olefin amidation/C−H activation.299  




amine and dimethoxy benzoic acid) was iodinated using iodine and silver triflate to afford 
iodoamide 2.124. A vinyl unit was inserted into compound 2.124 via Stille coupling to yield 
vinylamide 2.125. After optimizing reaction conditions, C−N and C−C bonds were formed in a 
single step by intramolecular tandem amidation/C−H activation sequence to produce 8-




Owing to their widespread occurrence in nature, diverse biological activity, and unique chemical 
properties, THPB alkaloids have become interesting targets for organic synthesis. In the past two 
decades a large number of chiral and racemic synthetic methods have been reported for the 
synthesis of THPB scaffold. General approaches adopted to synthesize THPB alkaloids include, 
Bischler-Napieralski cyclization/simple reduction or catalytic hydrogenation (for enantioselective 
methodologies) followed by either Mannich type condensation or ipso directing strategies to close 
the second ring. Newer trends have been based on diastereoselective syntheses using chiral 
auxiliaries, annexed either to or around the nitrogen atom. In this context, the addition of carbon 
nucleophile from a tetrasubstituted benzyl moiety to the isoquinoline C=N double bond has been 
the most often explored strategy.  
Although THPB compounds are readily synthesized in a racemic manner, still there is a 
demand to develop simple and efficient methods that would be applicable to the preparation of 
enantiopure compounds. Generally the available methodologies bear various limitations such as: 
e.g., multistep procedures, lack of diversity, moderate to poor yields, unsatisfactory regio- and 
stereo-selectivity, etc. Therefore, exploration of more efficient and simpler synthetic strategies still 
need to be undertaken. 
 
2.4 Biological activities of tetrahydroprotoberberine alkaloids 
Plants containing THPBs alkaloids have long been used traditionally in China, India, Japan 
and other Eastern Asian countries as analgesics, anti-inflammatory, anti-infectious, anti-allergic, 
anxiolytic, anti-venom, anti-arrhythmic, and in the treatment of rheumatism, gastric issues, and 
duodenal ulcers.267, 269, 271, 300 Major attention has been developed towards the pharmacological 
importance of THPB alkaloids (-)-SPD (2.1), (-)-THP (2.2), and (-)-govadine (2.11) have been 
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studied for schizophrenia and psychostimulant drug abuse because of their dopamine receptor 
pharmacological profiles.  
 
2.4.1 CNS activities of THPB alkaloids 
In functional assays, (-)-SPD (2.1) has been identified as an agonist at the dopamine D1 
receptor and as an antagonist at the dopamine D2 and D3 receptor.301, 302 Also, the online database 
of the National Institute of Mental Health (NIMH), Psychoactive Drug Screening Program (PDSP) 
revealed (-)-SPD (2.1) to have high affinity mostly for dopaminergic receptors (Ki value for D1 = 
5.9, D2 = 974.3, D3 = 30.1, D4 = 3748, D5 = 4.4 nM). (-)-SPD (2.1) significantly potentiated the 
therapeutic effects of typical antipsychotic drugs (phenothiazenes or butyrophenones) and 
markedly reduced the EPS induced by these drugs. Additionally, (-)-SPD (2.1) alone also exhibited 
a significant antipsychotic effect.303 (-)-SPD (2.1) was demonstrated to be superior to perphenazine 
(2.1) in antipsychotic efficacy and treating the negative symptoms, and, unlike perphenazine, (-)-
SPD induced no extrapyramidal symptoms.304 The effects of (-)-SPD (2.1) in increasing forelimb 
and hindlimb retraction time (FRT and HRT) in the paw test and in reversing the apomorphine 
induced disruption of prepulse inhibition was investigated.305 In the paw test, all antipsychotics 
increase the HRT and only the typical antipsychotics affect the FRT allowing a differentiation 
between typical and atypical antipsychotics. The data show that (-)-SPD (2.1) behaved like an 
antipsychotic with more similarity to clozapine. In the paw test, (-)-SPD (2.1) dose dependently 
increased the HRT, while it only increased the FRT at the highest dose tested.305 Since 
theoretically, an agent with partial D1 receptor agonistic and D3 antagonistic properties may 
reduce drug abuse liability, the potential role of THPBs in the treatment of drug abuse has recently 
received greater attention. Clinical trial and animal studies demonstrated that THPBs including (-
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)- SPD (2.1), (-)-ICP (2.3), and (-)-THP (2.2) are potential candidates for the treatment of drug 
abuse. A study in animals showed that (-)-SPD (2.1) inhibits acquisition, maintenance, and re-
acquisition of morphine conditioned place preference (CPP).306 The effect of pretreatment with (-
)-SPD (2.1) on heroin-seeking behavior induced by heroin priming was investigated. Pretreatment 
with (-)-SPD (2.1) inhibited the heroin-induced reinstatement of heroin-seeking behavior. 
Importantly, (-)-SPD (2.1) did not affect locomotion, indicating that the observed effects of (-)-
SPD (2.1) on reinstatement are not the result of motor impairments. 307 In a pharmacological study 
in mice, (-)-SPD (2.1) was shown to increase dose-dependently c-Fos gene expression in neurons 
of the ventrolateral preoptic area, a sleep center in the anterior hypothalamus. That indicates, (-)-
SPD initiates and maintains non rapid eye movement sleep with activation of the sleep center, 
suggesting its potential application for the treatment of insomnia.308 In Parkinson’s disease rat 
model,  (-)-SPD (2.1) was demonstrated to attenuate the development and expression of L-DOPA 
induced dyskinesia.309  
In various investigations, the effects of (-)-THP (2.2) on cocaine self-administration and 
cocaine-induced reinstatement have exhibited promising results towards the treatment of cocaine 
addiction.310, 311 (±)-THP (2.2) possesses anxiolytic effects avoiding sedation and myorelaxation 
when administrated orally to mice at low dose regime. Results from the elevated plus-maze show 
that (±)-THP (2.2)  increases the percentage of entries and time spent by rats in open arms to basal 
levels in this model for anxiety.312 The antinociceptive effect of (±)-THP (2.2) was evaluated using 
different pain models including formalin-induced nociception, writhing test and bee venom-
induced hyperalgesia. Results suggested that (±)-THP (2.2)  more effectively inhibited visceral 
nociception and hyperalgesia than persistent nociception.313, 314  
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Effect of (-)-ICP (2.3) on cocaine addiction was evaluated using animal models. 
Administration of (-)-ICP (2.3) before cocaine reduced cocaine-induced locomotor sensitization 
and conditioned place preference (CPP).315 Pseudo-THPB alkaloid (-)-govadine (2.11) exhibited 
antipsychotic efficacy and rodent models of positive symptoms through antagonism of DA-D2 
receptors.316 (-)-govadine (2.11) demonstrated its ability to improve performance of the 
dizocilpine-induced impairment in the paired associate learning task. This behavioral effect 
correlates the ability of (-)-govadine to its antipsychotic potential.317  
 
2.4.2 Non-CNS activities of THPB alkaloids 
Investigations also suggest that (-)-SPD (2.1) possesses pronounced hypotensive effect 
mediated through α1-adrenoceptor inhibition.318 In vitro, (-)-SPD (2.1) inhibited lipid peroxidation 
and scavenged hydroxyl free radicals due to its free hydroxyl group as well as other properties.319 
(-)-SPD (2.1) improved cell differentiation, contact suppression, and expression of the tumour 
suppressor gene protein (p53), and it inhibited cell growth, colony formation, and expression of 
proto-oncogenes (C-myc bcl-2).320 Lin and group members studied the anti-hypertensive effects 
of (±)-THP (2.2)  and found it to act via 5-HT2A and/or D2 receptor antagonism.321 In a similar 
study, (-)-THP (2.2), (-)-THB (2.4)  and (-)-SPD (2.1) showed anti-ischemia and cardio-protective 
property, acting directly on cardiomyocytes.322 The anti-inflammatory effect of (-)-THP (2.2) was 
studied in vitro using human monocytic cell line. It was found that (-)-THP (2.2) inhibited 
lipopolysaccharide (LPS) induced interleukin-8 (IL-8) production in a dose-dependent manner via 
mitogen activated protein kinase (MAPK) inhibition.323 
Significant inhibition of spore germination was seen against several phytopathogenic fungi 
by (-)-ICP (2.3) and (-)-corydalmine (2.12).324 Recently, corydalmine (2.12), and other THPB 
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alkaloids were demonstrated to have antibacterial activity toward methicillin-resistant 
Staphylococcus aureus.325 Lee and co-workers isolated various THPB alkaloids from C. 
turtschaninovii and studied their inhibition activity against low density lipoprotein oxidation. (-)-
demethylcorydalmine (2.27) and (+)-stylopine (2.6) were the most active alkaloids with IC50 
values of 2.1 and 2.0 µM.326 Antiplasmodial activity of (-)-SCL (2.5) was studied along with other 
alkaloids isolated from C. dubia and it has shown remarkable activity against TM4/8.2 (transgenic 
plasmodium) strain with IC50 values of 1.78 µg ml-1.327 In a similar manner coraximine (2.85) 
exhibited antimalarial activity against P.falciparum.328 Experimental results obtained in a study 
demonstrate that (±)-canadine (2.4) is effective in anti-lipid peroxide production and acts as an 
antioxidant agent.329 (-)-canadine (2.4) also showed more than 80% inhibition in platelet 
aggregation induced by different platelet aggregating agents.330 Many different THPB alkaloids 
including (-)-THP (2.2), (-)-ICP (2.3), (-)-canadine (2.4), and (-)-stylopine (2.6) have displayed 
chemopreventive and anti-tumor activity.331 
 
2.5 Structure-activity relationship studies at dopamine receptors 
Since THPBs and dopamine share some structural similarities, various natural and 
synthetic derivatives of THPBs have been studied for their binding affinity at dopamine receptors, 
more specifically at DA D1 and DA D2 receptors.  
In one study, the influence of the trisubstitution with methoxy, hydroxyl or chloro at the 2, 
3- and 9 or 11 positions in THPB was evaluated for dopaminergic activity. Eleven trisubstituted 
analogues of THPB (2.72–2.82, shown in Figure 2.7) were synthesized and tested for their binding 
affinity (Table 2.3) at DA D1 and D2 receptors.332 Results of this SAR study indicate that protected 
phenolic hydroxyls showed a lower affinity for DA D1 and D2 receptors than their corresponding 
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homologues with free hydroxyl groups (see 2.72 vs 2.73, 2.74 vs 2.75, 2.77 vs 2.79, 2.78 vs 2.80 
in Table 2.3). Introduction of the chlorine atom in to ring A of THPBs increases affinity for both 
D1 and D2 receptors (2.73 vs 2.79, Table 2.3). A decrease in affinity  
 





2.72 3-Cl-2,11-diMeO 1.80 2.05 1.1 
2.73 3-Cl-2,11-diOH 0.10 0.19 1.9 
2.74 2,3-diBnO-11-MeO 40.60 40.87 1.0 
2.75 2,3-diOH-11-MeO 1.10 0.08 0.07 
2.76 2,3-OCH2O-11-MeO 2.40 1.33 0.5 
2.77 2,3,11-triMeO 4.31 8.54 2.0 
2.78 2,3,9-triMeO 3.923 0.39 0.1 
2.79 2,3,11-triOH 2.96 0.40 0.1 
2.80 2,3,9-triOH 3.78 0.09 0.02 
2.81 2,3-OCH2O-11-OH 33.00 7.51 0.2 
2.82 2,3-OCH2O-9-OH 0.34 0.04 1.1 
 
at the D2 receptor was observed in 2.76c and 2.81e after the introduction of a methylenedioxy 
group at 2, 3 positions. Compounds 2.73b and 2.82f in this series displayed the highest affinity for 
73 
 
both DA D1 and D2 receptors. This study demonstrated that affinity for DA receptors was higher 
with analogues having hydroxyl group in position 9 than in position 11 (2.82 versus 2.81).    
In two sets of SAR studies, Hong Liu and group members designed and synthesized a series 
of novel as well as known tetrahydroprotoberberine compounds (representative novel analogues 
2.83-2.89 are shown in Figure 2.8) by introducing various substituents (such as methyl, methoxy, 
hydroxymethyl, and methylenedioxy groups) at different positions of the THPB 
pharmacophore.333, 334. The binding affinity data for these analogues at dopamine D1 and D2 
receptors is summarized in Table 2.4.    
 
Tetra-alkoxy analogues ((-)- THP 2.2 and (-)-canadine 2.4) exhibited reduced binding 
affinity for both DA D1 (Ki = 231 nM and 66 nM respectively) and D2 receptors (Ki = >5000 nM 
and 119 nM respectively).  Monohydroxy compound 2.3 ((-)-ICP) shows higher selectivity than 
parent compound (-)-SPD (2.1) at D1 receptor over D2. Changing the C9, C10 di-methoxy 
substitution in ring D of (-)-ICP (2.3) to C9, C11 di-methoxy produced highly D1 receptor selective 
and potent compound 2.83. In addition, a congener of 2.83, compound 2.84 with C10-C11 
methylenedioxy substitution possess similar high binding affinity at the D1 and D2 receptors (4.2 
nM for D1 receptor and 32.1 nM for D2 receptor) with (-)-ICP (2.3). However, analogue 2.84 
shows functional antagonism at DA D1 receptor in contrast to (-)-ICP (2.3), which is a D1 partial 
agonist.   
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Table 2.4: Structures of and binding affinity data for THPB analogues 
 




2.1 H OH CH3O CH3O OH H 3.4 11 3.2 
2.2 H CH3O CH3O CH3O CH3O H 231 >5000 >21.6 
2.4 H OCH2O  CH3O CH3O H 66 119 1.8 
2.3 H OH CH3O CH3O CH3O H 4.5 91 20.2 
2.83 H OH CH3O CH3O H CH3O 2.5 - - 
2.84 H OH CH3O H OCH2O  4.2 32 7.6 
2.34 H OCH2O  CH3O OH H 6.3 145 23.0 
2.85 H OCH2CH2  CH3O OH H 7.5 - - 
2.18 H CH3O CH3O OH CH3O H 443 - - 
2.86 H OCH2O  OH CH3O H 60 >5000 >83 
2.17 H CH3O OH CH3O CH3O H 310 - - 
2.87 H CH3O OH OH CH3O H 530 >5000 >9.4 









These results suggest that the hydroxyl group at C2 may be essential to maintain potency 
at the D1 and D2 receptors. Compounds 2.34 and 2.85 showed a similar high binding affinity (Ki 
= 6.3 and 7.5 nM) and selectivity to the D1 receptor, indicating that apart from the C2 hydroxyl, 
the C10 hydroxyl group is also crucial for D1 receptor activity. Compounds 2.18 and 2.86 
containing only a hydroxyl group at C9 showed reduced binding affinity for the D1 receptor with 
Ki values of 334 and 60 nM. Compound 2.17 having a hydroxyl group at C3 retained a moderate 
affinity for the D1 receptor, with a Ki value of 310 nM. On the contrary, 2.87 containing two 
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hydroxyl groups at C3 and C9 with a Ki value of 530 nM were less potent than 2.17 at the D1 
receptor. Compound 2.88 and 2.89 in which two phenolic hydroxy groups on the A- and D-rings 
were removed, exhibited high D1 receptor binding affinity (Ki = 8.0 nM and 23 nM) and 
selectivity. Functional assays revealed that both these analogues were full D1 receptor antagonists.  
Similar to the naturally derived alkaloids, R enantiomer of all these compounds showed 
remarkably weakened binding affinity to the dopamine receptors, indicating that the C14-S 
configuration in THPBs is an important determinant of receptor binding affinity. 
As shown in Figure 2.9 and explained below, the previous SAR study of THPB scaffold at 
DA receptor can be summarized as below; 
 
• Either C2 or C10 hydroxyl group is necessary for dopamine D1 receptor activity (example 
2.3, 2.34, and 2.85). This indicates, the hydrogen bonding donor (OH) at C2 and C10 is a 
determining factor to D1 receptor binding. 
• Antagonist activity shown by compound 2.83, 2.88 and 2.89 reveals that 2, 3, 9, 10 
tetrasubstituted pattern is crucial for D1 agonistic activity 
• Reduced affinity of compound 2.17, 2.18, 2.86, and 2.87  signifies the importance of C3 
and C9 alkoxy group for the dopamine receptor activity  
• S configuration of the C14 position in the THPB skeleton is a critical factor determining 







Chapter 3: Synthesis and evaluation of stepholidine and its analogues at 
dopamine receptors  
 
3.1 Background 
(-)-SPD (2.1) shows a strong preference for binding to dopamine receptors as revealed by 
data from the Psychoactive Drug Screening Program (PDSP) and by many previous studies 
(discussed in chapter 2). (-)-SPD (2.1) has high affinity for D1 and D3 receptors (Ki = 5.9 and 30 
nM respectively) and moderate affinity for the D2 receptor (Ki = 974 nM).335 (-)-SPD (2.1) has 
been studied primarily due to its multi-receptor targeted profile.302, 336-338 In this regard, its 
interesting pharmacological profile has led to a number of animal studies where it has shown 
potential as an antipsychotic and as an anti-drug abuse agent.  
The THPB scaffold of (-)-SPD (2.1), which is characterized by a 2,3,9,10 tetra-substituted 
pattern and the presence of two phenol groups, makes it a distinct THPB scaffold.339 Although 
several syntheses of THPBs have been reported (discussed in chapter 2, section 2.3), an efficient, 
high yielding, and concise synthesis of (-)-SPD (2.1) is yet to emerge. Moreover, the extremely 
low content (~0.1%) of this compound in natural sources265 and the need for large amounts of the 
compound for further pharmacological research necessitate its total synthesis.  
Though having an interesting novel, pharmacological profile, there is a need to further 
optimize the potency of (-)-SPD (2.1) at dopamine receptors. In that regard compounds with <10 
nM affinity at D1 and D3 receptors and with higher degrees of selectivity versus D2 receptor, will 




Until now, limited SAR data is available for this THPB scaffold332-334, 337 and it is restricted to 
structural modifications in the core pharmacore including:  
I. Switching the position of phenolic hydroxyl group and methoxy moiety in aromatic 
rings  
II. Introducing methoxy, methylenedioxy and benzyloxy substituents  
III. Insertion of a halogen atom in the ring A  
IV. Effect of mono, di and tri hydroxy substitution on binding affinity  
Additionally, all SAR studies have been performed (discussed in chapter 2, section 2.5) at DA 
D1 and D2 receptors, no SAR data is available at the D3 receptor. Deficiency of enough structure 
activity relationship (SAR) data at DA D1 and D3 receptor for this THPB scaffold has to be filled.  
The pharmacokinetics of (-)-SPD (2.1) and its delivery to the brain was studied in rats.340 Key 
findings in this study reveal that although (-)-SPD (2.1) exhibits good brain penetration, it has a 
very poor oral bioavailability (< 2%) because of extensive pre-systemic metabolism. Findings 
suggest that rapid and extensive pre-systemic metabolism of (-)-SPD (2.1), predominantly by O-
glucuronidation and O-sulphation of phenolic hydroxyl groups restricts its favorable biological 
profile.341  
Our work addresses the above mentioned shortcomings via; 
I. Developing a practical and versatile synthetic methodology which can provide SPD 
(2.1)  and its analogues in larger amount for further pharmacological studies 
II. Synthesizing and studying binding affinity at dopamine receptors of diversely 
substituted C3 and C10 THPB analogues  
III. Studying the effect of various substitutions on THPB scaffold on metabolic stability 
against hepatic enzymes 
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Our efforts and the results we have obtained are discussed in this chapter.  
3.2 Synthesis of (±)-SPD  
3.2.1 Retrosynthesis 
For the synthesis of (±)-SPD (2.1), late stage construction of the berberine bridge (ring C) 
via a Mannich-type reaction is challenging because there is a substituent ortho (i.e. the methoxy 
group) to the site of ring closure.  In our retrosynthetic analysis (as shown in Figure 3.1), we 
visualized constructing the berberine bridge in the final stage of synthesis. We planned to 
synthesize (±)-SPD (2.1) from compound 3.1, which has previously established berberine bridge 
carbon on ring D that can be utilized to close ring C. We envisaged that the tetrahydroisoquinoline 
moiety in compound 3.1 could be prepared from amide intermediate 3.2 via Bischler-Napieralski 
cyclization/reduction conditions. Amide intermediate 3.2 is derivable from acid 3.3 (via amide 
coupling with the corresponding amine). Compound 3.3, we reasoned would serve as an easily 
reachable synthetic surrogate for the ring D of SPD (2.1). The acid 3.3 would be prepared from 




3.2.2  Synthesis  
Commercially available bromo cresol 3.5 was protected as the ethoxymethyl ether by 
reaction with chloromethoxyethane affording 3.6. Thereafter reaction of 3.6 with Lithium 
diisoproylamide in the presence of dimethylmalonate gave diester 3.7.342, 343 This reaction 
presumably proceeds via nucleophilic attack of malonate anion on benzyne intermediate generated 
from dehydrobromination of 3.6.344 Selective hydrolysis of the aliphatic ester group was 
accomplished with K2CO3 in refluxing H2O/MeOH to give acid 3.8. This acid was coupled to 
readily available amine 3.9 with 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI) to 
provide key amide precursor 3.10. Bischler-Napieralski cyclization on amide 3.10 proved to be 
successful with POCl3 as dehydrating agent and acetonitrile as solvent.  
This cyclization was accompanied by simultaneous removal of the ethoxymethyl 
protecting group. Other dehydrating conditions (shown in Table 3.1) and solvents 
(dichloromethane or toluene) were tried but gave inferior yields of imine product. Bischler-
Napieralski cyclization was followed by immediate reduction (due to instability of the intermediate 
imines of this type) with NaBH4 to afford the 8-oxotetrahydroprotoberberine 3.11. Reduction of 
the 8- oxo group of 3.11 with LAH provided an intermediate tertiary amine, which was 
subsequently heated with concentrated HCl, thus effecting debenzylation to give (±)-SPD (2.1). 
Thus we accomplished synthesis of (±)-SPD (2.1) with overall yield of 30% over 8 synthetic steps 










Solvent Time Temperature 
PCl5 (1.5 eq.) DCM 10 h 0  ̊ C – rt No reaction 
P2O5 (10 eq.) DCM 10 h rt No reaction 
POCl3
 
(neat) POCl3 10 min 





(6 eq.) Toluene 2 h 100   ̊C 58% 
POCl3 (6 eq.) CH3CN 3 h 60  ̊ C 82% 
 
3.3 Enantioselective synthesis of (-)-SPD 
3.3.1 Retrosynthesis  
In this section we describe our attempt to develop a practical route to synthesize (-)-SPD 
(2.1). It is not restricted to only synthesis of (-)-SPD (2.1); the main consideration behind our aim 
is to develop a versatile synthetic method that can be extended to synthesize optically pure C3 
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analogues of (-)-SPD (2.1). Following a similar approach employed in our racemic synthesis of 
(±)-SPD (2.1) (section 3.2), we planned to synthesize (-)-SPD (2.1) from compound 3.11, which 
has a previously established berberine bridge carbon on ring D (Figure 3.2). Compound 3.11 can 
be synthesized from amide ester 3.10 via Bischler-Napieralski cyclization followed by Noyori’s 
asymmetric hydrogenation of the intermediate imine.345 Amide ester 3.10 can be synthesized from 
acid 3.8 and amine 3.9 as shown in Scheme 3.1. 
 
3.3.2  Synthesis  
3.3.2.1  Unsuccessful attempts via ester 3.10 
Bischler-Napieralski cyclization of amide 3.10 was achieved using POCl3 to give 
intermediate imine 3.12 (shown in Scheme 3.2). The imine formed was then subjected to Noyori’s 
asymmetric hydrogenation conditions. To our surprise this did not yield the desired chiral 
tetrahydroisoquinoline 3.13. Instead the 8-oxoprotoberberine 3.14 was produced. One possible 
cause for failure of the reduction is due to formation (and subsequent isomerization) of an acyl 
iminium ion formed from reaction of the imine nitrogen (from Bischler-Napieralski reaction) with 
the aryl ester group. Another possibility is that when the imine derived from 3.10 (i.e., compound 
3.12) is subjected to Noyori’s reduction conditions, isomerization of the imine to an enamine 
precedes the cyclization of ring C. We found that treatment of 3.12 with triethylamine (the base 
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used in the Noyori’s reduction) gives 3.14. Presumably, the isomerization/cyclization steps occur 




Nevertheless, through this attempt to achieve an enantioselective synthesis of (-)-SPD 
(2.1), it was recognized that naturally occurring 8-oxoprotoberberines could be synthesized by 
variations of this method. Previous syntheses of the 8-oxoprotoberberine skeleton have required 
several synthetic steps and/or suffer from low yielding steps.346-349 Thus to demonstrate the 
pliability of the route, compound 3.14 was transformed to the natural product oxypalmatine (3.15, 
Scheme 3.3) by removal of the C2 benzyl group followed by Williamson ether methylation. Insofar 
as synthesis of oxypalmatine is concerned, this method is comparable to published methods in both 
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yield and number of steps (seven steps and 22% overall yield for the present synthesis; nine steps 
10% yield for the previous synthesis).350 
It was postulated that the reason for formation of 3.14 was due to nucleophilic attack by 
the imine nitrogen on the methyl ester in intermediate 3.12.  This would form an acyl iminium 
intermediate that later isomerized to form 3.14. To avert this transformation, we planned to make 
t-butyl ester 3.17 which can provide steric hindrance against approaching nitrogen. To synthesize 
t-butyl ester 3.17, we attempted transesterification using t-BuOH and ester 3.10 in presence of 
sulfuric acid but this was unsuccessful. In another attempt at synthesizing 3.17 (shown in Scheme 
3.4), the ester 3.10 was hydrolyzed to acid 3.16 and then various conditions for esterification 
(shown in Table 3.2) were applied on acid 3.16. However, none of the conditions that were tried 
worked and we recovered starting material. Steric hindrance might be the factor at play here. 
 
       
Table 3.2: Unsuccessful esterification conditions for compound 3.16 (step b, Scheme 3.4) 
Entry Reagents Solvent 
1 DCC, DMAP t-BuOH 
2 H2SO4, MgSO4 t-BuOH 
3 (t-BuO)2O DCM 
 
After unsuccessfully attempting to synthesize 3.17, our efforts were directed towards 
synthesis of di-amide 3.18. It was envisaged that the aromatic amide group in 3.18 would not be 
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as susceptible to ring closure via the intermediate imine (akin to compound 3.12).   Thus 3.18 was 
synthesized as shown in Scheme 3.5. Bischler-Napieralski cyclization of diamide 3.18 followed 
by Noyori’s catalytic hydrogenation produced enamine 3.19.  This result tends to suggest that 
imine 3.12 first isomerizes to an enamine which then cyclizes to form the enamide 3.14, contrary 
to our initial postulate that cyclization preceded isomerization.  
 
After unsuccessful attempts to stop the formation of enamine 3.14, we planned to reduce 
ester 3.10 to primary alcohol 3.20 and the resultant alcohol could then be advanced to synthesize 
(-)-SPD (2.1). We tried various conditions to reduce ester 3.10 (as shown in Table 3.3); in which 
DIBAL (at -78 ̊ C) and NaBH4 (in refluxing THF) produced a complex TLC profile, while treating 
with LAH at 0  ̊ C gave cyclic imide 3.21. Formation of imide 3.21 after the reaction with LAH 
and NaBH4 revealed that cyclization of ring C occurs before ester reduction.  
Reduction with LiBH4 at 0  ̊ C to room temperature did not furnish the desired alcohol 3.20, 
but we received unexpected primary alcohol 3.22. We found similar literature precedence wherein 
cyclic imide 3.23 was shown to transform to an opened ring aliphatic alcohol 3.24 in the presence 
of excess NaBH4 (Scheme 3.7).351 We tried to cyclize imide 3.21 using POCl3, having thought that 
cyclization would occur at aliphatic carbonyl and further advancing the intermediate iminium ion 




Table 3.3: Reduction of compound 3.10 (Scheme 3.6) 
Reducing agent Temperature Solvent Product Yield 
NaBH4 rt to reflux THF/MeOH NA NA 
DIBAL -78  ̊ C THF NA NA 
LAH 0  ̊ C THF 3.21 46% 
NaBH4 0  ̊ C to rt MeOH 3.21 54% 




Finally, we planned to reduce enamide 3.14 (derived from ester 3.10) via enantioselective 
hydrogenation using ruthenium catalyst as per the reported procedure (Scheme 3.8), wherein 




Table 3.4: Hydrogenation conditions (step a, Scheme 3.9) 
Hydrogen 
Pressure (atm) 
Temperature ( ̊ C) 
1  rt 
5  rt 
10  rt 
20  rt 
40  rt 
50  rt 
20  50  
40  50  
50  50  
a. All conditions were unsuccessful 
treated with (S)- Ru(OAc)2(BINAP) under hydrogen pressure in a stainless steel high pressure  
reactor.  We applied different hydrogen pressure ranging from 1atm to 50 atm at different 
temperature (shown in Table 3.4); however none of the conditions furnished the expected product 
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(-)-3.11. As per our assumption the cyclic conjugation between two aromatic rings makes this 
enamide double bond quite inert against hydrogenation. 
 
3.3.2.2  Synthesis via lactone 2.62 
After all ineffective efforts to reduce ester 3.10 to primary alcohol 3.20 as well as 
asymmetric hydrogenation of enamide 3.14, we redesigned our route (shown in Figure 3.4) to 
synthesize (-)-SPD (2.1) via lactone 2.102, which can be synthesized from diester 3.7 via selective 
reduction of aromatic ester.   
 
As depicted in Scheme 3.10, our synthesis of (-)-SPD (2.1) commenced with compound 
3.7 which was synthesized as per Scheme 3.1 from 4-bromoguaiacol (3.5). The ethoxymethyl 
group of 3.7 was exchanged for a benzyl protecting group in two high yielding steps. Here, 3.7 
was refluxed in acidic methanol to effect deprotection of the ethoxymethyl group and this was 
followed by protection of resulting phenol as the benzyl ether to give 3.27. Global hydrolysis of 
the ester functionalities of 3.27 and subsequent selective esterification of the aliphatic acid 
functionality, generated acid 3.28. The acid 3.28 was converted to an intermediate activated ester 
via reaction with EDCI/HOBt. This ester group was selectively reduced with NaBH4 to provide an 
alcohol which was then cyclized to the lactone 2.62. Thereafter the route developed by Yang was 




To provide unequivocal stereostructural proof, we determined the 3-dimensional structure 
of 2.1 by single crystal X-ray diffraction. Figure 3.5 shows a representation of the x-ray structure, 
in which a water molecule co-crytallizes with 2.1. The synthesis of 2.1 was accomplished in 23% 
overall yield from compound 3.5 in a fourteen step sequence. This route involves an alternative 
preparation of the vital intermediate compound 2.102. The synthetic manipulations to afford 2.102 
are straightforward, scalable ( > 5 g) and generally high yielding. 
 





3.3.2.3  Discussion 
Herein, a new synthesis of (±)-SPD (2.1) is delineated, which features the use of the easily 
obtainable diester intermediate 3.7. (±)-SPD (2.1) was prepared in eight steps from a readily 
available precursor 4-bromoguaiacol in 30% overall yield. The route is attractive due to its 
efficiency and practical ease; no chromatographic purification was necessary for a number of steps. 
The present approach has the advantages of brevity, ease of synthetic manipulations and superior 
overall yield as compared to previous reported syntheses of (±)-SPD (2.1). This method has 
addressed a solution to the key problem in synthesis of THPBs, to set up the 2,3,9,10 
tetrasubstituted pattern, by employing diester 3.7. The key amide intermediate (3.10), that is, used 
for (±)-SPD (2.1) synthesis can also be used to prepare a 9,10-oxygenated-8-oxoprotoberberine 
core, and we adapted this method to prepare oxypalmatine (3.15). Hence, the route examined here 
is a versatile one for the preparation of 9,10-oxygenated THPBs as well as their 8-
oxoprotoberberine analogues.353 
The enantioselective synthesis of (-)-SPD (2.1) was accomplished in 23% overall yield 
from compound 3.5 in a fourteen step sequence. The crystal structure of (-)-SPD (2.1) was 
determined by single crystal X-ray diffraction, and validated the success of this method. This is 
comparable to Yang’s first synthesis where a 24% yield of (-)-SPD (2.1) was obtained in eleven 
steps (from a 4-benzyloxy-3-hydroxy phenylacetic acid precursor).293 This, route involves an 
alternative, reliable preparation293 of the vital intermediate compound 2.102. The synthetic 
manipulations to afford 2.102 are straightforward, scalable and generally high yielding. This 





3.4  Synthesis and evaluation of (±)-C10 analogues  
3.4.1  Rationale 
 
As mentioned previously in section 3.1, others have investigated the replacement of the C2 
and C10 hydroxyl groups of (±)-SPD (2.1) with methoxy, methylenedioxy and benzyloxy motifs. 
Based on the results obtained in previous studies, either C2 or C10 hydroxyl group are pre-
requisites for dopamine D1 activity. Base to this premise, in this project, we planned to probe the 
tolerance of larger lipophilic substituents and steric bulk as well as hydroxyl group homologs at 
C10 position while keeping the C2 hydroxyl group free. The rationale behind this study was to get 
an insight about optimum size of the alkoxy group required at C10 position for dopamine D1 and 
D3 receptor affinity and selectivity. To this end, molecules 3.29a-3.29h (Figure 3.6) were designed 
to test the effect of extended alkyl chain, three carbon cyclic ring and hydroxyl homologs on the 
affinity and activity at D1, D2 and D3 receptors.  
 
3.4.2  Results and discussion  
3.4.2.1  Synthesis 
Using our newly developed synthetic method (Scheme 3.1), we synthesized amide 3.11 in 
large amount from diester 3.7, and it was reduced to tertiary amine 3.30 using LAH. Compound 
3.30 was deployed to synthesize C10 analogues (3.29a-3.29h) of (±)-SPD (2.1) via alkylation with 
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appropriate alkyl halide followed by debenzylation using concentrated HCl (as shown in Scheme 
3.11).  
 
3.4.2.2  Structure-activity correlations 
This series of analogues along with (±)-SPD (2.1) were assayed for binding affinity to 
human dopamine D1, D2 and D3 receptors by the Psychoactive Drug Screening Program (PDSP). 
This data is presented in Table 3.5. (±)-SPD (2.1) displayed approximately 20-fold stronger 
affinity for the D1 receptor as compared to the D2 and D3 receptors (Ki of 5.6, 115.5 and 101 nM 
at D1, D2 and D3 respectively). Alkylation tends to reduce D1 affinity, with the analogues showing 
a 1.2 to 7-fold decrease in affinity as compared to (±)-SPD (2.1). The C10 phenol plays role but is 
not absolutely required for D1 affinity, given the relatively small drop in affinity seen for some 
analogues (for example 3.29c and 3.29g). This result is in accordance with observations from 
previous SAR work on the THPB framework by others.19 
Methyl and ethyl substituents resulted in an approximately 2-fold decrease in affinity 
(compounds 3.29a and 3.29b respectively). In the n-propyl (3.29c) to n-hexyl (3.29f) homologous 
series, a progressive decrease in affinity was observed. The D1 receptor affinity seen for the 
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hydroxypropyl analogue 3.29g was comparable to that observed for (±)-SPD (2.1) and the n-butyl 
analogue 3.29d (6.7, 5.6 and 11 nM respectively). This suggests that the hydroxyl group in 3.29g 
plays a relatively minor role in binding to the D1 receptor. The presence of the hydroxypropyl 
substituent in 3.29d restores the D1 affinity of (±)-SPD (2.1), improves the selectivity versus the 
D2 receptor (20.6 versus 31.5 for D2/D1 selectivity for (±)-SPD (2.1) and 3.29d respectively) and 
retains the selectivity versus the D3 receptor (18 versus 16-fold for D3/D1 selectivity). Among the 
alkylated analogues, a 3 carbon chain length seems to be optimal for D1 affinity (consider 3.29c 
and 3.29g). The cyclopropylmethyl analogue (3.29h) had similar affinity to the n-butyl analogue 
3.29d and ethyl analogue 3.29b. Thus some degree of branching on the alkyl chain may be 
tolerated for D1 affinity. On a whole, the D2 affinity of the analogues was lower than their D1 
affinities. Thus the compounds retained selective affinity for the D1 receptor, as was observed in 
the lead molecule (±)-SPD (2.1). However, most compounds had lower than the 20-fold D1 
selectivity seen for (±)-SPD (2.1) (except for compounds 3.29f and 3.29g).  
Compounds in the homologous series from a methyl group to an n-butyl chain (3.29a-
3.29d), had D2 affinities that are similar to (±)-SPD (2.1), ranging from 99 to 159 nM. However, 
compounds with the larger n-pentyl and n-hexyl chains had reduced affinities; in fact, the n-hexyl 
analogue (3.29f) did not show any appreciable affinity for the D2 receptor (<50% inhibition) in 
the primary assay. The cyclopropylmethyl analogue (3.29h) was the only compound in this series 




Table 3.5: Binding affinity data (Ki nM) for C10 analogues at dopamine receptors 
 
Compound R 
Ki (nM)a Selectivity 
D1b D2c D3d D2/D1 D3/D1 D2/D3 
(±)-2.1 H 5.6e 115.5e 101e 20.6 18.0 1.1 
3.29a Me 15 102 37 6.8 2.5 2.8 
3.29b Et 12.4 159 44 12.8 3.5 3.6 
3.29c n-Pr 7.8 99 53 12.7 6.8 1.9 
3.29d n-Bu 11 121 65 11 5.9 1.9 
3.29e n-Pent 19 283 101 14.9 5.3 2.8 
3.29f n-Hex 40 NAf 220 NDg 5.5 NDg 
3.29g Hydroxypropyl 6.7 211 110 31.5 16.4 1.9 
3.29h Cyclopropylmethyl 12 54 54 4.5 4.5 1 
aExperiments carried out in triplicate - SEM values are within 13% of reported Ki; b[3H]SCH2390 used as radioligand/(+)-butaclamol 
used as reference compound - Ki = 2.3 nM; c[3H]N-methylspiperone used as radioligand/haloperidol used as reference compound - 
Ki = 9.6 nM; d[3H]N-methylspiperone used as radioligand/chlorpromazine used as reference compound - Ki = 11.0 nM; eexperiments 
carried out in duplicate; f NA- not active (<50% in primary assay); g ND-not determined. 
 
There was a clear trend in the methyl to n-hexyl series at the D3 receptor, where an increase 
in the alkyl chain length was associated with a progressive decrease in affinity for the receptor. 
However, methyl to n-butyl analogues demonstrated improved binding affinity at the D3 receptor 
as compared to the lead compound (±)-SPD (2.1) (37 to 65 nM versus 101 nM). The hydroxypropyl 
analogue had similar affinity for the D3 receptor as compared to (±)-SPD (2.1). In the case of the 
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cyclopropylmethyl analogue, D3 receptor affinity was improved two-fold as compared to (±)-SPD 
(2.1) (54 nM vs 101 nM). 
 
3.4.3  Molecular docking study at D3 receptor 
The phenolic group at C10 of SPD (2.1) does not seem to play a major role in its binding 
to dopamine D1 and D2 receptors (given the similarity in D1 and D2 affinities of the analogues as 
compared to SPD (2.1)). In the case of the D3 receptor, a number of analogues had moderately 
improved affinity as compared to SPD (2.1). Therefore it seems that the C10 phenolic group is not 
an absolute necessity for affinity of SPD (2.1) to the D3 receptor. Based on the SAR trend observed 
(increasing alkyl chain length decreases D3 affinity), it is apparent that the C10 alkoxy substituents 
of the analogues might project into a shallow hydrophobic pocket in the receptor. To get further 
clarity into this possibility and to aid in rationalizing the D3 affinity trend observed, docking 
evaluations were performed on SPD (2.1) and analogues 3.29a-3.29h at the D3 receptor. 
Investigation of the docked ligand poses and recognition of key protein–ligand interactions 
provides insights into the SAR outcomes of the series of C10 analogues and the de-rigidified 
compounds with respect to D3. In this study, ligand docking was performed retrospectively in 
order to elucidate and rationalize the measured D3 affinity data. Overall, the calculated binding 
energies for SPD (2.1) and the C10 analogues are in reasonable agreement with activities derived 
from the experimental data as shown in Table 3.6.  
Compounds SPD (2.1) and 3.29a-3.29h were docked into a pre-prepared 3-dimensional 
structure of the D3 receptor derived from the crystal structure with PDB code 3PBL.354 A 
representation of the docked poses for the ligands SPD (2.1), 3.29a-3.29f and 3.29h within the D3 
receptor binding pocket is depicted in Figure 3.7. Each ligand generated multiple binding  
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Table 3.6: Predicted binding affinity from Glidescore for C10 analogues in D3 receptor docking 
study 
Compound R Glidescore 
Ki (nM) at D3 
receptor 
3.29h Cyclopropylmethyl -7.3 54 
3.29f n-Hex -7.3 220 
3.29b Et -7.4 44 
3.29d n-Bu -7.4 65 
3.29a Me -7.5 37 
3.29c n-Pr -7.5 53 
3.29e n-Pent -7.5 101 
SPD (2.1) H -7.9 101 
3.29g Hydroxypropyl -8.1 110 
 
modes and the structures shown display the top ranked poses according to Glidescore (+ligand 
strain). These poses maintain key receptor–ligand interactions, including the critical protonated 
tertiary N—Asp110 salt bridge motif, H-bonds to Ser192 and Cys181 and hydrophobic 
interactions to Phe106 and Phe345 (Figure 3.7). The analogues are positioned such that the aryl 
substituents project into hydrophobic cavities in the receptor (depicted in Figure 3.7b for 
compound 3.29a). The estimated binding energies according to Glidescore are very similar for this 
series of C10 analogue ligands, covering a narrow range from -7.9 to -7.3 kcal/mol. Overall, the 
relatively small decrease in the predicted binding energy as the length of the alkyl chain increases 
for compounds 3.29a-3.29f qualitatively matches the decrease in the measured affinity for these 
ligands. Quantitatively, the binding energy differences are very small compared to the wider, yet 
still relatively low, variation in measured affinities. The Glidescore value for SPD (-7.9 kcal/ mol) 
was found to be lower than that for the other C10 analogues, including the cyclopropylmethyl 
analogue (-7.3 kcal/mol), in contrast to the experimental measurements.  
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a)   
b)  
Figure 3.7: (a) Docked poses of the lead molecule SPD (2.1) and the C10 analogues 3.29a-3.29f 
and 3.29h. Key hydrogen bonding interactions are given by the yellow dashed lines and 




However, in a similar manner to the measured affinities, the hydroxypropyl analogue, with docked 
pose illustrated in Figure 3.8, had a predicted binding energy that is close to that of SPD (2.1) (-
8.1 kcal/mol vs -7.9 kcal/mol, respectively). Examination of the D3 receptor binding site shows 
that the alkyl, cyclopropylmethyl and hydroxypropyl groups of the C10 analogues fit into the 
extracellular hydrophobic region of the binding pocket, consisting of the extracellular loops and 
the junction of several helices, without incurring any significant clashes with the protein structure. 
Hence, the small difference in predicted binding energies for these systems is unsurprising. The 
hydroxyl group in compound 3.29g also forms an additional H-bond to Glu90 (Figure 3.8).  
 
Figure 3.8: Docked pose of the hydroxypropyl analogue, compound 3.29g 
 
Others have investigated docking of SPD (2.1)  at the D3 receptor computationally.355 As 
compared to prior work, we found similarities in the key residues that are important for affinity of 
SPD (2.1) (and the C10 analogues), particularly Asp110, Ser192 and Phe345. Apart from the key 
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protonated nitrogen- Asp110 salt bridge interaction, in both studies Ser192 interacts with an 
aromatic hydroxyl group via a hydrogen bond and Phe345 interacts with an aromatic ring via 
aromatic stacking (Figure 3.6a). The main difference is that the orientation of SPD (2.1) in our 
Glide docking study is reversed compared to the AutoDock derived pose in the previous work. 
Thus in our case Ser192 is H-bonded to the phenolic hydroxyl in ring A and Phe345 interacts with 
ring A, whereas in prior work Ser192 and Phe345 have interactions with the ring D hydroxyl and 
ring D respectively. Given the close to symmetric structure of the molecule and its high rigidity, 
this reversal has little impact on the interactions with the receptor pocket, except for the formation 
of an additional H-bonding interaction between the phenolic group in ring D of SPD (2.1) and the 
backbone O of Cys181 in our docked pose.  
 
3.4.4 Structure-activity relationship study at σ receptors 
3.4.4.1  Background 
There are two types of σ receptors - σ1 and σ2, as borne out by differential binding of 
selective radioligands as well as other biochemical and pharmacological studies.356-358 σ receptors 
are distributed in the central nervous system (CNS) and in peripheral tissue.359, 360 Within the CNS, 
σ1 receptors are concentrated in the hippocampus and other limbic regions which control cognition 
and emotion.361, 362 Thus these receptors have been implicated in a number of neuropsychiatric 
disorders and have been targets for the development of treatment interventions for such 
diseases.363-365 σ2 receptors are found predominantly in regions responsible for motor functions in 
the CNS and are also highly expressed in the lung, liver and kidneys.361, 362  The σ1 receptor has 
been cloned but the σ2 receptor has not, and there is some debate about the identity of the σ2 
receptor.366 Recent studies suggest that the σ2 receptor is Progesterone Receptor Membrane 
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Component 1 (PGRMC1).367, 368 σ2 receptors are overexpressed in tumor cells and are upregulated 
in rapidly proliferating cells and this receptor has attracted interest as a biomarker for cancer 
proliferation.369, 370 Some σ2 ligands (particularly σ2 receptor agonists) display cytotoxic 
activity.371 Thus, σ2 ligands have been of interest for the development of "stand alone" antitumor 
drugs, targeted drug delivery agents and Positron Emission Tomography (PET) tools for imaging 
the proliferative status of various cancers.367, 372-374 σ2 receptor ligands have been predominantly 
from four structural classes: 6,7-dimethoxytetrahydroisoquinolines, indoles, tropanes and 
cyclohexylpiperazines (Figure 3.9). Many of these compounds lack sufficient selectivity or are 
otherwise hampered by unfavorable pharmacokinetic drawbacks that limit their usefulness as 
drugs, anticancer drug delivery vehicles or tools. New, potent and selective σ2 receptor ligands are 
sought after to fully exploit the potential of the σ2 receptor as a target for cancer diagnosis and 
therapy. 
(-)-SPD (2.1) also shows good affinity for σ2 (Ki = 54 nM), as revealed by data from the 
Psychoactive Drug Screening Program (PDSP) database.335 Given the comparatively high σ2 
affinity of (-)-SPD (2.1), we considered that the C10 THPB analogues we made are also exploitable 
towards the development of novel potent and selective σ2 receptor ligands. Since, no SAR studies 
have been performed on THPBs in relation to their σ2 receptor affinity, such studies could propel 
our understanding of the potential utility of this scaffold towards obtaining novel, selective σ2 






3.4.4.2  Structure-activity correlations 
All C10 THPB analogues assayed for binding affinity to human σ1 and σ2 receptors by the 
Psychoactive Drug Screening Program (PDSP). Binding affinity data is shown in Table 3.7. At the 
σ1 receptor, all analogues tested showed increased affinity as compared to (±)-SPD (2.1) (ranging 
from approximately 2-fold to 22-fold increase in σ1 affinity). Therefore, the C10 phenol 
functionality is not required for σ1 receptor affinity. No clear SAR trend could be discerned in the 
homologous series 3.29a-3.29f. The n-butyl analogue 3.29d had the highest affinity of the 
compounds in this series (Ki = 13 nM for 3.29d vs 269 nM for (±)-SPD (2.1)). The hydroxypropyl 
analogue 3.29g had lower affinity than 3.29d (53 vs 13 nM) which suggests that the hydroxyl 
group in 3.29g does not have any significant binding interactions with the σ1 receptor (akin to 
observations at the D1 receptor). The cyclopropylmethyl and n-butyl analogues had similar σ1 
affinities- approximately 12 nM (a situation that mirrors results for 3.29h at the D1 receptor). It 
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thus appears that the cyclopropylmethyl group may function as a less hydrophobic bioisostere of 
the n-butyl group in this series at σ1 receptors. A clear trend was seen at the σ2 receptor for 
analogues 3.29a-3.29f, wherein there was a progressive decrease in σ2 receptor affinity as the alkyl 
chain was extended. Compounds 3.29a and 3.29b had the highest affinity of all compounds 
assayed (1 nM and 1.3 nM respectively), representing an approximately 7- to 9-fold higher σ2 
receptor affinity than (±)-SPD (2.1). With respect to  
 






(±)-2.1 H 269 9 30 
3.29a Me 106 1 106 
3.29b Et 124 1.3 95 
3.29c n-Pr 57 6.7 8.5 
3.29d n-Bu 13 49 0.27 
3.29e n-Pent 119 97 1.22 
3.29f n-Hex 37 107 0.35 
3.29g hydroxypropyl 53 3.8 13.9 
3.29h cyclopropylmethyl 12 2.4 5 
a[3H](+)-pentazocine used as radioligand/haloperidol used as reference compound - Ki = 1.1  




binding at σ receptors, both 3.29a and 3.29b exhibited higher σ2 receptor selectivity than 
compound (±)-SPD (2.1) (approximately 100-fold for 3.29a and 3.29b versus 30-fold for 
compound (±)-SPD (2.1). All other analogues had decreased selective affinity for the σ2 receptor 
as compared to the σ1 receptor. In fact, this σ receptor selectivity was reversed for compounds 
3.29d and 3.29f which both showed approximately 3-fold higher selectivity for σ1 versus σ2 
receptors. Analogues 3.29a-3.29c had higher affinity than (±)-SPD (2.1), indicating that small C10 
alkoxy groups are better tolerated than the C10 phenolic group at the σ2 receptor. Compounds 
3.29g and 3.29h displayed very high σ2 receptor affinity, comparable to 3.29a and 3.29b; thus 
there is some tolerance for small polar or hydrophobic groups at C10 for σ2 affinity. 
As alluded to before, some compounds have shown cytotoxic actions that are attributable to their 
interaction with σ receptors. We were curious to determine the extent to which our newly identified 
high affinity σ2 receptor ligands displayed cytotoxicity. Therefore, 3.29a, the most potent and 
selective σ2 ligand identified in this study, was selected for cytotoxicity evaluation in an Alamar 
Blue assay.375 Compound 3.29a lacked significant cytotoxic activity in this assay, with an IC50 of 
178 μM. Since σ2 receptor agonists are generally cytotoxic,376-378 this result tends to imply that 
compound 3.29a is a σ2 receptor antagonist (although this needs to be ratified with further assays).  
 
3.5  Synthesis and evaluation of (-)-C3 analogues 
3.5.1  Rationale and analogue design 
Substituent pattern investigated at the C3 position in previous SAR studies was limited to 
methoxy, methylenedioxy or hydroxy functionalities (discussed in chapter 2, section 2.5). These 
SAR studies indicate that having hydroxyl group at C3 position diminishes the activity at 
dopamine receptors and an alkoxy group is necessary for the activity. Still much chemi9cal 
diversity space is present to explore this site using various alkoxy chains having different carbon 
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length. Filling this deficient element, our project was aimed to design, synthesize and evaluate C3 
alkoxy analogues of (-)-SPD (2.1) at dopamine receptors. Examining the binding affinity of these 
variant bulk analogues would provide some idea about the size of the binding pocket in the vicinity 
of C3 at the various receptors.. Compounds 3.35a-3.35f (Figure 3.10) have been designed to test 
the effect of extended alkyl chain and fluorine-containing homologs on the affinity and activity at 
D1, D2 and D3 receptors.  
 
 
3.5.2  Results and discussion  
3.5.2.1  Synthesis 
Compounds 3.35a-3.35f were synthesized using the procedure developed for (-)-SPD (2.1) 
as shown in Scheme 3.12. Commercially availably dihydroxy benzaldehyde (3.36) was selectively 
protected with benzyl group as per the reported procedure to give compound 3.37.379 The phenolic 
group of aldehyde 3.37 was protected with silyl group and the intermediate was subjected to 
Henry’s condensation reaction to give nitrostyrene 3.38. Reduction of nitro compound 3.38 using 
LiBH4 yielded primary amine 3.39.  Aminolysis of lactone 2.102 with primary amine 3.39 was 
carried out to give amide alcohol 3.40, which was acetylated to afford 3.41.  Ring B of the THPB 
scaffold was formed via Bischler-Napieralski cyclization followed by asymmetric hydrogenation 
using Noyori’s catalyst and formic acid/triethylamine mixture to generate 3.42 with good yield 
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(88%).345 Hydrolysis of acetyl group and subsequent chlorination endowed the tetracyclic scaffold 
of THPB in compound 3.43. The enantiomeric excess of this precursor was found to be 90.2% 
(chiral HPLC) and it was used for further analogue generation. Alkylation of compound 3.43 




3.5.2.2  Structure-activity correlations 
All C3 analogues were assayed for binding affinity to human dopamine D1, D2 and D3 
receptors by the PDSP. This data is presented in Table 3.8. The highest activity at D1 receptor was 
demonstrated by compounds 3.35b and 3.35a, which were 2.5 and 3-fold lower than parent 
compound (-)-SPD (2.1) respectively. This result suggests that an increase in the alkyl chain length 
at C3 position decreases affinity at D1 receptor, the same trend also exhibited by other compounds. 
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In comparison to other analogues, compound 3.35b showed 2.3 to 3.5 times higher binding affinity 
at the D1 receptor. D1 receptor affinity was increased 1.2 to 1.7 fold while moving from four 
carbon chain to five and six carbon chain (3.35c vs 3.35d and 3.35e). As displayed by compound 
3.35f, terminal introduction of the fluoro group to the ethyl chain decreases the affinity 2 times 
when compared with 3.35a. The selectivity for D1 versus D2 receptor was slightly improved for 
compound 3.35b when compared with (-)-SPD (2.1). Though 3.35f and 3.35a have slightly 
decreased selectivity at D1 receptor, they are comparable with (-)-SPD (2.1).   
Table 3.8: Binding affinity (Ki nM) for C3 analogues at dopamine receptors 
 
Compound R 
Ki (nM)a Selectivity 
D1b D2c D3d D2/D1 D2/D3 D3/D1 
3.35a Et 17.0 2089.0 40.0 122.9 52.2 2.4 
3.35b n-Pr 15.0 2682.0 46.0 178.8 58.3 3.1 
3.35c n-Bu 53.0 2739.0 51.0 51.7 59.5 1 
3.35d n-Pen 31.0 1433.0 33.0 46.2 43.4 1.1 
3.35e n-Hex 42.0 1491.0 26.0 35.5 57.4 0.6 
3.35f 2-fluoroethyl 34.0 5045.0 86.0 148.4 58.7 2.5 
(-)-SPD 2.1 Me 5.9 974.3 30.1 165.1 32.4 5.1 
aExperiments carried out in triplicate - SEM values are within 13% of reported Ki; b[3H]SCH2390 used as radioligand/(+)-
butaclamol used as reference compound - Ki = 2.3 nM; c[3H]Nmethylspiperone used as radioligand/haloperidol used as reference 
compound - Ki = 9.6 nM; d[3H]N-methylspiperone used as radioligand/chlorpromazine used as reference compound - Ki = 11.0 
nM. 
 
D1 versus D2 receptor selectivity progressively decreases from four carbon alkoxy chain 
to six carbon alkoxy chain (3.35c-3.35e). All C3 analogues displayed a reduced affinity at D2 
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receptor from 1.47 to 5.2 fold as compared to (-)-SPD (2.1). This reveals the importance of these 
substitutions in suppressing the dopamine D2 receptor activity. The affinity observed at D3 
receptor was comparable between C3 analogues and (-)-SPD (2.1). Slightly improvement in 
affinity was seen in 3.35e (26.0 nM vs 30.1 nM), while a 2.8 fold reduced activity was found in 
compound 3.35f. At the same time, the selectivity at D3 receptor versus D2 receptor is enhanced 
by 1.3 to 1.8 fold as measured against (-)-SPD for all C3 compounds. Compounds 3.35e (8.5 
times), 3.35c (5.1 times) and 3.35d (4.6 times) have higher selectivity for D3 versus D1 receptor 
than (-)-SPD (2.1). That confers that larger lipophilc chains are more tolerated at this site for D3 
receptor activity. Other compounds (3.35a, 3.35b, 3.35f) have comparable selectivity between 1.6-
2.1 fold for D3 receptor versus D1 receptor as (-)-SPD (2.1). 
 
3.6 Metabolic stability study 
3.6.1 Rationale 
Although (-)-SPD (2.1) possesses favorable properties for delivery to the CNS, rapid and 
extensive pre-systemic metabolism restricts its application. Previous pharmacokinetic and 
metabolic stability study of (-)-SPD (2.1) suggests that the phenolic hydroxyl groups of (-)-SPD 
(2.1) are molecular targets for the unwanted pre-systemic metabolism via O-glucuronidation and 
O-sulfation.340  
It is very crucial to evaluate the effect of substitutions at C3 and C10 position on metabolic 
stability of phenolic hydroxyl groups of (-)-SPD (2.1). In this project we aimed to study the 
metabolic stability of the representative C3 and C10 analogues that we have synthesized using rat 
hepatocytes. Among the routinely used in vitro systems, such as microsomes and hepatocytes,380 
microsomes are usually used to determine cytochrome P450-mediated metabolism (phase I). 
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Hepatocytes, having intact cell membranes and physiological concentrations of enzymes and 
cofactors, are believed to be a model close to whole liver for drug clearance measurements.381-384 
Though human hepatocytes mimic the ideal environment of hepatic metabolism,385 we chose rat 
hepatocytes because of their cost effectiveness and because they are easily available as compared 
to human hepatocytes. Our next goal in this context is to study metabolic stability study using 
human hepatocytes. 
This study would provide us a valuable comparison of metabolic stability pattern of (-)-
SPD (2.1) and its various analogues. It would add a significant piece of information while 
searching for a metabolically stable THPB scaffold having superior biological activity at dopamine 
receptors. As shown in Figure 11, compounds (-)-SPD (2.1), 3.29a, 3.29f, 3.35e, 3.35f, and 3.44 
as representative analogues from C3 and C10 series were studied for in vitro metabolic stability 
using rat hepatocytes.  Analogue 3.44 was selected to serve as a member of tetra-alkoxy substituted 
THPB scaffold.   
 
3.6.2 Results  
For tested compounds, the % AUC was calculated from the LC/MS peak abundance in 
comparison with that total AUC. The % AUC data for each compound during the 36 h time course 





Table 3.9: Metabolic stability study data for representative compounds 
Time (h) 
% of total AUC at given time point 
(-)-SPD 
(2.1) 
3.29a 3.29f 3.35e 3.35f 3.44 
0 100 100 100 96 100 100 
1 98 95 95 81 97 100 
2 91 92 86 89 89 100 
3 82 74 72 78 66 100 
6 52 23 31 47 26 100 
12 10 22 3 10 0 100 
24 10 8 3 1 3 99 





 Figure 3.12: % of total AUC at given time period of incubation for representative analogues  
According to % AUC derived at particular time point, it was found that within six hours, 
all of the compounds were metabolized to more than 50% except tetrasubstituted analogue 3.44. 
Mono glucuronidated metabolite was predominant for all the tested compounds (shown in Figure 
3.13; 3.45 for 2.1, 3.46 for 3.29a, 3.47 for 3.29f, 3.48 for 3.35e, and 3.49 for 3.35f). Peak 
abundance of sulfate metabolites for each compound was very minor (< 0.5% of total AUC), which 
suggests that O-glucuronidation is the major pathway for THPB metabolism in liver. These results 




































No difference was demonstrated in the rate of metabolism between dihydroxy and 
monohydroxy analogues (3.29a, 3.29f versus 2.1, 3.35e, 3.35f). As per our expectation, no 
metabolism was observed during the whole course of experiment for tetrasubstituted analogue 
3.44.  Previous study has revealed that C10 hydroxyl group is the primary site for metabolism and 
it get glucuronidated first in (-)-SPD (2.1).341 This trend can be applied to other C3 analogues 
(3.35e and 3.35f) having C2 and C10 free phenolic hydroxyl group similar to (-)-SPD (2.1). C10 
analogues 3.29a and 3.29f do not have a free C10 hydroxyl group, but those having the C2 
hydroxyl group free, get glucuronidated at similar rates as (-)-SPD. This indicates that the C2 
phenol is also susceptible to glucuronidation to a similar extent as the C10 phenolic hydroxyl. 
Based on results of previous study and our results here, we surmise that having C2alkoxy/C10 
hydroxyl pattern in the THPB scaffold affords a similar rate of metabolism as the C2, C10-
dihydroxy analogues (2.1, 3.35e, 3.35f). 
Tetrasubstituted analogue (3.44) remained stable during the 36 hour time period of the 
assay with same abundance (% AUC); no metabolism was observed during whole experiment. We 
reasoned that the unavailability of free phenolic OH group is responsible for inertness of this 
compound towards metabolism. Steric hindrance due to the bulkier benzyl moieties at C2 and C10 
position is also another possibility for metabolic stability of compound 3.44, as this could slow 
down oxidative dealkylation of the alkoxy groups. To examine this prospect, compounds having 
smaller alkoxy tetrasubstitutions, for instance (-)-THP (2.2), need to be tested for stability in the 






In our work we have addressed prominent issues and missing gaps towards the synthesis 
and SAR studies of THPBs at dopamine D1, D2 and D3 receptors. We have developed a novel 
route to synthesize (±)-SPD (2.1) in eight synthetic steps with 30% overall yield via the 
intermediacy of easily obtainable diester 3.7. Compared to previous reported syntheses, this 
approach is advantageous in terms of conciseness, ease of synthetic manipulations and superior 
overall yield. Additionally, this route is applicable to prepare 8-oxoprotoberberine analogues as 
exemplified by oxypalmatine (3.15).                   
The enantioselective synthesis of (-)-SPD (2.1) was accomplished in 23% overall yield 
from compound 3.5 in a fourteen step sequence. The crystal structure of (-)-SPD (2.1) was 
determined by single crystal X-ray diffraction, which validated the success of this method. This is 
comparable to Yang’s first synthesis where a 24% yield of (-)-SPD (2.1) was obtained in eleven 
steps (from a 4-benzyloxy-3-hydroxy phenylacetic acid precursor).293 This, route involves an 
alternative, reliable preparation of the vital intermediate compound 2.102. The synthetic 
manipulations to afford 2.102 are straightforward, scalable and generally high yielding. This 
synthetic pathway we applied to generate of C3 chiral analogues of (-)-SPD (2.1) for bioactivity 
studies. 
While searching for selective D1/D3 receptor ligands, we have designed and synthesized 
C10 alkoxy THPB analogues 3.29a-3.29h. The C10 THPB analogues seem to exhibit a general 
preference for the D1 receptor. The lowest D1 affinity seen for any analogue was 40 nM (for 
compound 3.29f). Thus the C10 position seems to be fairly tolerant of alkoxy substituent groups 
with respect to D1 affinity. Among the 3 dopamine receptors, affinity was generally highest for 
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the D1 receptor and lowest for the D2 receptor. Overall, the general order of affinities for C10 
analogues at the dopamine receptors evaluated is D1>D3>D2. The clear trend observed in the 
methyl to n-hexyl series at the D3 receptor, where an increase in the alkyl chain length was 
associated with a progressive decrease in affinity for the receptor, indicates tolerance of smaller 
alkoxy substituents at C10 position of THPB core. Methyl to n-butyl analogues have demonstrated 
improved binding affinity at D3 receptor as compared to lead compound (±)-SPD (2.1) (37 to 65 
nM versus 101 nm).  
The ligand binding energies from the D3 receptor docking studies show some similarities 
and minor discrepancies compared to the experimentally derived affinities. This is not surprising 
as empirical scoring functions, such as Glidescore used in this study, cannot rank order correctly 
and quantitatively discriminate all protein-ligand complexes based on the predicted scores. Further 
exploration of a significantly larger and structurally more diverse ligand library would be required 
to provide deeper understanding and quantitative evaluation of the effectiveness of our in silico 
modeling process. 
Using our enantioselective method to synthesize (-)-SPD (2.1), we have produced optically 
pure C3 analogues (3.35a-3.35f) of THPB. The results for binding affinity data suggest that 
introducing the alkyl chain substitution at C3 position, somewhat decreases D1 affinity, maintains 
or slightly decreases D3 receptor affinity while improving selectivity at D3 versus D2 receptor 
when compared with (-)-SPD (2.1). All C3 analogues displayed a reduced affinity at the D2 
receptor from 1.47 to 5.2 fold as compared to (-)-SPD (2.1). This reveals the significance of C3 
alkoxy substituents to suppress the dopamine D2 receptor affinity. In contrast to the C10 analogue 
series, larger lipophilic substituents are well tolerated at the C3 position for D3 receptor affinity as 
demonstrated by n-hexyl (3.35e) and n-pentyl (3.35d) compounds.  
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In our efforts to examine the effect of C10 and C3 alkoxy substituents on the metabolic 
stability against hepatic enzymes, we studied representative analogues having di, tri and tetra 
alkoxy substituents on the THPB scaffold. The results of this metabolic study indicate that having 
phenolic hydroxyl group at C2 and/or C10 on THPB scaffold engenders susceptibility to hepatic 
metabolism. Since this study was done using rat hepatocytes, further studies need to be done using 





4-bromo-1-(ethoxymethoxy)-2-methoxybenzene (3.6)  
Compound 3.5 (8.0 g, 39.4 mmol) and diisopropylethyl amine (13.7 mL, 78.8 mmol) were 
stirred in DCM (100 mL) at 0  ̊ C for 15 min. Ethoxycholoromethyl ether (5.48 mL, 59.1 mmol) 
was added dropwise to the solution at 0  ̊ C. The solution was allowed to stir at rt for 1 h.  The 
reaction mixture was washed with 0.1N HCl (120 mL). The organic layers were combined, dried 
over sodium sulfate and evaporated to dryness to give 3.6   (11.1 g, quantitative) as a brownish oil.  
This product was used in the subsequent reaction without any further purification: 1H NMR 
(CDCl3, 500 MHz) δ 7.06-7.00 (m, 3H), 5.24 (s, 2H), 3.86 (s,3H), 3.76 (q, J = 7.1 Hz, 2H), 1.22 
(t, J = 7.1 Hz, 3H); 13C NMR (CDCl3, 125 MHz) δ 150.5, 145.9, 123.6, 117.7, 115.2, 114.4, 94.2, 






Diisopropylamine (11.49 mL, 84.3 mmol) was stirred in dry THF (100 mL) at -78 ºC in an 
oven-dried round bottom flask for 15 min. n-butyllithium (2.5 M in hexane, 100 mL) was added 
and the solution allowed to stir at -78 ºC for 30 min.  Dimethylmalonate (18.85 mL, 164.7 mmol) 
in 60 mL dry THF was added.   After stirring the solution at -78 ºC for 1 h, a solution of 3.6 (10.0 
g, 38.3 mmol) in 50 mL dry THF was added. After 45 min, the reaction mixture was quenched 
with a saturated solution of ammonium chloride. THF was evaporated and the crude mixture was 
extracted with dichloromethane (4 × 100 mL). The solvent was reduced in vacuo and the crude 
product was purified via flash chromatography on silica gel (10% acetone/hexanes) to afford 
compound 3.7 (6.7 g, 56%) as a yellowish oil: 1H NMR (CDCl3, 500 MHz) δ 7.20 (d, J = 8.5 Hz, 
1H), 6.96 (d, J = 8.5 Hz, 1H), 5.26 (s, 2H), 3.90 (s, 3H), 3.89 (s, 3H), 3.75 (q, J = 7.1 Hz, 2H), 
3.68 (s, 3H), 3.62 (s, 2H), 1.23 (t, J = 7.1 Hz, 3H); 13C NMR (CDCl3, 125 MHz) δ 171.5, 167.6, 
149.7, 147.6, 129.0, 126.4, 125.6, 118.0, 93.8, 64.6, 61.7, 52.2, 52.1, 38.4, 15.1; HRMS (ESI) m/z 
calcd. for C15H20O7 ([M+Na]+), 335.1101, found 335.1104. 
2-[4-(ethoxymethoxy)-3-methoxy-2-(methoxycarbonyl)phenyl]acetic acid (3.8) 
Compound 3.7 (5.8 g, 18.4 mmol) and potassium carbonate (5.1 g, 36.8 mmol) were 
refluxed in a 1:1 water/methanol mixture (150 mL) for 1 h.  The methanol was evaporated and the 
crude mixture was acidified with 0.1N HCl. The solution was extracted with ethyl acetate (3 × 100 
mL) and dried over sodium sulfate.  Filtration and evaporation of the ethyl acetate extract afforded 
3.8 (5.4 g, 98%) as a yellowish oil.  This was used in the next step without purification: 1H NMR 
(CDCl3, 500 MHz) δ 7.21 (dd, J = 8.4, 2.7 Hz, 1H), 6.97 (dd, J = 8.4, 3.2 Hz , 1H), 5.26 (d, J = 
1.8 Hz, 2H), 3.90 (d, J = 3.7 Hz, 3H), 3.88 (d, J = 2.0 Hz, 3H), 3.76 (q, J = 1.75 Hz, 2H), 3.64 (s, 
2H), 1.27-1.21 (m, 3H);  13C NMR (CDCl3, 125 MHz) δ 171.1, 168.8, 150.0, 147.9, 128.3, 126.6, 
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125.4, 118.5, 93.7, 64.6, 61.7, 52.7,  38.9, 15.1; HRMS (ESI) m/z calcd. for C14H18O7 ([M+Na]+), 
321.0945, found 321.0948. 
Methyl-6-(2-((4-(benzyloxy)-3-methoxyphenethyl)amino)-2-oxoethyl)-3-(ethoxymethoxy)-2-
methoxybenzoate (3.10) 
Compound 3.8 (5.0 g, 16.8 mmol) was dissolved in 60 mL DCM and stirred at 0 ̊ C for 15 
min. EDCI (3.2 g, 16.8 mmol) was added portion-wise to the solution at 0  ̊ C and the mixture 
allowed to stir at rt for 1 h. A solution of 3.9 (4.3 g, 16.8 mmol) in 60 mL DCM was added to the 
above reaction mixture at 0  ̊ C and allowed to stir overnight at rt. 50 mL DCM was added to the 
reaction mixture and it was washed with sodium bicarbonate and 0.1N HCl consecutively. The 
organic layer was dried, filtered and concentrated in vacuo to afford 3.10 (7.3 g, 81%) as a brown 
oil : 1H NMR (CDCl3, 500 MHz) δ 7.43 (d, J = 7.4 Hz, 2H), 7.36 (t, J = 7.3 Hz , 2H),  7.30 (d, J = 
7.4 Hz, 1H), 7.17 (d, J = 8.5, 1H),  6.98 (d, J = 8.5 Hz, 1H), 6.74 (d, J = 8.1 Hz, 1H), 6.68 (d, J =  
1.9 Hz, 1H), 6.51 (dd, J = 8.1, 1.9 Hz, 1H), 5.25 (s, 2H), 5.11 (s, 2H), 3.88 (s, 6H), 3.84 (s, 3H), 
3.75 (q, J = 7.05 Hz, 2H), 3.43-3.39 (m, 4H), 2.67 (t, J = 7.1 Hz, 2H), 1.23 (t, J = 7.1 Hz, 3H); 13C 
NMR (CDCl3, 125 MHz) δ 170.3, 168.4, 149.7, 149.6, 147.3, 146.7, 137.4, 132.1, 128.8, 128.5, 
128.5, 127.8, 127.3, 127.3, 126.8, 126.1, 120.6, 118.5, 114.2, 112.4, 93.8,  71.1, 64.7, 61.6, 55.9, 




Compound 3.10 (5 g, 9.3 mmol) and POCl3 (5.2 mL, 55.8 mmol) were refluxed in 80 mL 
acetonitrile for 2 h. The solvent was evaporated and the residue was dissolved in 120 mL DCM. 
The resulting solution was washed with sodium bicarbonate and then dried over sodium sulfate. 
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The organic solvent was removed in vacuo and methanol (100 mL) was added. Sodium 
borohydride (0.7 g, 18.6 mmol) was added at 0  ̊ C and the mixture allowed to stir overnight.  The 
reaction was quenched with water and methanol was evaporated. The residue was extracted with 
DCM (3 × 80 mL).  The organic layer was dried, filtered and evaporated to dryness to afford 3.11 
(3.3 g, 82% over two steps). It was used in the next step without further purification: 1H NMR 
(CDCl3, 500 MHz) δ 7.44 (d, J = 7.2 Hz, 2H), 7.38 (t, J = 7.2 Hz , 2H),  7.33 (d, J = 7.3 Hz, 1H),  
7.06 (d, J =8.1 Hz, 1H), 6.85 (d, J = 8.1 Hz, 1H), 6.71 (s, 1H), 6.68 (s, 1H), 5.15 (s, 2H), 5.00-4.98 
(m,1H), 4.68 (dd, J = 13.0, 3.4, 1H), 4.00 (s, 3H), 3.90 (s, 3H), 2.95-2.71 (m, 5H); 13C NMR 
(CDCl3, 125 MHz) δ 162.5, 149.0, 148.8, 147.3, 147, 137.0, 130.7, 128.6, 128.6, 128.1, 127.9, 
127.51, 127.4, 127.4, 121.5, 122.8, 118.1, 112.6, 111.9, 71.6, 62.4, 56.1, 54.9, 38.9, 38.3, 29.4; 
HRMS (ESI) m/z calcd. for C26H25NO5 ([M+H]+), 432.1805, found 432.1809. 
(±)-SPD (2.1) 
Lithium aluminum hydride (40 mg, 1.1 mmol) was stirred in THF at 0 ̊ C for 10 min. 
Compound 3.11 (0.3 g, 0.7 mmol) in THF was added to the reaction mixture at 0 ̊ C and it was 
allowed to reflux for 2 h. The reaction mixture was allowed to cool to rt and excess of lithium 
aluminum hydride was quenched with water. THF was evaporated and crude mixture was 
extracted with dichloromethane. The organic layer was dried over sodium sulfate, filtered and 
evaporated to dryness. The crude product was refluxed in mixture of methanol (5 mL) and 
concentrated hydrochloric acid (5 mL) for 3 h. The reaction mixture was basified by ammonia 
solution and extracted with dichloromethane (20 mL × 2). The combined organic layer was dried 
over sodium sulfate and concentrated to give the crude product, which was purified by flash 
column chromatography on silica gel (2%-6% methanol/dichloromethane) to give compound 2.1 
(0.29 g, 81% over two steps): Yellowish white crystals, mp 157  ̊ C;   1H NMR (CDCl3, 400MHz) 
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δ 6.83-6.78 (m, 3H), 6.60 (s, 1H), 4.20 (d, J = 15.8 Hz, 1H), 3.87 (s, 3H), 3.81 (s, 3H), 3.58-3.53 
(m, 2H), 3.27-3.10 (m, 3H), 2.80 (dd, J = 15.9, 11.4 Hz, 1H),  2.70-2.62 (m, 2H); 13C NMR (CDCl3, 
400MHz) δ 146.4, 145.1, 144.0, 143.1, 130.4, 127.8, 127.3, 125.9, 125.0, 114.1, 111.3, 110.6, 
60.7, 59.3, 55.9, 58.9, 51.7, 36.1, 29.1; HRMS (ESI) m/z calcd. for C19H21NO4 ([M+H]+), 
328.1551, found 328.1543. 
2-(benzyloxy)-10-hydroxy-3,9-dimethoxy-5,6-dihydro-8H-isoquinolino[3,2-a]isoquinolin-8-
one: (3.14)  
Compound 3.10 (0.2 g, 0.37 mmol) and POCl3 (0.28 mL, 2.97 mmol) were refluxed in 10 
mL acetonitrile for 3 h. The solvent was evaporated and the residue was dissolved in 25 mL DCM. 
The resulting solution was washed with sodium bicarbonate and then organic layer was dried over 
sodium sulfate. The organic solvent was removed in vacuo and the residues were dissolved in 10 
mL dry DCM. Triethylamine (1.6 mL, 0.103 mmol) was added to the solution and allowed to stir 
at rt for 2 h. Reaction mixture was washed with 0.1N HCl and extracted with DCM (3 × 15 mL). 
The combined organic layer was evaporated and concentrated to give the crude product, which 
was purified by flash column chromatography on silica gel (1.5%-3% methanol/dichloromethane) 
to give compound 3.14 (0.11 g, 70% over two steps):    1H NMR (CDCl3, 500MHz) δ 7.49 (d, J 
=7.4 Hz, 2H), 7.40 (t, J = 7.3 Hz , 2H),  7.35-7.30 (m,2H), 7.27 (s, 1H), 7.20 (d, J = 8.6 Hz, 1H), 
6.75 (s, 1H), 6.60 (s, 1H), 5.21 (s, 2H),  4.31 (t, J = 6.1 Hz, 2H), 4.04 (s, 3H), 3.93 (s, 3H), 2.92 (t, 
J = 6.1 Hz, 2H); 13C NMR (CDCl3, 125 MHz) δ 159.7, 151.0, 147.7, 147.6, 145.5, 136.9, 135.3, 
132.2, 129.0, 128.5, 128.5, 127.9, 127.4, 127.4, 122.9, 122.3, 121.1, 118.1, 111.3, 111.0, 101.4, 





Compound 3.14 (0.1 g, 0.23 mmol) was refluxed in a mixture of methanol (5 mL) and 
concentrated hydrochloric acid (3 mL) for 3h. Methanol was evaporated and the resultant mixture 
was basified with ammonia solution and extracted with dichloromethane (3 × 10 mL). The 
combined organic layer was dried and concentrated to give a crude product, which was used in the 
next step without further purification. Crude residues were dissolved in 5 mL DMF. Potassium 
carbonate (63 mg, 0.46 mmol) and methyl iodide (0.04 mL, 0.7 mmol) were added and reaction 
mixture was stirred at rt for 6 h. DMF was evaporated and 0.1 N HCl (10 mL) was added in it. The 
crude mixture was extracted with dichloromethane (3 × 10 mL). The combined organic layer was 
dried over sodium sulfate the crude product was purified by flash column chromatography on silica 
gel (1% - 3% methanol/dichloromethane) to yield oxypalmatine (3.15) (0.07 g, 79%) as yellowish 
solid. mp: 178-185  ̊ C. 1H NMR (CDCl3, 500 MHz) δ 7.33 (d, J =8.8 Hz, 1H), 7.3 (d, J = 8.7 Hz 
, 1H), 7.23 (s, 1H), 6.76 (s, 1H), 6.73 (s, 1H), 4.32 (t, J = 6.1 Hz, 2H), 4.02 (s, 3H), 3.98 (s, 3H), 
3.96 (s, 3H), 3.94 (s, 3H), 2.93 (t, J = 6.1 Hz, 2H); 13C NMR (CDCl3, 125 MHz) δ 160.3, 151.4, 
150.1, 149.6, 148.4, 135.6, 132.4, 128.5, 122.3, 122.1, 119.4, 118.9, 110.5, 107.5, 100.9, 61.6, 
56.9, 56.24, 56.0, 39.4, 28.2; HRMS (ESI) m/z calcd. for C21H21NO5 ([M+H]+), 368.1492, found 
368.1497. 
2-(4-(benzyloxy)-3-methoxyphenethyl)-7-(ethoxymethoxy)-8-methoxyisoquinoline-
1,3(2H,4H)-dione (3.21)  
Compound 3.10 (0.1 g, 0.18 mmol) was dissolved in MeOH (5 mL) and reaction mixture 
was allowed to cool at 0  ̊C. NaBH4 (14 mg, 0.36 mmol) was added slowly in to reaction mixture 
and it was stirred for 1 hr at rt.  Excess NaBH4 was quenched with water and then solvent was 
evaporated. Crude mixture was extracted with DCM (2 X 10 mL), combined organic layer was 
dried over Na2SO4, and concentrated under reduced pressure to obtain crude residue, which was 
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purified by column chromatography on silica gel using 1:99 MeOH:DCM as eluent to afford 
compound 3.21 (0.05 g, 54%); 1H NMR (500 MHz, CDCl3) δ 7.44 (m, 3H), 7.37 (t, J = 5.0 Hz, 
2H), 7.29 (t, J = 7.3 Hz, 1H), 6.94 (d, J = 8.4 Hz, 1H), 6.86 (d, J = 1.2  Hz, 1H), 6.81-6.77 (m, 
2H),  5.29 (s, 2H), 5.12 9s, 2H), 4.17-4.14 (m, 2H), 3.94-3.88 (m, 8H), 3.78 (q, J = 7.1 Hz, 2H), 
2.86-2.83 (m, 2H), 1.23 (t, J = 7.1 Hz, 3H); 13C NMR (500 MHz, CDCl3) δ 169.6, 162.6, 151.9, 
150.7, 149.5, 146.7, 137.3, 131.9, 128.5 X 2, 128.3, 127.7, 127.3, 122.9, 122.4, 121.0, 119.6, 
114.2, 114.1, 112.6, 94.2, 71.1, 64.7, 61.5, 56.0, 41.6, 36.4, 33.7, 15.1; HRMS (ESI) m/z calcd for 
C29H31NO7 ([M+H]+), 506.2179, found 506.2168.  
2-(4-(benzyloxy)-3-methoxyphenethyl)-7-(ethoxymethoxy)-8-methoxyisoquinoline-
1,3(2H,4H)-dione (3.22)  
Solution of compound 3.10 (0.1 g, 0.18 mmol) in THF (5 mL) was added to the suspension 
of LiBH4 (8 mg, 0.36 mmol) in THF at 0  ̊C and reaction mixture was allowed to stir for 2 hr at rt.  
Excess LiBH4 was quenched with water and then solvent was evaporated. Crude mixture was 
extracted with DCM (2 X 10 mL), combined organic layer was dried over Na2SO4, and 
concentrated under reduced pressure to obtain crude residue, which was purified by column 
chromatography on silica gel using 2:98 MeOH:DCM as eluent to afford compound 3.22 (0.05 g, 
52%); 1H NMR (500 MHz, CDCl3) δ 7.42 (d, J = 7.3 Hz, 2H), 7.3 (t, J = 7.7 Hz, 2H), 7.30-7.27 
(m, 1H), 7.17 (d, J = 8.5 Hz, 1H), 6.93 (d, J = 8.5 Hz, 1H), 6.82-6.81 (m, 2H), 6.72 (dd, J = 8.2, 
2.0 Hz, 1H), 6.29 (s, 1H), 5.24 (s, 2H), 5.13 (s, 2H), 3.90-3.84 (m, 4H), 3.80-3.71 (m, 8H), 2.87 
(t, J = 7.0, 2H), 2.73 (t, J = 6.0, 2H), 1.23 (t, J = 7.1 Hz, 3H); 13C NMR (500 MHz, CDCl3): δ 
167.7, 149.8, 148.7, 146.9, 146.3, 137.3, 131.9, 131.8, 128.5, 127.8, 127.3, 126.0, 120.7, 118.0, 
114.4, 112.5, 93.8, 71.1, 64.5, 63.8, 61.8, 56.0, 41.0, 35.5, 35.2, 15.1; HRMS (ESI) m/z calcd for 
C29H35NO7 ([M+H]+), 510.2486, found 510.2489. 
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methyl 3-(benzyloxy)-2-methoxy-6-(2-methoxy-2-oxoethyl)benzoate (3.27):  
Compound 3.7 (2 g, 6.4mmol) was refluxed in methanol with conc. HCl (1 mL) for 2 hr. 
Solvent was evaporated and the residues were dissolved in acetonitrile (50 mL). K2CO3 (1.7g, 12.8 
mmol) and benzyl bromide (0.77 mL, 6.5 ) were added. Reaction mixture was refluxed for 3 hrs. 
Solvent was evaporated and residues were extraced with water (30 mL) and ethyl acetate (20 mL 
x3). Ethyl acetate layer was dried over sodium sulfate and evaporated to dryness to give compound 
3.27 ( 2.2 g, quant.) as brown oily liquid. This product was used in the subsequent reaction without 
any further purification: 1H NMR (CDCl3, 400 MHz) δ 7.44-7.33 (m, 5H), 6.98-6.92 (m, 2H), 5.12 
(s, 1H), 3.92 (s, 3H), 3.91 (s, 3H), 3.67 (s, 3H), 3.62 (s, 3H) 13C NMR (CDCl3, 100 MHz) δ 171.56, 
167.67, 151.11, 147.42, 136.65, 129.06, 128.64 x 2, 128.05, 127.24 x 2, 126.27, 124.79, 115.81, 
70.95, 61.62, 52.25, 52.06, 38.34; (ESI) m/z calcd. for C19H20O6 ([M+Na]+), 367.1152, found 
367.1161. 
3-(benzyloxy)-2-methoxy-6-(2-methoxy-2-oxoethyl)benzoic acid (3.28):  
Compound 3.27 (2.1 g, 6.1 mmol) was relfuxed with 10% NaOH (10 mL ) in ethanol (20 mL ) for 
1 hr. Solvent was evaporated and the residues were acidified with 3 N HCl and it was extraced 
with ethyl acetate (20 mL x 3). Organic layer was dried over sodium sulfate and evaporated to 
dryness. Residues were dissolved in to methanol and SOCl2 (0.11 mL, 1.5 mmol) was added and 
allowed it to stir overnight at rt. Mehanol was evaporated and residues were washed with water 
(50 mL) and ethyl acetate (20 mL x 3). Ethyl acetate layer was dried over sodium sulfate and 
evaporated to dryness to give compund 3.28 (1.97 g, 98%) as yellowish viscous liquid. This 
product was used in the subsequent reaction without any further purification: 1H NMR (CDCl3, 
400 MHz) δ 7.45-7.34 (m, 5H), 7.08 (d, J = 8.4 Hz, 1H), 6.99 (d, J = 8.4 Hz, 1H), 5.15 (s, 2H), 
4.04 (s, 3H), 3.88 (s, 2H), 3.71 (s, 3H); 13C NMR (CDCl3, 100 MHz) δ 172.20, 166.79, 150.88, 
148.53, 136.16,  128.75, 128.41 x 2, 128.31, 128.15, 127.35 x 2, 124.50, 117.09, 71.16, 62.28, 
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52.03, 39.78; (ESI) m/z calcd. for C18H18O6 ([M+Na]+), 335.0996, found 335.1003. 2-(benzyloxy)-
3,9,10-trimethoxy-5,8,13,13a-tetrahydro-6H- isoquinolino[3,2-a]isoquinoline (3.30) 
Compound 3.11 (3.3 g, 7.6 mmol) in 50 mL THF was added to a suspension of lithium 
aluminum hydride (0.6 g, 15.2 mmol) at 0  ̊C and the reaction mixture allowed to come down at 
room temperature and then it was refluxed for 1 h. The reaction mixture was allowed to cool to rt 
and excess of lithium aluminum hydride was quenched with water. THF was evaporated and the 
crude mixture was extracted with dichloromethane (4 × 50 mL). Combined organic layers were 
dried over sodium sulfate and concentrated  in vacuo  and the crude product was purified via flash 
chromatography on silica gel (2% MeOH/DCM) to afford compound 3.30 (2.7 g, 84%) 1H NMR 
(CDCl3, 500 MHz ) δ 7.46 (d, J = 7.4 Hz , 2H),  7.39-7.35 (m, 2H), 7.31 (t, J = 7.4 Hz, 1H), 6.78 
(dd, J = 10.3, 8.3 Hz, 2H), 6.74 (s, 1H), 6.64 (s, 1H), 5.14 (s, 2H), 4.19 (d, J =  15.3 Hz, 1H), 3.88 
(s, 3H), 3.80 (s, 3H), 3.56-3.49 (m, 2H), 3.20-3.06 (m, 3H), 2.73-2.61 (m, 3H); 13C NMR (CDCl3, 
125 MHz) δ 148.3, 146.5, 146.5, 143.1, 137.3, 129.6, 128.5, 128.5, 128.0, 127.8, 127.5, 127.5, 
127.4, 127.3, 125.0, 114.0. 112.2, 111.9, 71.6, 60.7, 59.3, 56.0, 53.9, 51.5, 36.2, 29.1  HRMS (ESI) 
m/z calcd. for C26H27NO4 ([M+H]+), 418.2013, found 418.2007. 
 
General procedure for synthesis of compounds 3.29a-3.29h (as described for compound 
3.29a): 
3,9,10-trimethoxy-5,8,13,13a-tetrahydro-6H-isoquinolino[3,2-a]isoquinolin-2-ol (3.29a) 
Compound 3.30 (0.1 g, 0.24 mmol) was dissolved in DMF. Potassium carbonate (0.07 g, 
0.48 mmol) and methyl iodide (0.02 mL, 0.36 mmol) were added and the reaction mixture was 
stirred overnight at rt. The crude reaction solution was filtered and the filtrate was evaporated to 
dryness. The residue was refluxed in a mixture of MeOH (5 mL) and concentrated HCl (3 mL) for 
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3 h. The MeOH was evaporated and the crude mixture was basified with ammonia solution and 
extracted with DCM (3 × 15 mL). The combined organic layer was dried over anhydrous Na2SO4 
and concentrated to give the crude product, which was purified by flash column chromatography 
on silica gel (2% MeOH/DCM) to give compound 3.29a (0.052 g, 64%) as an off-white solid; mp 
208-210  ̊ C;  1H NMR (CDCl3, 400 MHz) δ 6.87-6.77 (m, 3H), 6.60 (s, 1H),  5.56 (s, 1H), 4.24 
(d, J = 15.7 Hz, 1H), 3.87 (s, 3H), 3.85 (s, 6H), 3.54-3.50 (m, 2H), 3.26-3.11 (m, 3H), 2.81 (dd, J 
= 16, 11.5 Hz, 1H),  2.68-2.61 (m, 2H); 13C NMR (CDCl3, 100 MHz) δ 150.2, 145.1, 143.9, 143.9, 
130.6, 128.7, 127.9, 126.1, 124.0, 111.3, 111.0, 110.6, 60.2, 59.3, 59.3, 55.9, 54.0, 51.7, 36.3, 29.2; 
HRMS (ESI) m/z calcd. for C20H23NO4 [M+H]+, 342.1700, found 342.1704. 
10-ethoxy-3,9-dimethoxy-5,8,13,13a-tetrahydro-6H-isoquinolino[3,2-a]isoquinolin-2-ol 
(3.29b) 
Yield 67%; off-white powder, mp 186-188  ̊ C ; 1H NMR (CDCl3, 400 MHz) δ 6.85-6.77 
(m, 3H), 6.60 (s, 1H),  4.24 (d, J = 15.8 Hz, 1H), 4.06 (q, J = 7.0 Hz, 2H), 3.88 (s, 3H), 3.87 (s, 
3H), 3.52 (d, J = 15.3 Hz, 2H), 3.27-3.10 (m, 3H), 2.84-2.61 (m, 3H), 1.44 (t, J = 7.0 Hz, 3H); 13C 
NMR (CDCl3, 100 MHz) δ 147.5, 143.5 143.2, 142.0, 128.7, 126.7, 125.9, 124.2, 122.0, 110.5, 
109.5, 108.7, 62.5, 58.2, 57.4, 54.0, 52.2, 49.8, 34.4, 27.3, 13.1; HRMS (ESI) m/z calcd. for 
C21H25NO4 [M+H]+, 356.1856, found 356.1861. 
3,9-dimethoxy-10-propoxy-5,8,13,13a-tetrahydro-6H-isoquinolino[3,2-a]isoquinolin-2-ol 
(3.29c) 
Yield 68%; brown solid, mp 87-90  ̊ C; 1H NMR (CDCl3, 500 MHz) δ 6.84-6.78 (m, 3H), 
6.60 (s, 1H), 4.23 (d, J = 15.8 Hz, 1H), 3.94 (dt, J = 6.7, 1.8 Hz, 2H), 3.87 (s, 6H), 3.51 (d, J = 
15.3 Hz, 2H), 3.25-3.10 (m, 3H), 2.80 (dd, J = 15.6, 11.4 Hz, 1H), 2.68-2.60 (m, 2H), 1.84 (sex, J 
= 7.1 Hz, 2H), 1.06 (t, J = 7.4 Hz, 3H); 13C NMR (CDCl3, 125 MHz) δ 149.6, 145.3, 145.1, 144.0, 
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130.6, 128.6, 127.8, 126.0, 123.8 112.3, 111.3, 110.6, 70.4, 60.2, 59.2, 55.9, 54.1, 51.7, 36.3, 29.2, 
22.8, 10.7; HRMS (ESI) m/z calcd. for C22H27NO4 [M+H]+, 370.2013, found 370.2020. 
10-butoxy-3,9-dimethoxy-5,8,13,13a-tetrahydro-6H-isoquinolino[3,2-a]isoquinolin-2-ol 
(3.29d) 
Yield 73%; orange oil; 1H NMR (CDCl3, 400 MHz) δ 6.84-6.77 (m, 3H), 6.60 (s, 1H), 4.24 
(d, J = 15.7 Hz, 1H) 3.98 (dt, J =1.0, 6.45 Hz, 2H), 3.86 (s, 6H), 3.52 (d J = 15.0 Hz, 2H), 3.25-
3.10 (m, 3H), 2.80 (dd, J = 15.2, 11.3 Hz, 1H), 2.67-2.60 (m, 2H), 1.80 (quin, J =  6.9 Hz, 2H), 
1.52 (sex, J = 7.6 Hz, 2H), 0.98 (t, J = 7.4 Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ 149.6, 145.3, 
145.1, 143.9, 130.5, 128.5, 127.7, 126.0, 123.8, 112.2, 111.3, 110.6, 68.5, 60.1, 59.2, 55.9, 54.0, 




Yield 65%; brown oil; 1H NMR (CDCl3, 400 MHz ) δ 6.84-6.76 (m, 3H), 6.60 (s, 1H), 4.23 
(d, J = 15.8 Hz, 1H), 3.97 (dt, J =1.5, 6.55 Hz, 2H), 3.87 (s, 6H), 3.51 (d, J = 15.2 Hz, 2H), 3.26-
3.10 (m, 3H), 2.80 (dd, J = 15.7, 11.5 Hz, 1H), 2.68-2.60 (m, 2H), 1.82 (quin, J =  6.7 Hz, 2H), 
1.49-1.36 (m, 4H), 0.93 (t, J = 7.2 Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ 149.6, 145.3, 145.0, 
143.9, 130.6, 128.6, 127.7, 126.1, 123.8, 112.3, 111.3, 110.6, 68.9, 60.2, 59.2, 55.9, 54.6, 51.6, 






Yield 70%; dark brown oil; 1H NMR (CDCl3, 500MHz ) δ 6.84-6.76 (m, 3H), 6.60 (s, 1H), 
4.23 (d, J = 15.7 Hz, 1H), 3.97 (t, J = 6.6 Hz , 2H), 3.86 (s, 6H), 3.53-3.50 (m, 2H), 3.26-3.10 (m, 
3H), 2.80 (dd, J = 15.8, 11.6 Hz, 1H), 2.68-2.60 (m, 2H), 1.81 (quin, J =  6.7 Hz, 2H), 1.48 (quin, 
J= 7.2, 2H), 1.34 (sex, J = 3.8 Hz, 4H), 0.91 (t, J= 7.0 Hz, 3H); 13C NMR (CDCl3, 125 MHz) δ 
149.6, 145.3, 145.0, 143.9, 130.6, 128.6, 127.7, 126.1, 123.8, 112.3, 111.4, 110.6, 68.9, 60.2, 59.2, 
55.9, 54.1, 51.7, 36.3, 31.6, 29.4, 29.2, 25.8, 22.6, 14.0; HRMS (ESI) m/z calcd. for C25H33NO4 
[M+H]+, 412.2482, found 412.2429. 
10-(3-hydroxypropoxy)-3,9-dimethoxy-5,8,13,13a-tetrahydro-6H-isoquinolino[3,2-
a]isoquinolin-2-ol (3.29g) 
Yield 76%; reddish-brown solid, mp 73-78  ̊ C; 1H NMR (CDCl3, 500MHz ) 6.87-6.80 (m, 
3H), 6.60 (s, 1H),  4.22 (d, J = 15.7 Hz, 1H), 4.16 (td, J = 6.1, 1.5 Hz, 2H), 3.91-3.84 (m, 8H), 
3.52 (d, J = 15.4 Hz, 2H), 3.27-3.10 (m, 3H), 2.80 (dd, J = 15.7, 11.6 Hz, 1H), 2.68-2.61 (m, 2H), 
2.07 (quin, J =  5.8 Hz, 2H); 13C NMR (CDCl3, 125 MHz) δ 149.4, 145.4, 145.1, 143.9, 130.5, 
128.8, 128.4, 126.1, 124.1, 112.5, 111.3, 110.6, 67.5, 61.0, 60.3, 59.2, 55.9, 54.0, 51.6, 36.3, 32.1, 
29.2; HRMS (ESI) m/z calcd. for C22H27NO5 [M+H]+, 386.1884, found 386.1897. 
10-(cyclopropylmethoxy)-3,9-dimethoxy-5,8,13,13a-tetrahydro-6H-isoquinolino[3,2-
a]isoquinolin-2-ol (3.29h) 
Yield 81%; yellow oil; 1H NMR (CDCl3, 500 MHz ) δ  6.83-6.76 (m,3H), 6.60 (s, 1H), 
4.23 (d, J = 15.7 Hz, 1H), 3.90- 3.83 (m, 8H), 3.51 (d, J = 15.1 Hz, 2H), 3.26-3.11 (m, 3H), 2.80 
(dd, J = 15.0, 12.0 Hz, 1H), 2.68-2.62 (m, 2H), 1.31-1.27 (m, 1H), 0.61 (q, J = 5.7 Hz, 2H), 0.36 
(q, J = 4.85 Hz, 2H); 13C NMR (CDCl3, 125 MHz) δ 149.5, 145.7, 145.0, 143.9, 130.6, 128.6, 
128.1, 126.1, 123.8, 113.1, 111.3, 110.6, 73.9, 60.2, 59.2, 55.9, 54.1, 51.6, 36.3, 29.2, 10.5, 3.2, 




To a stirring solution of 3,4-dihydroxybenzaldehyde, 3.36 (2.5 g, 18.1 mmol) in anhydrous 
Acetonitrile (50 mL), was added K2CO3 (2.5 g, 18.1 mmol) followed by benzyl bromide (3.2 mL, 
27.15 mmol) slowly, at room temperature, under an inert atmosphere. Resulting reaction mass was 
heated to reflux temperature and stirring was continued for 2 h. The reaction solvent was removed 
by evaporation under reduced pressure and to the resulted residue was added cold 10% NaOH 
solution and stirred for 10 min. and added the ethyl acetate (2 x 50 mL). Resulted biphasic mixture 
was separated and aqueous layer was acidified using 4N HCl and extracted with DCM (3 x 30 
mL), combined organic layer was washed with brine solution, water, dried on Na2SO4, and 
concentrated under reduced pressure to obtain the residue, which was purified by crystallization 
using ethylacetate to afford, 3.37 (2.7 g, 65%); 1H NMR (400 MHz, CDCl3) δ 9.83 (s, 1H), 7.46-
7.38 (m, 7H), 7.03 (d, J = 8.2 Hz, 1H), 5.81 (s, 1H), 5.20 (s, 2H); 13C NMR (400 MHz, CDCl3) δ 
190.9, 150.9, 146.3, 135.2, 130.8, 128.9 X 2, 128.8, 127.9 X 2, 124.3, 114.4, 111.5, 71.2; HRMS 




Compound 3.37 (2.7 g, 11.8 mmol) was dissolved in anhydrous DCM (50 mL). Imidazole 
(1.6 g, 23.6 mmol) and DMAP (0.1 g, 0.12 mmol) were added in to reaction mixture and allowed 
it to stir at 0  ̊C for 10 minute. To the reaction mixture, TBDPSCl (4.6 mL 17.7 mmol) was added 
and the reaction was allowed to stir overnight at rt. Reaction mixture was acidified with 2N HCl 
and extracted with (2 x 40 mL) DCM. Combined organic layer was washed with brine solution, 
water, dried on Na2SO4, and concentrated under reduced pressure to obtain the crude residue, 
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which was used in the next step without further purification. Residues were dissolved in 50 mL 
acetic acid, NH4OAc (1.0 , 12.98 mmol) and CH3NO2 (2.5, 47.2 mmol) were added in it and 
allowed it to reflux for 8 hr. Solvent was evaporated and the residues were basified using 10% 
NaOH and extracted with DCM (2 x 50 mL). Combined organic layer was dried over Na2SO4, and 
concentrated under reduced pressure to obtain a crude residue, which was purified by column 
chromatography on silica gel using 10:90 EtOAC:Hexanes as eluent to afford compound 3.38 (5.1 
g, 85% over two steps); 1H NMR (400 MHz, CDCl3) δ 7.73-7.63 (m, 5H), 7.46-7.27 (m, 11H), 
7.05-7.00 (m, 2H), 6.86-6.77 (m, 2H), 4.97 (s, 2H), 1.10 (s, 9H); 13C NMR (400 MHz, CDCl3) δ 
153.5, 145.8, 139.1, 136.1 X 2, 135.4 X 2 , 135.3 X 2, 135.0, 134.8, 132.8, 130.1, 129.7, 128.5 X 
3, 128.0 X 2, 127.8 X 4, 127.4 X 2, 124.8, 122.7, 119.5, 113.5, 70.5, 26.6;  HRMS (ESI) m/z calcd 
for C31H31NO4Si ([M+H]+), 510.2101, found 510.2098. 
2-(4-(benzyloxy)-3-((tert-butyldiphenylsilyl)oxy)phenyl)ethan-1-amine (3.39) 
In a dry round bottom flask, LiBH4 (1.8 g, 82.4 mmol), was suspended in THF (30 mL) 
and TMSCl (5.3 mL, 41.2 mmol) was added slowly. Solution of compound 3.38 (5.1 g, 10.3 mmol) 
in THF (30 mL) was added slowly in to reaction mixture and allowed to reflux overnight. Reaction 
was allowed to cool at rt and excess LiBH4 was quenched with MeOH. 10% NaOH (20 mL) was 
added to the reaction and it was filtered through celite. Solvent was evaporated and the crude 
mixture was extracted with DCM (2 x 50 mL).  Combined organic layer was dried over Na2SO4, 
and concentrated under reduced pressure to obtain compound 3.39; 1H NMR (400 MHz, CDCl3) 
δ 7.72-7.68 (m, 5H), 7.41-7.27 (m, 10H), 6.74 (d, J = 6.6 Hz, 1H) 6.62 (dd, J = 1.4, 6.5 Hz, 1H), 
6.4 (d, J = 1.5 Hz, 1H), 4.88 (s, 2H), 2.72 (t, J = 5.8 Hz, 2H), 2.59 (t, J = 5.8 Hz, 2H), 1.08 (s, 9H); 
13C NMR (400 MHz, CDCl3) δ 147.5, 144.4, 136.1, 134.4 X 2 , 135.3 X 2, 133.7, 132.2,  129.1, 
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128.7 X 3, 128.6, 127.2 X 4, 126.8 X 2, 126.7, 126.4 X 2, 120.7, 119.7,  113.2 X 2, 69.6, 40.9, 
34.5, 25.5;  HRMS (ESI) m/z calcd for C31H35NO2Si ([M+H]+), 482.2515, found 482.2509. 
2-(4-(benzyloxy)-2-(hydroxymethyl)-3-methoxyphenyl)-N-(4-(benzyloxy)-3-((tert-
butyldiphenylsilyl) oxy)phenethyl)acetamide (3.40)  
Compound 2.102 (1.5 g, 5.3 mmol) and primary amine 3.39 (2.5g, 5.3 mmol) were refluxed 
in to ethanol (20 mL) for 16 h.  Solvent was evaporated and the residues were purified by column 
chromatography (2 % MeOH/DCM) to yield 3.40 (3.2g, 78%). 1H NMR (CDCl3, 600 MHz) δ 7.69 
(dd, J = 8.1, 1.3 Hz, 4H), 7.43-7.36 (m, 6H), 7.33-7.28 (m, 10H), 6.82 (d, J = 8.4 Hz, 1H), 6.72 (d, 
J = 8.4 Hz, 1H), 6.70 (d, J = 8.1 Hz, 1H), 6.42-6.38 (m, 2H), 5.56 (s, 1H), 5.10 (s, 2H), 4.93 (s, 
2H), 4.64 (d, J = 6.2 Hz, 2H), 3.93 (s, 3H), 3.55 (t, J = 6.2 Hz, 1H), 3.35 (s, 2H), 3.11 (q, J = 6.4 
Hz, 2H), 2.41 (t,  J = 6.6 Hz, 2H), 1.09 (s, 9H); 13C NMR (CDCl3, 150 MHz) δ 171.4, 151.1, 148.7, 
145.5, 137.3, 137.0, 135.5 X 3, 134.2, 133.4, 131.4, 129.8 X 3, 128.6 X 3, 128.3 X 3, 128.0 X 3, 
127.7 X 2, 127.6 X 2, 127.4 X 2, 127.2 X 2, 125.6, 121.8, 120.6, 114.3, 114.1, 70.8 X 2, 61.8, 
56.6, 40.7, 40.6, 34.3, 26.6 X 3, 19.7; (ESI) m/z calcd. for C48H51NO6Si ([M+Na]+), 788.3378, 
found 788.3416. 
3-(benzyloxy)-6-(2-((4-(benzyloxy)-3-((tert-butyldiphenylsilyl)oxy)phenethyl)amino)-2-
oxoethyl)-2-methoxybenzyl acetate (3.41) 
To the solution of compound 3.40 (3.1 g, 4.1 mmol) in DCM (20 mL) was added pyridine 
(0.6 mL, 8.2 mmol) and DMAP (10 mg, 0.08 mmol). The mixture was cooled to 0  ̊ C and acetic 
anhydride (0.8 mL, 8.2 mmol) was added dropwise. The solution was allowed to stir for 1.5 h at 
room temperature, the reaction mixture was diluted with DCM (20 mL), washed with 1 N HCl and 
dried over sodium sulfate and concentrated. The residue was purified by flash chromatography 
(1.5% MeOH/DCM) to afford 3.41 (3.1 g, 92%). 1H NMR (CDCl3, 500 MHz) δ 7.66 (dd, J = 8.1, 
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1.3 Hz, 4H), 7.41-7.36 (m, 6H), 7.33-7.27 (m, 10H), 6.88 (d, J = 8.4 Hz, 1H), 6.78 (d, J = 8.4 Hz, 
1H), 6.68 (d, J = 8.4 Hz, 1H), 6.40-6.38 (m, 2H), 5.14 (s, 2H), 5.08 (s, 2H), 4.88 (s, 2H),  3.88 (s, 
3H), 3.45 (s, 2H), 3.10 (q, J = 6.7 Hz, 2H), 2.40 (t, J = 6.8 Hz, 2H), 1.97 (s, 3H), 1.07 (s, 9H);); 
13C NMR (CDCl3, 125 MHz) δ 170.8, 170.5, 151.1, 149.2, 148.3, 145.4, 137.2, 136.6, 135.4 X 3, 
133.3, 131.2, 129.7 X 3, 128.6 X 3, 128.3 X 3, 128.0 X 3, 127.6 X 4, 127.4 X 2, 127.2 X 2, 126.2, 
121.6, 120.5, 114.8, 114.1, 70.7 X 2, 61.4, 58.4, 40.5, 40.4, 34.5, 26.6 X 3, 20.9, 19.7; (ESI) m/z 
calcd. for C50H53NO7Si ([M+Na]+), 830.3489, found 830.3491. 
(S)-3-(benzyloxy)-6-((7-(benzyloxy)-6-hydroxy-1,2,3,4-tetrahydroisoquinolin-1-yl)methyl)-
2-methoxybenzyl acetate (3.42)  
To the solution of 3.41 (3.0 g, 3.7mmol) in dry acetonitrile (20 mL) was added POCl3 (2.1 
mL, 22.3 mmol) and the mixture was refluxed for 1 h. The reaction mixture was cooled to room 
temperature and the solvent was evaporated. The residue was dissolved in DCM (30 mL) and 
washed with saturated NaHCO3 (15 mL). The organic layer was dried over sodium sulfate and 
evaporated to dryness. The yellow solid residue was dissolved in DMF (15 mL) and RuCl[(R,R)-
TsDPEN(P-cymene)] (20 mg, 0.03 mmol) was added under nitrogen. The solution was purged 
Nitrogen gas for 15 minutes. The mixture of formic acid (0.8 mL, 20.7 mmol ) and triethyl amine 
(0.3 mL 2.21 mmol) was added in to the reaction mixture and allowed it to stir overnight at rt.  The 
reaction mixture was adjusted pH to 8 with saturated NaHCO3 and extracted with ethyl acetate (3 
X 35 mL). The combined organic layer was washed with brine, dried over Na2SO4 and 
concentrated. The crude product was purified by column chromatography on silica gel using 3:97 





Compound 3.42 (1.4 g, 2.5 mmol) was dissolved in ethanol (20 mL) and added 10% NaOH 
(10 mL) to the solution then the mixture was refluxed for 1 h. The mixture was cooled and ethanol 
was evaporated. The residue was extracted with ehylacetate (2 X 30 mL) and the combined organic 
layer was washed dried over Na2SO4 and evaporated to dryness. The residues were dissolved in 
dry DCM (15 mL) and the solution was cooled 0  ̊ C. Thionyl chloride (0.9 mL, 12.5 mmol) was 
added dropwise to the reaction mixture and allowed it to stir for 1 hr. Reaction solution was cooled 
to 0  ̊ C and saturated NaHCO3 (30 mL) was added to it and allowed it stir for 1 h.  Reaction 
mixture was extracted with DCM (2 X 50 mL), combined organic layer was dried over sodium 
sulfate and evaporated to dryness. The crude product was purified by column chromatography on 
silica gel using 1:99 MeOH:DCM as eluent to afford compound, 3.43  (1.1 g, 88% over two 
steps).1H NMR (CDCl3, 500 MHz) δ 7.45-7.37 (m, 10H), 6.83 (s, 2H), 6.78 (s, 1H), 6.71 (s, 1H), 
5.58 (s, 1H), 5.14-5.06 (m, 4H), 4.25 (d, J = 15.8 Hz, 1H), 3.90 (s, 3H), 3.55-3.52 (m, 2H), 3.20-
3.08 (m, 3H), 2.80 (dd, J = 11.5, 15.4 Hz, 1H), 2.67-2.60 (m, 2H); 13C NMR (CDCl3, 120 MHz) δ 
149.3, 145.6, 144.3, 144.2, 137.2, 136.4, 129.2, 128.9, 128.7 X 2, 128.5 X 2, 128.4, 128.2, 128.0, 
127.9, 127.8 X 2, 127.3 X 2, 123.7, 114.4, 113.1, 109.4, 71.4, 70.9, 60.3,  59.3, 54.0, 51.5, 36.5, 
28.9; (ESI) m/z calcd. for C32H31NO4 ([M+H]+), 494.2326, found 494.2330. 
General synthetic procedure for the compounds 3.35a-3.35f as demonstrated for 3.35a 
(S)-3-ethoxy-9-methoxy-5,8,13,13a-tetrahydro-6H-isoquinolino[3,2-a]isoquinoline-2,10-diol 
(3.35a) 
Compound, 3.43 (1.0 eq) was dissolved in anhydrous DMF and added K2CO3 (2.0 eq) 
followed by ethyl bromide (1.2 eq). Resulted reaction mass was allowed to stir at rt for 5 h. The 
reaction mass was quenched with cold water and extracted with ethyl acetate (3 x 50 mL). 
Combined organic layer was washed with brine solution, dried over Na2SO4 and concentrated to 
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obtain a residue, which was used in the next step without further purification. Residues were 
dissolved in ethanol (10 mL) and refluxed with conc. HCl (4 mL) for 3 hr. The reaction mixture 
was concentrated in vacuo and residue was basified using aqueous ammonia solution and extracted 
with ethyl acetate (2 X 20 mL). Combined organic layer was washed with brine solution, dried 
over Na2SO4 and concentrated under reduced pressure to obtain a residue, which was purified by 
column chromatography on silica gel using 2:98 MeOH:DCM as eluent to afford compound 3.35a. 
Yield 71 %, white solid, Mp 104 ⁰C; 1H NMR (CDCl3, 500 MHz) δ 6.84-6.79 (m, 3H), 6.59 (s, 
1H), 4.20 (d, J = 15.4 Hz, 1H), 4.10 (q, J = 7.0 Hz, 2H), 3.81 (s, 3H), 3.58-3.53 (m, 2H), 3.27-3.09 
(m, 3H), 2.80 (dd, J = 11.4, 15.9 Hz, 1H), 2.67-2.62 (m, 2H), 1.45 (t, J = 7.0, 3H); 13C NMR 
(CDCl3, 125 MHz) δ 146.4, 144.3, 144.0, 143.1, 130.3, 127.9, 127.3, 125.8, 125.0, 114.0, 111.4, 
111.2, 64.4, 60.7, 59.3, 53.9, 51.7, 36.2, 29.1, 14.0; (ESI) m/z calcd. for C20H23NO4 ([M+H]+), 
342.1700, found 342.1697. 
(S)-9-methoxy-3-propoxy-5,8,13,13a-tetrahydro-6H-isoquinolino[3,2-a]isoquinoline-2,10-
diol (3.35b) 
Yield 75%, dark brown solid, Mp 82 ⁰C; 1H NMR (CDCl3, 500 MHz) δ 6.85-6.81 (m, 3H), 
6.59 (s, 1H), 4.28 (d, J = 15.4 Hz, 1H), 3.99 (t, J = 6.6 Hz, 2H), 3.82 (s, 3H), 3.65-3.58 (m, 2H), 
3.28-3.24 (m, 2H), 3.15 (td, J = 5.6, 16.7 Hz, 1H), 2.84 (dd, J = 11.8, 16.0 Hz, 1H), 2.70-2.66 (m, 
2H), 1.84 (sext, J  = 7.1 Hz, 2H), 1.05 (t, J = 7.5, 3H); 13C NMR (CDCl3, 125 MHz) δ 146.5, 144.5, 
144.1, 143.2, 130.3, 127.9, 127.3, 125.8, 125.0, 114.2, 111.5, 111.2, 70.4, 60.7, 59.4, 53.9, 51.7, 





Yield 76%, yellowish powder, Mp 85 ⁰C; 1H NMR (CDCl3, 500 MHz) δ 6.85-6.81 (m, 
3H), 6.59 (s, 1H), 4.28 (d, J = 15.4 Hz, 1H), 3.99 (t, J = 6.6 Hz, 2H), 3.82 (s, 3H), 3.65-3.58 (m, 
2H), 3.28-3.24 (m, 2H), 3.15 (td, J = 5.6, 16.7 Hz, 1H), 2.84 (dd, J = 11.8, 16.0 Hz, 1H), 2.70-2.66 
(m, 2H), 1.84 (sext, J  = 7.1 Hz, 2H), 1.05 (t, J = 7.5, 3H); 13C NMR (CDCl3, 125 MHz) δ 146.5, 
144.5, 144.0, 143.1, 130.2, 127.8, 127.3, 125.8, 125.0, 114.2, 111.4, 111.1, 68.6, 60.7, 59.4, 53.9, 




2,10-diol (3.35d)  
Yield 73%, brown solid, Mp 73 ⁰C; 1H NMR (CDCl3, 500 MHz) δ 6.83-6.79 (m, 3H), 6.59 
(s, 1H), 5.56 (s, 1H), 4.20(d, J = 15.3 Hz, 1H), 4.02 (t, J = 6.6 Hz, 2H), 3.81 (s, 3H), 3.58-3.55 (m, 
2H), 3.27-3.10 (m, 3H), 2.80 (dd, J = 11.6, 15.8 Hz, 1H), 2.67-2.62 (m, 2H), 1.82 (pent, J  = 6.6 
Hz, 2H), 1.48-1.36 (m, 4H), 0.94 (t, J = 7.2, 3H); 13C NMR (CDCl3, 125 MHz) δ 146.4, 144.5, 
144.1, 143.1, 130.2, 127.8, 127.3, 125.8, 125.0, 114.1, 111.4, 111.1, 68.9, 60.7, 59.4, 53.9, 51.7, 
36.1, 29.0, 28.9, 28.2, 22.4, 14.0 ; (ESI) m/z calcd. for C23H29NO4 ([M+H]+), 384.2169, found 
384.2165. 
(S)-3-(hexyloxy)-9-methoxy-5,8,13,13a-tetrahydro-6H-isoquinolino[3,2-a]isoquinoline-2,10-
diol (3.35e)  
Yield 70%, dark brown powder, Mp 61 ⁰C; 1H NMR (CDCl3, 500 MHz) δ 6.83-6.79 (m, 
3H), 6.59 (s, 1H), 4.22 (d, J = 15.3 Hz, 1H), 4.02 (t, J = 6.6 Hz, 2H), 3.81 (s, 3H),  3.58(d, J = 14.7 
Hz, 2H), 3.28-3.12 (m, 3H), 2.84-2.79 (m, 1H), 2.69-2.64 (m, 2H), 1.81 (pent, J  = 6.7 Hz, 2H), 
1.49-1.43 (m, 2H), 1.34 (sext, J = 3.7, 4H), 0.91 (t, J = 7.0, 3H); 13C NMR (CDCl3, 125 MHz) δ 
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146.4, 144.5, 144.0, 143.1, 130.2, 127.9, 127.3, 125.8, 125.0, 114.1, 111.4, 111.1, 68.9, 60.7, 59.4, 
53.9, 51.7, 36.2, 31.5, 29.2, 29.1, 25.7, 22.6, 14.0; (ESI) m/z calcd. for C24H31NO4 ([M+Na]+), 
398.2326, found 398.2319. 
(S)-3-(2-fluoroethoxy)-9-methoxy-5,8,13,13a-tetrahydro-6H-isoquinolino[3,2-
a]isoquinoline-2,10-diol (3.35f) 
Yield 87%, yellow powder, Mp 95 ⁰C; 1H NMR (CDCl3, 500 MHz) δ 6.85-6.79 (m, 3H), 
6.61 (s, 1H), 4.82 (t, J = 3.9 Hz, 1H), 4.73 (t, J = 3.9 Hz, 1H), 4.32-4.19 (m, 3H), 3.81 (s, 3H), 
3.58-3.54 (m, 2H), 3.27-3.10 (m, 3H), 2.80 (dd, J = 11.5, 15.7 Hz, 1H), 2.68-2.62 (m, 2H);  13C 
NMR (CDCl3, 125 MHz) δ 146.4, 144.3, 143.8, 143.1, 131.5, 127.8, 127.2, 126.0, 125.0, 114.2, 
112.4, 111.9, 82.4, 81.0, 68.5, 68.3, 60.7, 59.3, 53.8, 51.6, 36.0, 29.0; (ESI) m/z calcd. for 
C20H22FNO4 ([M+Na]+), 360.1606, found 360.1599. 
 
3.8.2 Biological evaluation: primary and secondary radioligand binding assays 
Both the assays were done at the PDSP facility. In the primary binding assays, compounds 
were tested at single concentrations (10 μM) in quadruplicate in 96-well plates. Compounds that 
showed a minimum of 50% inhibition at 10 μM were tagged for secondary radioligand binding 
assays to determine equilibrium binding affinity at specific targets. In the secondary binding 
assays, selected compounds were usually tested at 11 concentrations (0.1, 0.3, 1, 3, 10, 30, 100, 
300 nM, 1, 3, 10 μM) and in triplicate (3 sets of 96-well plates). Both primary and secondary 
radioligand binding assays were carried out in a final of volume of 125 μl per well in appropriate 
binding buffer. The hot ligand concentration was usually at a concentration close to the Kd (unless 
otherwise indicated). Total binding and nonspecific binding were determined in the absence and 
presence of 10 μM appropriate reference compound, respectively. In brief, plates were usually 
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incubated at room temperature and in the dark for 90 min (unless otherwise indicated). Reactions 
were stopped by vacuum filtration onto 0.3% polyethyleneimine (PEI) soaked 96-well filter mats 
using a 96-well Filtermate harvester, followed by three washes with cold wash buffer. Scintillation 
cocktail was then melted onto the microwave-dried filters on a hot plate and radioactivity was 
counted in a Microbeta counter.For detailed experimental details please refer to the PDSP website 
http://pdsp.med.unc.edu/ and click on ‘Binding Assay’ or ‘Functional Assay’ on the menu bar. 
 
3.8.3 Metabolic stability study 
The procedure is described below that was used for in vitro metabolic stability study.  
A 48-well plate seeded with fresh Sprague Dawley rat hepatocytes, having cell density 
0.75-1.5 X 105 cells/well was obtained from TRL, LLC (Durham, NC, USA). After receiving the 
plated hepatocytes, the shipping media was aspirated and replaced with maintenance media and 
the plate was incubated in 5% CO2 incubator at 37 ⁰C for 16 h to resume the cellular activity.  
After 16 h, the maintenance media was replaced with 250 µL of fresh maintenance media. 
2 µL of stock solution of each compound prepared in DMSO was diluted with cell culture media 
(198 µL) to achieve the final incubation concentration 2 µM of compound and 0.4 % DMSO V/V. 
Each of these solutions (200 µL) were added in to plate wells in duplicate and the plate was placed 
into the 37 ⁰C incubator, set at 95% relative humidity and 5% CO2. The sample aliquots were taken 
at the time point of 0h, 1h, 2h, 3h, 6h, 12h, 24h and 36h, and transferred in to microcentrifuge tube 
preloaded with 100 µL of cold acetonitrile as stop solution. The microcentrifuge tubes were 
centrifuged at 13,000 rpm for 6 min and the supernatant layer was separated and each sample was 
analyzed via LC/MS in duplicate.  
 
3.8.4  Alamar Blue Cytotoxicity Assay 
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Pre-assay optimization protocol 
Cells (MDA MB 231) were plated in a range from (105-102) per well in triplicates in 96 
well plate and they are incubated at 37 oC for 24 h. 25 µl of Alamar blue [10% v/v of 440µM 
solution of resazurin (Sigma #R7017)] was added to each well and incubated at 37 oC for 5 h. 
Fluorescence intensity was measured (Alamar blue, 561 dichroic mirror from bottom).  A standard 
graph between log (fluorescence intensity) and log (number of cells) was plotted and the optimal 
number of cells required for the assay was determined from the linear range of the standard graph.  
 
Cytotoxicity assay protocol 
10000 cells were plated (optimal cell number obtained from the standard graph) in 100 µL 
wells in 96 well plate and were incubated at 37 oC for 24 h. Serial dilutions of the compound (30 
mM - 300 nM) were made in the cell growth media. The media in each well was replaced with 
media containing the compound, with triplicates for each dilution. The cells were then incubated 
at 37 oC for 24 h. Subsequently, 25 µl of Alamar blue (10%v/v of 440 µM solution of resazurin) 
was added to each well and incubated at 37 oC for 5 h. Fluorescence intensity was measured 
(Alamar blue, 561 dichroic mirror from bottom). The number of cells after treatment in each well 






Chapter 4: Synthesis and evaluation of de-rigidified THPB analogues at 
dopamine receptors 
 
4.1  Background and rationale 
THPBs share the common structure consisting of a four-ring main structural backbone 
(isoquinoline ring) with substituent methoxyl or hydroxyl groups at the two benzene rings. The 
dopaminergic activity of THPB scaffold resides in the structural alikeness between dopamine and 
THPB (as shown in Figure 4.1). Based on previous SAR studies it was found that C2 or C10 
hydroxyl groups of THPB play key roles in determining the intrinsic activities and affinity at DA 
receptors (Chapter 2, Section 2.5).332-334 The, rigid THPB pharmacophore is devoid of flexibility 
of the free ethtylamine chain of dopamine. It is quite interesting to know the results of de-
rigidifying this rigid scaffold on dopaminergic affinity and activity.  We hypothesized that the rigid 
tetracyclic THPB core is not required for affinity and activity at the dopamine receptors and that 






To test this hypothesis, we planned to prepare compounds 4.1, 4.2a-4.2c and 4.3a-4.3d 
(shown in Figure 4.2) having a flexible core structure and which do not have an intact THPB 
scaffold. Compound 4.1 has broken ring C although having similar carbon skeleton as of SPD 
(2.1). Analogues 4.2a-4.2c posses complete flexibility and are devoid of an intact ring B and ring 
C of the THPB core. While having complete THIQ portion of THPB scaffold, analogues 4.3a-
4.3d carry rest of the segment of THPB impaired. These molecules will test the necessity of the 
rigid core structure of THPB for the dopaminergic receptor activity. This approach is attractive 
because if it is found that rigidity is not required, compound library synthesis and hence ligand 
optimization would be more efficient since the synthesis of these molecules would be shorter and 
simpler.  
In the design and development of novel D3 receptor ligands, a primary challenge is 
achieving a high degree of selectivity for D3 receptor over the highly homologous D2 receptor for 
ligands with druglike characteristics. These issues, as well as the progress made in the development 
of D3 receptor selective ligands, have been the subject of several reviews.75, 142, 386-389 A typical 
pharmacophore for dopamine D3 receptor ligands, possess a general pattern, which is divided into 
three subunits (as shown in Figure 4.2): an aryl moiety, which is connected to an amide (first 
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subunit) and further linked via an alkyl or aryl spacer (second subunit) to a basic residue with aryl 
substituent (third subunit).390 For example, as shown in Figure 4.3, SB-277011A or BP-897 contain 
arylpiperazine or tetrahydroisoquinoline basic subunit and n-butyl or cyclohexyl ethyl spacer 
attached to arylamide group.233, 238, 391 
 
In our efforts towards the discovery of novel, selective and potent D3 receptor ligands, we 
planned to incorporate the THIQ portion of the THPB scaffold into typical pharmacophore of D3 
ligands to generate a hybridized D3 receptor ligand as shown in Figure 4.3. This hybrid moiety is 
different from previously made analogues in having a mono-protected catechol moiety on the 
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THIQ ring and we presumed that this would add potency and preference for the D3 receptor.392 
Based on this hybridization pattern, we planned to synthesize series of compounds 4.4a-4.4l 
(Figure 4.4) with variant arylamide functionalities.  
 
4.2   Results and discussion 
4.2.1  Synthesis  
As shown in the Scheme 4.1, we deployed secondary amine 4.4 to synthesize de-rigidified 
analogues 4.1 and 4.2a-4.2c. Starting with primary amine 3.9, it was subjected to reductive 
amination with 3-benzyloxy-2-methoxy benzaldehyde derived from 2, 3-dihydroxybenzaldehyde 
to give secondary amine 4.5.393 Pictet-Spengler reaction with 1,1, diethoxyethane followed by 
debenzylation produced compound 4.1 from secondary amine 4.5.394, 395 Reductive amination of 
an appropriate aldehyde and amine 4.5 and subsequent debenzylation gave the desired tertiary 





THIQ based flexible analogues 4.3a-4.3d were synthesized from primary amine 3.9 via 
tetrahydroisoquinoline derivative 4.6 (Scheme 4.2). Primary amine 3.9 was subjected to Pictet-
Spengler reaction with paraformaldehyde in presence of formic acid to afford THIQ derivative 
4.6.396   Reductive amination with appropriate aldehyde followed by acid catalyzed debenzylation 




Synthesis of tetrahydroisoquinoline-arylamide hybrid analogues was carried out as 
depicted in Scheme 4.3. Compound 4.7 was prepared from compound 4.6 via four carbon chain 
elongation with 4-bromobutyronitrile followed by reduction of the intermediate nitrile group to 
primary amine 4.7 using LAH.237 Appropriate acids were coupled with primary amine 4.7 and the 
final analogues 4.4a-4.4l were synthesized after debenzylation of intermediate amide compounds.  
 
 
4.2.2  Structure-activity correlations 
The data for binding affinity to human dopamine D1, D2 and D3 receptors is presented in 
Table 4.1. Dismantling the THPB scaffold via truncation of ring B and ring C (in compounds 4.2a-
4.2c) results in significantly lower affinity for all dopamine receptors. Thus, intact THPB core 
seems to be very important for affinity to dopamine receptors. Compounds 4.2a-4.2c which lacked 
a tetrahydroisoquinoline motif had lower affinities for the dopamine receptor than compounds 4.1 
and 4.3a-4.3d possess such motif. THIQ derivatives 4.3a, 4.3c and 4.3d have shown good affinity 
and selectivity at D3 receptor, specifically compound 4.3c has notable selectivity at D3 versus D1 
receptor (286.9) and D2 receptors (33.3).  Therefore it would appear that the presence of an intact 
THIQ moiety contributes significantly to better D3 receptor affinity and selectivity.  
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Compounds 4.4a-4.4l were submitted to the PDSP for evaluation of D1, D2 and D3 
receptor affinity and activity. The binding affinity data is shown in Table 4.2. The primary binding 
assay data suggest that the % inhibition at D3 receptor is very high when compared with % 
inhibition at D1 and D2 receptor. Many compounds including 4.4d-4.4g, 4.4k and 4.4l have 
exhibited less than 50% inhibition (10 µM concentration) at D1 and D2 receptor in the primary 
binding assay so they could not carried further for secondary binding assay as per PDSP protocol.  
 In the secondary binding assay analogues 4.4a and 4.4b having bulkier aryl substituents 
have shown high and similar potency (2.7 nM) at D3 receptor while retaining some affinity at D1 
and D2 receptors. Higher binding affinity for these compounds suggests the possibility of presence 
of hydrophobic pocket at this position of the D3 binding site. Very similar binding profile was 
demonstrated by p-chlorobenzyl analogue 4.4h, which possess the highest binding affinity in the 
series  at D3 receptor (2.1 nM) and having low affinity at D1 (683 nM) and D2 (1060 nM) 
receptors. Compound 4.4c retain heteroatom in the ring showed 8 fold reduced affinity at D3 
receptor as compare to similar analogue (4.4b) without heteroatom. In a similar manner, 4.4d 
having pyridine heteroaromatic ring, displayed the least D3 receptor affinity (24  
nM) among all analogues tested. Surprisingly, 4-methoxybenzyl analogue 4.4k presented higher 
affinity at D3 receptor as compared to 4-hydroxybenzyl analogue 4.4e (Ki value of 5.9 nM for 4.4k 
versus 8.7 nM for 4.4e) and both these analogues were inactive at D1 and D2 receptors. Compound 
4.4f with 3-methoxy substitution exhibited 2 fold reduced affinity as compared to 4-methoxy 
analogue 4.4k (12 nM for 4.4f versus 5.9 nM for 4.4k). 
Table 4.1: Binding affinity data (Ki nM) for de-rigidified analogues at dopamine receptors 
Compound 
Ki (nM)a Selectivity 
D1b D2c D3d D2/D3 D1/D3 
4.1 833 1095 1367 1.2 0.6 
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4.2a >10,000 >10,000 1811.0 5.5 5.5 
4.2b 3111.0 >10,000 2680.0 3.7 1.1 
4.2c >10,000 >10,000 >10,000 1 1 
4.3a 6479.0 1593.0 92.0 17.3 70.4 
4.3b 3318.0 3450.0 191.0 18.1 17.4 
4.3c 4590.0 533.0 16.0 33.3 286.9 
4.3d 3255.0 1972.0 41.0 48.1 79.4 
aExperiments carried out in triplicate - SEM values are within 13% of reported Ki; b [3H]SCH2390 used as radioligand/(+)-
butaclamol used as reference compound - Ki = 2.3 nM; c[3H]Nmethylspiperone used as radioligand/haloperidol used as reference 
compound - Ki = 9.6 nM; d[3H]N-methylspiperone used as radioligand/chlorpromazine used as reference compound - Ki = 11.0 
nM. 
Analogues 4.4g, 4.4k, and 4.4l bearing 4-fluoro, 4-methoxy and 4-cayno benzyloxy 
substituent possess similar range of binding affinity at D3 receptor (Ki value 4.4 nM, 5.9 nM and 
6.3 nM respectively). Additionally, none of 4.4g, 4.4k, and 4.4l is active at dopamine D1 and D2 
receptors. Amongst all 4-halogenated analogues, fluoro compound 4.4g have shown the highest 
selectivity for D3 receptor while, its chloro congener 4.4h expressed highest potency (2.1 nM) at 
D3 receptor with some retention of affinity at D1 and D2 receptors (683 nM and 1060 nM). The 
general order of affinities for halogenated analogues evaluated at the D3 receptors was 
chloro>bromo>fluoro>iodo. Compound 4.4i with bromo substitution have shown noticeable 








D1b D2c D3d 
4.4a 1-Biphenyl 788.0 787.0 2.7 
4.4b 2-Naphthyl 809.0 668.0 2.7 
4.4c 4-Quinolyl 1808.0 NAe 22.0 
4.4d 4-Pyridyl NAe NAe 24.0 
4.4e 4-Hydroxybenzyl NAe NAe 8.7 
4.4f 3-methoxybenzyl NAe NAe 12.0 
4.4g 4-Fluorobenzyl NAe NAe 4.4 
4.4h 4-Chlorobenzyl 683.0 1060.0 2.1 
4.4i 4-Bromobenzyl 495.0 >10,000 3.4 
4.4j 4-Iodobenzyl 1573.0 NAe 10.0 
4.4k 4-Methoxybenzyl NAe NAe 5.9 
4.4l 4-Cyanobenzyl NAe NAe 6.3 
aExperiments carried out in triplicate - SEM values are within 13% of reported Ki; b [3H]SCH2390 used as radioligand/(+)-
butaclamol used as reference compound - Ki = 2.3 nM; c[3H]Nmethylspiperone used as radioligand/haloperidol used as reference 
compound - Ki = 9.6 nM; d[3H]N-methylspiperone used as radioligand/chlorpromazine used as reference compound - Ki = 11.0 
nM. ND = not determined; eNA- not active (<50% in primary assay). 
 
Overall, all of the para substituted benzyl amide analogues (4.4e-4.4l) endowed with <10 
nM D3 receptor binding affinity and most of them were only active at D3 receptor except 4.4h, 
4.4i, and 4.4j. In general, this series of analogues have demonstrated very high potency and 




4.3  Molecular docking study at D3 receptor 
Molecular docking evaluations were performed on analogues 4.1, 4.2a, and 4.2b at the D3 
receptor. Investigation of the docked ligand poses and recognition of key protein-ligand 
interactions provides insights into the SAR outcomes of the series the de-rigidified compounds 
with respect to D3. In this study, ligand docking was performed retrospectively in order to 
elucidate and rationalize the measured D3 affinity data. The docked posses maintain key receptor–
ligand interactions, including the critical protonated tertiary N—Asp110 salt bridge motif and H-
bonds to Ser192 in flexible compound 4.1 (Figure 4.5a). As shown in Figure 4.5b, hydrophobic 
interaction was observed between compounds 4.2a and 4.2b and imidazole ring of His349 as well 
as phenyl ring of Tyr373. 
In order to assess the binding stability of flexible compounds 4.1, 4.2a, and 4.2b the ligands 
were simulated in complex with D3 (crystal structure 3pbl).354 Ligand parameters were generated 
in Generalized Amber Force Field (GAFF),397 protein parameters were assigned from 
AMBERFF14SB,398 and the system was solvated in a 10 Å buffer of Tip4pew (~12000 water 
molecules). Ligands were allowed to move freely, however, protein heavy atoms were restrained 
with 2.5 kcal/Å2 harmonic restraints to maintain model accuracy (in the absence of lipids). The 
starting configuration utilized for these simulations was the top ranked docked poses discussed 
above. These configurations were minimized and heated to 300 K, then equilibrated for 20 ns in 
NPT, and finally run in a 100 ns production NVT molecular dynamics simulation sampling every 
1 ps. The results of these simulations show that the docking poses are stable within this D3 
configuration. Two metrics were utilized to assess ligand stability throughout the production 










(critical for binding shown in Figure 4.5). Ligand RMSD was computed for each frame of the 
production trajectories compared to the ligand configuration in the original docked pose. This 
analysis shows that while ligand positions fluctuated over the course of the simulation, however, 
this did not differ greatly from their starting poses (Figure 4.6). The distance between ligand center 
of mass and Asp110 was utilized to determine whether the ligand maintained this key contact over 
the course of the simulation. Though the distance does change by a small amount in compounds 
4.1 and 4.2b, all three ligands maintain a bound state during the simulation (Figure 4.7).  
a)  b)  
c)  
Figure 4.6: RMSD between all atom coordinates at each frame, compared to the coordinates of 
the docked pose of flexible compounds a) 4.1, b) 4.2a, and c) 4.2b  
 
These data suggest that compounds 4.1, 4.2a, and 4.2b maintain a configuration similar to 
the predicted docked pose during a molecular dynamics simulation and that these predicted poses 
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are stable with respect to the crystal D3 configuration. This supports the assertion that the 
difference in binding affinity is not likely due to destabilized binding, but rather the added ligand 
flexibility and decreased lipophilic interactivity. 
a)  b)  
c)  
Figure 4.7: Distance between flexible compounds a) 4.1, b) 4.2a, and c) 4.2b center of mass and 
the key aspartate Asp110 over the course of a 100 ns simulation. 
 
4.4 Metabolic stability study 
As discussed in Chapter 3 (Section 3.6b), metabolic susceptibility of (-)-SPD (2.1) against 
hepatic enzyme needs to be resolved to make it orally bioavailable. It is very crucial to evaluate 
the metabolic stability of synthesized analogues in order to get a comparative idea between 
metabolism of rigid scaffold of (-)-SPD (2.1) and flexible conformation of these analogues. To test 
the effect of structural flexibility in the metabolism we have studied the in  vitro metabolic stability 
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of representative flexible and THIQ/arylamide analogues (4.3c and 4.4l) along with C-3 and C-10 
analogues of THPB (Chapter 3, Section 3.6). 
Table 4.3: Metabolic stability study data for representative compounds 
Time (h) 
% of total AUC at given time point 
(-)-SPD (2.1) 4.3c 4.4l 
0 100 100 100 
1 98 99 93 
2 91 98 96 
3 82 94 92 
6 52 73 48 
12 10 25 46 
24 10 2 2 
36 11 4 2 
 
 
Figure 4.8: % of total AUC at given time period of incubation for representative analogues 
For tested compounds, the % AUC was calculated from the LC/MS peak abundance in 




































is shown in Table 4.3 and the time versus % AUC graph is depicted in Figure 4.8. In this study the 
major metabolite observed was O-glucuronidated one as similar to (-)-SPD (2.1) and other rigid 
THPB analogues. Results of the metabolic stability study show that flexible compounds have 
slightly slower rate of metabolism than parent compound (-)-SPD (2.1). At 6 hr time point, 52 % 
of active (-)-SPD (2.1) was present in the sample aliquot while 73% of compound 4.3c was present 
in active form at the same time point. In a same manner, 46% of active analogue 4.4l was present 
as compare to 10% of (-)-SPD (2.1) at 12 hr time point. These results indicate that, though it does 
not affect drastically, conformational flexibility has some impact on metabolic stability of THPB 
scaffold against hepatocyte enzymatic environment. Further study needs to be done to evaluate 
this fact using more diversely flexible analogues of (-)-SPD (2.1). 
 
4.5 Conclusion 
In conclusion, we have completed structure–activity relationship studies on various 
conformationally flexible analogues of (-)-SPD (2.1) with the goal of identifying a potential and 
selective DA D1 and D3 receptor ligand. Two categories of analogues were synthesized and 
assayed for binding affinity at DA receptors, one group (4.1, 4.2a-c and 4.3a-4.3d) having 
flexibility in (-)-SPD scaffold and second one (4.4a-4.4l) based on THIQ/arylamide hybridization 
concept. 
The results of this study revealed that intact THPB scaffold of (-)-SPD is necessary for all 
dopamine receptor activity and de-rigidification is detrimental to DA receptor activity. On the 
other hand, having THIQ moiety annexed with flexible arylamide subunit, generates high potency 
for and preference at DA D3 receptor. Analogue 4.4h was identified as the most potent compound 
in this series with Ki value of 2.1 nM. All compounds in this series (4.4a-4.4l) displayed high 
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selectivity at D3 along with very little affinities at other DA receptors (D1, D2, D4, and D5), 
however, compound 4.4l was found to be active solely at D3 receptor. To the best our knowledge, 
this is the first ever selective D3 ligand which does not have affinity at other DA receptors at all. 
Results from docking study (4.1, 4.2a, 4.2b) at D3 receptor revealed the key receptor–ligand 
interactions, including the protonated tertiary N—Asp110 salt bridge motif, H-bonds to Ser192, 
and hydrophobic interaction with imidazole ring of His349 as well as with phenyl ring of Tyr373.  
Overall, structure-activity relationship study of de-rigidified and THIQ/arylamide 
analogues revealed potent and selective D3 receptor ligands. Still more diverse analogues need to 
be synthesized and tested for D3 receptor affinity in order to retrieve compounds having 
subnanomolar potency. Also, compounds having metabolic stability against hepatic metabolism 
need to be discover as a potential candidate for the treatment of drug addiction. There is plenty of 
room for exploration to modify THIQ-arylamide hybrid ligands, for instance, replacement of the 








Amine 3.9 (0.25 g, 0.97 mmol) and 3-(benzyloxy)-2-methoxybenzaldehyde (0.24 g ,0.97 
mmol) were dissolved in 10mL DCM and allowed to stir the solution at 0 ⁰C for 10 minutes. 
Sodium triacetoxy borohydride (0.31 g, 1.5 mmol) was added in to the reaction mixture at 0 ⁰C 
and allowed it to stir for 3 h at room temperature. Reaction mixture was washed with saturated 
NaHCO3 and organic layer was dried over sodium sulfate and concentrated to give the compound 
4.5 (0.4 g, 83%)%) as brown oil; 1H NMR (CDCl3, 500MHz ) δ  7.40-7.27 (m, 10H), 6.98-6.95 
(m, 1H), 6.89-6.6.85 (m, 2H), 6.79-6.74 (m, 2H), 6.66 (dd, J = 1.6, 8.1 Hz, 1H),  5.12 (s, 2H), 5.10 
(s, 2H), 3.85-3.79 (m, 8H), 2.86 (t, J = 7.3, 2H), 2.77 (t, J = 7.3 Hz, 2H); 13C NMR (CDCl3, 
500MHz) δ 151.6, 149.5, 147.7, 146.5, 137.3, 137.0, 133.5, 133.0, 128.6, 128.5, 128.0, 127.7, 
127.3, 127.2, 123.8, 122.2, 122.1, 121.3, 120.6, 114.7, 114.1, 113.3, 112.4, 111.9, 71.1, 70.1, 60.7, 
55.9, 50.3, 48.8, 35.7 ; HRMS (ESI) m/z calcd. for C31H33NO4 ([M+H]+), 484.2488, found 
484.2475. 
7-(benzyloxy)-6-methoxy-1,2,3,4-tetrahydroisoquinoline (4.6)  
Mixture of primary amine 3.9 (4 g, 15.6 mmol) and formic acid (20 mL) was stirred at 0   ̊ 
C for 15 minutes. Paraformaldehyde (0.47 g) was added into the reaction mixture and allowed it 
stir at 50  ̊ C for 12 h. reaction mixture was concentrated in vacuo and residues were washed with 
saturated NaHCO3 and extracted with ethyl acetate (4 X 50 mL). Organic layer was combined, 
dried over sodium sulfate and concentrated. Crude product was purified by flash column 
chromatography on silica gel (3% methanol/dichloromethane)   to give the compound 4.6 (3.65 g, 
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87%) as brown oil; 1H NMR (CDCl3, 500 MHz) δ 7.41 (d, J  = 7.1 Hz, 2H), 7.37 (t, J = 7.6 Hz, 
2H), 7.31 (t, J = 7.1 Hz, 1H), 6.62 (s, 1H, 6.57 (s, 1H), 5.09 (s, 2H), 4.15 (s, 2H), 3.85 (s, 3H), 
3.65 (t, J = 6.2 Hz, 2H), 3.05 (t, J = 6.0 Hz, 2H); 13C NMR (CDCl3, 125 MHz) δ 149.3, 147.4, 
136.7, 128.6 X 2, 128.0, 127.3 X 2, 124.2, 119.6, 111.9, 111.6, 71.1, 56.0, 44.0, 41.6, 25.2; (ESI) 
m/z calcd. for C17H19NO2 ([M+H]+), 270.1489, found 270.1485. 
2-(3-hydroxy-2-methoxybenzyl)-6-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinolin-7-ol 
(4.1) 
Compound 4.5 (0.3 g, 0.6 mmol) was dissolved in 10 mL DCM. 1,1 diethoxyethane (0.13 
mL, 0.9 mmol) and TFA (0.14  mL, 1.8 mmol) were added in to the reaction mixture and allowed 
it to stir overnight. The reaction mixture was washed with 10 mL saturated NaHCO3 and organic 
layer was dried over sodium sulfate and evaporated to dryness. The residues were refluxed in to 
the mixture of methanol (5 mL) and concentrated HCl (3 mL) for 3 h. Methanol was evaporated 
and the crude mixture was basified with ammonia solution, and extracted with dichloromethane 
(10 mL × 3). The combined organic layers were dried over sodium sulfate and concentrated to 
give the crude product, which was purified by flash column chromatography on silica gel (3% 
methanol/dichloromethane)   to give the compound 4.1 (0.12 g, 60%) as yellow powder, mp 56-58 
 ̊ C;  1H NMR (CDCl3, 500MHz) δ 7.00-6.98 (m, 2H), 6.88 (dd, J =6.85, 2.8 Hz, 1H), 6.64 (s, 1H), 
6.55 (s, 1H), 3.85-3.79 (m, 8H), 3.67 (d, J = 13.6 Hz, 1H), 3.07-3.02 (m, 1H),  2.83-2.77 (m, 1H), 
2.68 (dt, J = 12.5, 4.5 Hz, 1H), 2.58 (dt, J = 13, 4.5 Hz, 1H), 1.37 (d, J = 6.6 Hz, 3H); 13C NMR 
(CDCl3, 500MHz) δ 149.0, 145.9, 144.9, 143.6, 133.0, 132.7, 125.6, 124.6, 122.1, 114.3, 113.0, 
110.6, 61.8, 56.3, 55.9, 52.2, 44.0, 27.0, 20.0; HRMS (ESI) m/z calcd. for C19H23NO4 ([M+H]+), 




General procedure to synthesize compounds 4.2a-4.2c and 4.3a-4.3d is described for 4.2a: 
3-(((4-hydroxy-3-methoxyphenethyl)(methyl)amino)methyl)-2-methoxyphenol (4.2a) 
Amine 4.5 (0.2 g, 0.41 mmol) and formaldehyde (0.06 mL, 1.64 mmol) were dissolved in 
10 mL DCM and allowed to stir the solution at 0 ⁰C for 10 minutes. Sodium triacetoxy borohydride 
(0.13 g, 0.62 mmol) was added in to the reaction mixture at ⁰C and allowed it to stir for 3 h at 
room temperature. Reaction mixture was washed with saturated NaHCO3 and organic layer was 
dried over sodium sulfate and concentrated. The residues were refluxed in to the mixture of 
methanol (5 mL) and concentrated HCl (3 mL) for 3 h. Methanol was evaporated and the crude 
mixture was basified with ammonia solution, and extracted with dichloromethane (10 mL × 3). 
The combined organic layers were dried over sodium sulfate and concentrated to give the crude 
product, which was purified by flash column chromatography on silica gel (3% 
methanol/dichloromethane)   to give the compound 4.2a (0.1 g, 74%) as yellow oil; 1H NMR 
(CDCl3, 500MHz) δ 7.0-6.89 (m, 3H), 6.82 (d, J = 8.1 Hz, 1H), 6.68-6.66 (m, 2H), 3.86 (s, 3H), 
3.80 (s, 3H), 3.64 (s, 2H), 2.79 (s, 2H), 2.70 (s, 2H), 2.33 (s, 3H); 13C NMR (CDCl3, 500MHz) δ 
149.0, 146.3, 145.9, 143.8, 124.7, 122.5, 121.2, 121.2, 114.2, 114.1, 114.0, 111.2, 61.7, 55.9, 55.7, 
52.2, 42.0, 33.3; HRMS (ESI) m/z calcd. for C18H23NO4 ([M+H]+), 318.1700, found 318.1693 
3-((ethyl(4-hydroxy-3-methoxyphenethyl)amino)methyl)-2-methoxyphenol (4.2b) 
Yield 68%, brown oil; 1H NMR (CDCl3, 500MHz ) δ 6.98-6.93 (m, 2H), 6.87 (dd, J = 2.0, 
7.5 Hz, 1H), 6.80 (d, J = 8.4 Hz, 1H), 6.65-6.64 (m, 2H), 3.85 (s, 3H), 3.80 (s, 3H), 3.67 (s, 2H), 
2.71 (s, 4H), 2.62 (q, J = 6.8 Hz, 2H), 1.1 (t, J = 7.0 Hz, 3H); 13C NMR (CDCl3, 500MHz) δ 149.0, 
146.3, 145.7, 143.7, 124.6, 122.3, 121.3, 121.3, 114.3, 114.1, 114.1, 111.2, 61.7, 55.8, 55.3, 51.9, 





Yield 67%, dark brown solid, mp 61 ̊ C; 1H NMR (CDCl3, 500 MHz) δ 7.00-6.95 (m, 4H), 
6.85 (dd, J = 2.1, 7.4 Hz, 2H), 6.72-6.68 (m, 2H), 6.56 (dd, J = 2.0, 8.2 Hz, 1H), 3.84 (s, 3H), 3.76 
(s, 6H), 3.70 (s, 4H), 2.74 (q, J = 6.0 Hz, 2H), 2.67 (q, J = 4.5 Hz, 2H); 13C NMR (CDCl3, 125 
MHz) δ 148.8 X 2, 145.7, 145.3 X2, 144.8, 133.7, 132.5, 124.7, 121.9 X 4, 120.1, 115.0, 114.2 X 
2, 110.5, 61.6 X 2, 56.0 X 2, 55.7, 52.2, 32.6; (ESI) m/z calcd. for C25H29NO6 ([M+H]+), 440.2068, 
found 440.2063. 
6-methoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-7-ol (4.3a) 
 Yield 72%, white powder, mp 164  ̊ C; 1H NMR (CDCl3, 500 MHz) δ 6.57 (s, 1H), 6.56 
(s, 1H), 3.85 (s, 3H), 3.46 (s, 2H), 2.83 (t, J = 7.4 Hz, 2H), 2.65 (t, J = 7.4 Hz, 2H), 2.43 (s, 3); 13C 
NMR (CDCl3, 125 MHz) δ 145.1, 143.6, 127.3, 125.0, 112.0, 110.6, 57.4, 55.9, 53.0, 46.1, 28.9; 
(ESI) m/z calcd. for C11H15NO2 ([M+H]+), 194.1176, found 194.1172. 
2-ethyl-6-methoxy-1,2,3,4-tetrahydroisoquinolin-7-ol (4.3b) 
Yield 65%, brown solid, mp 90  ̊ C; 1H NMR (CDCl3, 500 MHz) δ 6.59 (s, 1H), 6.7 (s, 
1H), 3.85 (s, 3H), 3.59 (s, 2H), 2.87 (t, J = 5.7 Hz, 2H), 2.78 (t, J = 5.7 Hz, 2H), 2.63 (q, J = 7.1 
Hz, 2H), 1.22 (t J = 7.2 Hz, 3H); 13C NMR (CDCl3, 125 MHz) δ 147.8, 146.2, 129.8, 128.0, 114.9, 







Yield 68%, yellow solid, mp 150  ̊ C; 1H NMR (CDCl3, 500 MHz) δ 7.01-6.97 (m, 2H), 
6.91-6.89 (m, 1H), 6.57 (s, 2H), 3.85 (s, 6H), 3.69 (s, 2H), 3.57 (s, 2H), 2.79 (t, J = 5.7 Hz, 2H), 
2.73 (t J = 5.6 Hz, 2H); 13C NMR (CDCl3, 125 MHz) δ 149.0, 145.9, 145.1, 143.6, 131.5, 127.5, 
125.6, 124.6, 122.3, 114.5, 112.2, 110.6, 61.9, 56.4, 55.9, 55.6, 50.6, 28.9; (ESI) m/z calcd. for 
C18H21NO4 ([M+H]+), 316.1543, found 316.1538. 
2-(4-hydroxy-3-methoxybenzyl)-6-methoxy-1,2,3,4-tetrahydroisoquinolin-7-ol (4.3d) 
Yield 70%, light brown powder, mp 62  ̊ C; 1H NMR (CDCl3, 500 MHz) δ 6.97 (d, J = 1.6 
Hz, 1H), 6.88 (d, J = 8.2 Hz, 1H), 6.81 (d J = 8.2, 1H), 6.57 (s, 1H), 6.54 (s, 1H), 3.89 (s, 3H), 
3.84 (s, 3H), 3.61 (s, 2H), 3.55 (s, 2H), 2.82 (t, J = 5.3 Hz, 2H), 2.74 (t J = 5.2 Hz, 2H); 13C NMR 
(CDCl3, 125 MHz) δ 145.8, 145.4, 145.1, 143.6, 125.5, 120.8 X 2, 115.4, 112.2, 110.6, 110.6, 
110.4, 62.0, 56.0 X 2, 55.3, 50.4, 28.5; (ESI) m/z calcd. for C18H21NO4 ([M+H]+), 316.1543, found 
316.1537. 
4-(7-(benzyloxy)-6-methoxy-3,4-dihydroisoquinolin-2(1H)-yl)butan-1-amine (4.7) 
Compound 4.6 (3.0 g, 11.2 mmol), K2CO3 (3 g, 22.4 mmol) and 4-bromobutyronitrile (1.1 
mL, 11.2 mmol) were refluxed in acetonitrile (30 mL) for 2 h. Reaction was cooled to room 
temperature and it was filtered. The filtrate was concentrated in vacuo and the residue was washed 
with sat. NaHCO3 and extracted with ethyl acetate (3 X 40 mL). Combined organic layer was dried 
over sodium sulfate and evaporated to get the crude product which was used in next step without 
further purification. The crude mass (3.4 g) was dissolved in THF and the solution was cooled to 
0  ̊ C for 10 minutes. LAH (0.6 g, 16.8 mmol) was added portion wise in to the solution and allowed 
it to sir for 2 h at rt.  Excess LAH was quenched with water and 10 % aqueous NaOH was added. 
Reaction mixture was filtered through celite, filtrate was evaporated to dryness and the residue 
was extracted with ethyl acetate (3 X 40 mL). The combined organic layers were dried over sodium 
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sulfate and concentrated to give the crude product, which was purified by flash column 
chromatography on silica gel (5% methanol/dichloromethane)   to give the compound 4.7 (2.9 g, 
76%) as yellow oil.  1H NMR (CDCl3, 500MHz) δ 7.43 (d, J = 7.8 Hz, 2H), 7.36 (t, J = 7.8 Hz, 
2H), 7.29 (t J = 7.1 Hz, 1H), 6.61 (s, 1H), 6.56 (s, 1H), 5.08 (s, 2H), 3.83 (s, 3H), 3.65 (s, 2H), 
2.86-2.81 (m, 6H), 2.57 (t, J =5.8 Hz, 2H), 1.82-1.73 (m, 4H); 13C NMR (CDCl3, 125 MHz) δ 
148.5, 146.7, 137.1, 128.6 X 2, 127.8, 127.3, 125.9, 124.4, 124.4 X 2, 111.9, 71.1, 56.5, 56.0, 54.8, 
49.7, 39.7, 27.2, 26.9, 24.9; (ESI) m/z calcd. for C21H28N2O2 ([M+H]+), 341.2224, found 341.2225. 
 
General procedure to synthesize compounds 4.4a-4.4l is described for 4.4a: 
N-(4-(7-hydroxy-6-methoxy-3,4-dihydroisoquinolin-2(1H)-yl)butyl)-[1,1'-biphenyl]-4-
carboxamide (4.4a) 
Compound 4.7 (100 mg, 0.3 mmol), EDCI (86 mg, 0.45 mmol) and biphenyl-4-carboxylic 
acid (89 mg, 0.45 mmol) were added in to DCM (5 mL). The reaction mixture was allowed to stir 
overnight at rt. Extra 10 mL of DCM was added in to the reaction and it was washed with sat. 
NaHCO3 (15 mL). Organic layer was dried over sodium sulfate and evaporated to dryness. The 
crude mass was dissolved in EtOH (5 mL). Conc. HCl (2 mL) was added into the reaction mixture 
and it was refluxed for 3 h. The solvent was evaporated and residue was basified with aqueous 
ammonia solution and extracted with ethyl acetate (2 X 15 mL). Combined organic layer was dried 
over sodium sulfate and evaporated to dryness. The crude product was purified using column 
chromatography (1% MeOH/DCM) to give 4.4a as yellow solid (94 mg, 73 %) mp 85  ̊ C; 1H 
NMR (CDCl3, 500MHz) δ  7.71 (d, J = 7.9 Hz, 2H), 7.57 (d, J = 7.5 Hz, 2H), 7.46-7.35 (m, 5H), 
6.58 (s, 1H), 6.52 (s, 1H), 3.78 (s, 3H), 3.57-3.51 (m, 4H), 2.77 (dd, J = 5.3, 22.1 Hz, 4H), 2.61 (s, 
2H), 1.79 (d, J = 2.9 Hz, 4H); 13C NMR (CDCl3, 125 MHz) δ 167.2, 145.4, 143.9, 143.5, 140.0, 
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133.3, 128.8 X 2, 127.8 X 2, 127.4 X 2, 127.1 X 2, 126.8 X 2, 125.3, 112.2, 110.5, 57.2, 56.0, 
55.9, 50.0, 39.8, 28.3, 27.3, 24.8; (ESI) m/z calcd. for C27H30N2O3 ([M+H]+), 431.2329, found 
431.2328. 
N-(4-(7-hydroxy-6-methoxy-3,4-dihydroisoquinolin-2(1H)-yl)butyl)-2-naphthamide (4.4b) 
Yield 76%, yellow  solid, mp 82  ̊ C; 1H NMR (CDCl3, 500MHz) δ  8.21 (s, 1H), 7.81-7.66 
(m, 5H),  7.49 (td, J = 7.9, 23.7 Hz, 2H), 6.52 (s, 1H), 6.41 (s, 1H), 3.77 (s, 3H), 3.56 (s, 4H), 2.75 
(s, 4H), 2.62 (s, 2H), 1.81 (s, 4H); 13C NMR (CDCl3, 125 MHz) δ 167.8, 145.3, 143.8, 134.5, 
132.5, 132.0, 128.9 X 2, 128.1, 127.6 X 2, 127.3 X 2, 126.3, 123.7, 112.2, 110.4, 57.3, 55.8, 55.7, 
50.2, 40.0, 28.1, 27.2, 24.7; (ESI) m/z calcd. for C25H28N2O3 ([M+H]+), 405.2173, found 405.2177. 
N-(4-(7-hydroxy-6-methoxy-3,4-dihydroisoquinolin-2(1H)-yl)butyl)quinoline-4-
carboxamide (4.4c) 
Yield 66%, yellow powder, mp 89  ̊ C 1H NMR (CDCl3, 500MHz) δ  8.80 (s, 1H), 8.62 (d, 
J = 4.3 Hz, 1H), 8.14 (d, J = 8.4 Hz, 1H),  8.04 (d, J = 8.5 Hz, 1H), 7.70(t, J = 7.2 Hz, 1H), 7.54 
(t, J = 7.8 Hz, 1H), 7.16 (d,  J = 4.3 Hz, 1H), 6.27 (s, 1H), 6.13 (s, 1H), 3.78 (s, 3H), 3.56 (d, J = 
5.5 Hz, 2H), 3.34 (s, 2H), 2.55 (pent, J = 7.3 Hz, 4H), 2.35(t, J = 5.6 Hz, 2H), 1.84-1.80 (m, 4H); 
13C NMR (CDCl3, 125 MHz) δ 167.4, 149.6, 148.3, 145.3, 143.7, 129.6, 129.5, 127.2 X 2, 125.5 
125.3, 124.5, 124.3, 118.3, 111.8, 110.1, 57.8, 55.7, 55.3, 50.5, 40.1, 27.9, 27.8, 25.1; (ESI) m/z 




Yield 70%, brown solid, mp 104  ̊ C 1H NMR (CDCl3, 600MHz) δ  8.44 (dd, J = 1.6, 3.7 
Hz, 2H), 8.29 (s, 1H), 7.46 (dd, J = 1.3, 3.8 Hz, 2H), 6.54 (s, 1H), 6.50 (s, 1H), 3.84 (s, 3H), 3.59 
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(s, 2H), 3.50 (q, J = 5.4 Hz, 2H), 2.79 (s, 4H), 2.65 (t, J = 6.1 Hz, 2H), 1.83-1.76 (m, 4H); 13C 
NMR (CDCl3, 150 MHz) δ 165.6, 150.1 X 2, 145.8, 144.3, 141.7, 124.6 X 2, 121.0 X 2, 112.3, 
110.6, 56.8, 56.0, 55.6, 50.0, 39.7, 27.8, 27.0, 24.4; (ESI) m/z calcd. for C20H25N3O3 ([M+H]+), 
356.1969, found 356.1976. 
4-hydroxy-N-(4-(7-hydroxy-6-methoxy-3,4-dihydroisoquinolin-2(1H)-yl)butyl)benzamide 
(4.4e) 
Yield 65%, yellow powder, mp 80  ̊ C 1H NMR (C5D5N, 500MHz) δ  9.03 (s, 1H), 8.42 (d, 
J = 8.4 Hz, 2H), 7.26 (d, J = 8.4 Hz, 2H), 6.97 (s, 1H), 6.75 (s, 1H), 3.87 (s, 2H), 3.75-3.71 (m, 
5H), 3.97 (s, 4H), 2.79 (s, 2H), 1.88-1.77 (m, 4H); 13C NMR (CD3OD, 125 MHz) δ 169.1, 161.1, 
147.6, 145.4, 129.2 X 2, 125.3, 123.3, 123.1, 115.0 X 2, 112.8, 111.3, 57.0, 55.3, 54.2, 50.7, 39.2, 
27.2, 26.5, 22.9; (ESI) m/z calcd. for C21H26N2O4 ([M+H]+), 371.1965, found 371.1969. 
N-(4-(7-hydroxy-6-methoxy-3,4-dihydroisoquinolin-2(1H)-yl)butyl)-3-methoxybenzamide 
(4.4f) 
Yield 80%, yellow solid, mp 68  ̊ C 1H NMR (CDCl3, 500MHz) δ 7.38 (s, 2H), 7.22 (d, J 
=7.5 Hz, 1H), 7.14 (t, J = 8.0 Hz, 1H), 6.96 (dd, J = 2.3, 8.1 Hz, 1H), 6.53 (s, 2H), 3.83 (s, 3H), 
3.81 (s, 3H), 3.67 (s, 2H), 3.49 (q,  J = 6.0 Hz, 2H), 2.88 (dd, J = 4.0, 13.3 Hz, 4H), 2.73 (t, J = 
6.6 Hz, 2H), 1.81 (pent, J = 6.9 Hz, 2H), 1.73 (pent, J = 6.3 Hz, 2H); 13C NMR (CDCl3, 125 MHz) 
δ 167.5, 159.6, 145.9, 144.2, 136.0, 129.3 X 2, 124.2, 118.8, 117.6, 112.3, 112.1, 110.6, 56.4, 55.9, 






Yield 78%, yellow solid, mp 57  ̊ C 1H NMR (CDCl3, 500MHz) δ 7.75 (s, 1H), 7.61-7.58 
(m, 2H), 6.81 (t, J = 8.7 Hz, 2H), 6.54 (s, 1H), 6.50 (s, 1H), 3.85 (s, 3H), 3.50-3.45 (m, 4H), 2.75-
2.68 (m, 4H), 2.56 (t, J = 6.1 Hz, 2H), 1.76 (t, J = 5.8 Hz, 4H); 13C NMR (CDCl3, 125 MHz) δ 
166.6, 164.3 (d, J = 249 Hz), 145.4, 143.9, 130.9 X 2, 129.2, 129.1, 126.8, 125.1, 115.2 (d, J = 
21.8 Hz), 112.2, 110.5, 57.5, 56.2, 55.9, 50.2, 40.0, 28.5, 27.3, 24.9; (ESI) m/z calcd. for 
C21H25FN2O3 ([M+H]+), 373.1922, found 373.1927. 
4-chloro-N-(4-(7-hydroxy-6-methoxy-3,4-dihydroisoquinolin-2(1H)-yl)butyl)benzamide 
(4.4h) 
Yield 76%, brown solid, mp 63  ̊ C 1H NMR (CDCl3, 500MHz) δ 7.93 (s, 1H), 7.53 (d, J = 
8.4 Hz, 2H), 7.09 (d, J = 8.4 Hz, 2H), 6.51 (s, 1H), 6.48 (s, 1H), 3.84 (s, 3H), 3.50-3.46 (m, 4H), 
2.70 (t, J = 3.0 Hz, 4H), 2.56 (s, 2H), 1.76 (s, 4H); 13C NMR (CDCl3, 125 MHz) δ 166.7, 145.5, 
144.0, 137.0, 133.1 X 2, 128.4, 126.5 X 2, 125.1 X 2, 112.2, 110.5, 57.4, 56.1, 55.9, 50.1, 40.0, 
28.3, 27.3, 24.; (ESI) m/z calcd. for C21H25ClN2O3 ([M+H]+), 389.1626, found 389.1624. 
4-bromo-N-(4-(7-hydroxy-6-methoxy-3,4-dihydroisoquinolin-2(1H)-yl)butyl)benzamide 
(4.4i) 
Yield 72%, yellow powder, mp 89  ̊ C 1H NMR (CDCl3, 500MHz) δ 7.98 (s, 1H), 7.48 (d, 
J = 8.4 Hz, 2H), 7.25 (d, J = 8.7 Hz, 2H), 6.53 (s, 1H), 6.48 (s, 1H), 3.84 (s, 3H), 3.53 (s, 2H), 3.46 
(d, J = 5.3 Hz, 2H), 2.73 (s, 4H), 2.59 (t, J = 5.6 Hz, 2H), 1.77 (s, 4H); 13C NMR (CDCl3, 125 
MHz) δ 166.7, 145.6, 144.0, 133.5, 131.3 X 2, 128.6, 126.1 X 2, 125.5, 125.0, 112.2, 110.5, 57.3, 





Yield 69%, brown solid, mp 95  ̊ C 1H NMR (CDCl3, 500MHz) δ 7.86 (s, 1H), 7.65 (dd, J 
= 1H), 7.48 (d, J = 8.1 Hz, 2H), 7.39 (d, J = 8.1 Hz, 2H), 6.55 (s, 1H), 6.53 (s, 1H), 3.86 (s, 3H), 
3.75 (s, 2H), 3.48 (q, J = 5.5 Hz, 2H), 2.96-2.95 (m, 2H), 2.86-2.84 (m, 2H), 2.80 (t, J = 6.9 Hz, 
2H), 1.86 (pent, J = 6.7 Hz, 2H), 1.75 (pent, J = 6.3 Hz, 2H); 13C NMR (CDCl3, 125 MHz) δ 166.9, 
145.9, 144.4, 137.4, 137.2, 134.0, 131.3 X 2, 128.7 X 2, 124.0, 112.2, 110.5, 97.9, 56.0, 55.8, 54.5, 
49.5, 39.1, 26.7, 23.4; (ESI) m/z calcd. for C21H25IN2O3 ([M+H]+), 481.0983, found 481.0986. 
N-(4-(7-hydroxy-6-methoxy-3,4-dihydroisoquinolin-2(1H)-yl)butyl)-4-methoxybenzamide 
(4.4k) 
Yield 83%, brown powder, mp 62  ̊ C 1H NMR (CDCl3, 500MHz) δ  7.70 (d, J = 8.3 Hz, 
2H), 7.41 (s, 1H), 6.75 (d, J = 8.3 Hz, 2H), 6.57 (s, 2H), 3.85 (s, 3H), 3.80 (s, 3H), 3.72 (s, 2H), 
3.49 (q, J = 5.5 Hz, 2H), 2.93-2.89 (m, 4H), 2.76 (s, 2H), 1.84 (pent, J = 6.6 Hz, 2H), 1.74 (pent, 
J = 6.2 Hz, 2H); 13C NMR (CDCl3, 125 MHz) δ 167.1, 161.8, 145.8, 144.2, 128.8 X 2, 126.8 X 2, 
124.2 X 2, 113.5, 112.3, 110.6, 56.1, 55.9, 55.3, 54.6, 49.7, 39.1, 29.5, 26.9, 23.5; (ESI) m/z calcd. 
for C22H28N2O4 ([M+H]+), 385.2122, found 385.2122. 
4-cyano-N-(4-(7-hydroxy-6-methoxy-3,4-dihydroisoquinolin-2(1H)-yl)butyl)benzamide 
(4.4l) 
Yield 68%, yellow solid, mp 115  ̊ C 1H NMR (CDCl3, 500MHz) δ  8.43 (s, 1H), 7.80 (d, 
J = 8.0 Hz, 2H), 6.45 (d, J = 8.2 Hz, 2H), 6.53 (s, 1H), 6.49 (s, 1H), 3.86 (s, 3H), 3.71 (s, 2H), 3.50 
(d, J = 5.3 Hz, 2H), 2.93-2.75 (m, 6H), 1.88 (pent, J = 6.3 Hz, 2H), 1.79 (pent, J = 6.4 Hz, 2H); 
13C NMR (CDCl3, 125 MHz) δ 166.0, 146.1, 144.5, 138.5, 132.0 X 2, 127.8 X 2, 123.9 X 2, 118.2, 
114.3, 112.1, 110.4, 56.2, 56.0, 54.9, 49.6, 39.3, 26.9, 26.6, 23.5; (ESI) m/z calcd. for C22H25N3O3 




4.6.2 Biological evaluation 
As per Section 3.8.2 
 
4.6.3 Metabolic stability study 
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